{"id":"61f58de2882a024a1000000a","question":"Which factor is inhibited by Milvexian?","long_answer":"Milvexian is a small molecule, active-site inhibitor of factor XIa (FXIa) being developed to prevent and treat thrombotic events.","answer":"XIa","context":"Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Milvexian (BMS-986177\/JNJ-70033093) is a small molecule, active-site inhibitor of factor XIa (FXIa) being developed to prevent and treat thrombotic events.  Additional data are needed regarding the efficacy and safety of milvexian, an oral factor XIa inhibitor. CONCLUSIONS: Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. SIONS: Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. (Fund BACKGROUND: Milvexian (BMS-986177\/JNJ-70033093) is an orally bioavailable factor XIa (FXIa) inhibitor currently in phase 2\u00a0clinical trials. S: Milvexian is an active-site, reversible inhibitor of human and rabbit FXIa (Ki 0.11 and 0.38\u00a0nM, respectively). Milvexian increased activat Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits. Milvexian (BMS-986177\/JNJ-70033093) is a small molecule, active-site inhibitor of factor XIa (FXIa) being developed to prevent and treat thrombotic events. The BACKGROUND: Milvexian (BMS-986177\/JNJ-70033093) is an orally bioavailable factor XIa (FXIa) inhibitor currently in phase 2\u00a0clinica Milvexian (BMS-986177\/JNJ-70033093) is a small molecule, active-site inhibitor of factor XIa (FXIa) being developed to prevent and treat thrombotic events. BACKGROUND: Milvexian (BMS-986177\/JNJ-70033093) is an orally bioavailable factor XIa (FXIa) inhibitor currently in phase 2\u00a0clinical trials.OBJECTIVES: To evaluate in vitro properties and in vivo characteristics of milvexian.METHODS: In vitro properties of milvexian were evaluated with coagulation and enzyme assays, and in vivo profiles were characterized with rabbit models of electrolytic-induced carotid arterial thrombosis and cuticle bleeding time (BT).RESULTS: Milvexian is an active-site, reversible inhibitor of human and rabbit coagulants. Additional data are needed regarding the efficacy and safety of milvexian, an oral factor XIa inhibitor.METHODS: In this parallel-group, phase 2 trial, we randomly assigned 1242 patients undergoing knee arthroplasty to receive one of seven postoperative regimens of milvexian (25 mg, 50 mg, 100 mg, or 200 mg twice daily or 25 mg, 50 mg, or 200 mg once daily) or enoxapari emostasis, even when combined with aspirin in rabbits. This study supports inhibition of FXIa with milvexian as a promising k of 30% (one-sided P<0.001). Bleeding of any severity occurred in 38 of 923 patients (4%) taking milvexian and in 12 of 296 patients (4%) taking enoxaparin; major or clinically relevant nonmajor bleeding occurred in 1% and 2%, respectively; and serious adverse events were reported in 2% and 4%, respectively.CONCLUSIONS: Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and "}
{"id":"6217d9de3a8413c653000025","question":"What is Granzyme B?","long_answer":"Granzyme B is a serine protease that is secreted by Natural Killer (NK) cells and cytotoxic T lymphocytes during a cellular immune response and can induce apoptosis.","answer":"Granzyme B is a serine protease","context":"expression of the non-specific cytotoxic cell marker (granzyme B, grb)  cytotoxic protein-positive cells, such as granzyme B cells Granzyme B is known to be a serine protease contained in granules of cytotoxic T cells.  including cytotoxic T cells (CD8, Granzyme B, OX40, Ki67),\n Granzyme B is a serine protease that is secreted by Natural Killer (NK) cells and cytotoxic T lymphocytes during a cellular immune response and can induce apoptosis.  markers of activated cytotoxic T lymphocytes (CD8, granzyme-B) "}
{"id":"6206c22ac9dfcb9c0900003e","question":"Which signaling pathway does LY294002 inhibit?","long_answer":"LY294002, can block the PI3K\/AKT signaling pathway.","answer":"PI3K\/AKT","context":"LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K\/Akt Signaling Pathway. PI3K inhibitor, LY294002, can block PI3K\/AKT signaling, further inhibit glycolysis to disturb ATP production, and finally induce cell apoptosis. "}
{"id":"6217db1b3a8413c653000027","question":"Which disease is caused by mutations in the gene PRF1?","long_answer":"The presence of mutations in PRF1, UNC13D, STX11 and STXBP2 genes in homozygosis or compound heterozygosis results in immune deregulation. Most such cases lead to clinical manifestations of haemophagocytic lymphohistiocytosis (HLH).","answer":"haemophagocytic lymphohistiocytosis (HLH)","context":"Spectrum mutations of PRF1, UNC13D, STX11, and STXBP2 genes in Vietnamese patients with hemophagocytic lymphohistiocytosis. The presence of mutations in PRF1, UNC13D, STX11 and STXBP2 genes in homozygosis or compound heterozygosis results in immune deregulation. Most such cases lead to clinical manifestations of haemophagocytic lymphohistiocytosis (HLH). Adult onset type 2 familial hemophagocytic lymphohistiocytosis with PRF1 c.65delC\/c.163C>T compound heterozygous mutations: A case report. Deleterious mutations in PRF1 result in lethal, childhood disease, familial hemophagocytic lymphohistiocytosis type 2 (FHL 2)."}
{"id":"62211f453a8413c653000072","question":"What protein is encoded by the GRN gene?","long_answer":"Loss-of-function mutations in the gene encoding for the protein progranulin (PGRN), GRN, are one of the major genetic abnormalities involved in frontotemporal lobar degeneration.","answer":"progranulin","context":"Loss-of-function mutations in the gene encoding for the protein progranulin (PGRN), GRN, are one of the major genetic abnormalities involved in frontotemporal lobar degeneration. Numerous kindreds with familial frontotemporal lobar degeneration have been linked to mutations in microtubule-associated protein tau (MAPT) or progranulin (GRN) genes. BACKGROUND: Progranulin protein (PGRN) is a cysteine-rich growth factor encoded by the progranulin gene (GRN). Due to the highly diverse biological functions of the progranulin (PGRN) protein, encoded by GRN, multiple possible disease mechanisms have been proposed. Single nucleotide polymorphisms (SNPs) in TMEM106B encoding the lysosomal type II transmembrane protein 106B increase the risk for frontotemporal lobar degeneration (FTLD) of GRN (progranulin gene) mutation carriers. BACKGROUND: Progranulin protein (PGRN) is a cysteine-rich growth factor encoded by the progranulin  GRN, the gene coding for the progranulin (PGRN) protein, was recognized as a gene linked to frontotemporal lobar degeneration (FTLD). Th Progranulin (PGRN) is a protein encoded by the GRN gene with multiple identified functions including as a neurotrophic factor, tumorigenic growth factor, anti-inflammatory cytokine and regulator of lysosomal function. A  Mutations in the GRN gene coding for progranulin (PGRN) are responsible for many cases of familial frontotemporal lobar degeneration (FTLD) with TAR DNA-binding protein 43 (TDP-43)-positive inclusions (FTLD-TDP). GRN ozygous loss-of-function mutations in the gene encoding the progranulin protein (Granulin Precursor, GRN) are a common cause of familial frontotemporal dementia (FTD). Gene t ne of these genes (GRN), which encodes progranulin, have been implicated in up to a quarter of cases of frontotemporal lobar degeneration with TDP-43 (TAR DNA-binding protein 43)-positive inclusions; currently, there are more than 60 known pathogenic mutations of the gene. We present the cl Mutation in the GRN gene, encoding the progranulin (PGRN) protein, shows a dose-dependent disease correlation, wherein haploinsufficiency results in frontotemporal lobar degeneration (FTLD) and complete loss results in neuronal ceroid lipofuscinosis (NCL). Altho e on FTD caused by mutations in the GRN gene, which encodes a secreted protein, progranulin (PGRN), that has diverse roles in regulating cell survival, immune responses, and autophagy and lysosome function in the brain. FTD-linked mutat to the highly diverse biological functions of the progranulin (PGRN) protein, encoded by GRN, multiple possible disease mechanisms have been proposed. Early   most common pathological subtype, FTLD with transactive response DNA-binding protein with a molecular weight of 43 kDa inclusions (FTLD-TDP), is often caused by autosomal dominant mutations in the progranulin gene (GRN) encoding the progranulin protein (PGRN). GRN pa Progranulin, a secreted glycoprotein, is encoded in humans by the single GRN gene. Homozygous or heterozygous mutations in the GRN gene, encoding progranulin (PGRN), cause neuronal ceroid lipofuscinosis (NCL) or frontotemporal dementia (FTD), respectively. Heterozygous loss-of-function mutations in the gene encoding the progranulin protein (Granulin Precursor, GRN) are a common cause of familial frontotemporal dementia (FTD). Progranulin (PGRN) is a protein encoded by the GRN gene with multiple identified functions including as a neurotrophic factor, tumorigenic growth factor, anti-inflammatory cytokine and regulator of lysosomal function. BACKGROUND: Progranulin (PGRN) encoded by the GRN gene, is a secreted glycoprotein growth factor that has been implicated in many physiological and pathophysiologica Progranulin (PGRN), encoded by the GRN gene in humans, is a secreted growth factor implicated in a multitude of processes ranging from regulation of inflammation to wound healing and tumorigenesis. Mutation in the GRN gene, encoding the progranulin (PGRN) protein, shows a dose-dependent disease correlation, wherein haploinsufficiency results in frontotemporal lobar degeneration (FTLD) and complete loss results in neuronal ceroid lipofuscinosis (NCL). We focus here on FTD caused by mutations in the GRN gene, which encodes a secreted protein, progranulin (PGRN), that has diverse roles in regulating cell survival, immune responses, and autophagy and lysosome function in the brain. By studying mice lacking progranulin (PGRN), the protein encoded by GRN, we discovered multiple lines of evidence that PGRN deficiency results in impairment of autophagy, a key cellular degradation pathway. Loss-of-function mutations in the progranulin gene (GRN), which encodes progranulin (PGRN), are a major cause of frontotemporal dementia (FTD). The recent discovery that mutations in the gene encoding for progranulin (GRN) cause frontotemporal lobar degeneration (FTLD), and other neurodegenerative diseases leading to dementia, has brought renewed interest in progranulin and its functions in the central nervous system. Heterozygous, loss-of-function mutations in the granulin gene (GRN) encoding progranulin (PGRN) are a common cause of frontotemporal dementia (FTD).  progranulin (PGRN). PGRN is a glycoprotein encoded by the GRN\/Grn gene with multiple cellular functions"}
{"id":"62190ca03a8413c653000035","question":"What is disrupted by ALS- and FTD-associated missense mutations in TBK1?","long_answer":"ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy.","answer":"mitophagy","context":"ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy."}
{"id":"621ecac13a8413c65300005f","question":"What is the mode of action of primaquine?","long_answer":"Primaquine (PQ) not only eliminates P. falciparum gametocytes but also kills liver dormant forms of P. vivax and P. ovale.","answer":"anti-Malarial","context":"Primaquine (PQ) not only eliminates P. falciparum gametocytes but also kills liver dormant forms of P. vivax and P. ovale.  The effect of primaquine in preventing P. vivax relapses from dormant stages is well established. the wide use of PQ to treat liver-stage malaria.  Primaquine (PQ) is one of the most widely used antimalarial drugs.  Low-dose primaquine is recommended to prevent Plasmodium falciparum malaria transmission Four amphipathic drugs, primaquine, propranolol, chlorpromazine and tetracaine, were used to cause endocytosis in glucose-depleted red cells, and the relative reduction of membrane surfaces was measured by the toluidine blue (TB) method. This pattern of inhibition of macromolecular biosyntheses suggests that the major in vivo action of primaquine in B. megaterium is to block protein synthesis. Quinine, chloroquine, primaquine, pyrimethamine, artemesinin, mefloquine and proguanil all down-regulated the expression of monocyte receptors by 40% or greater at the therapeutic concentrations of each drug. Mode of action of primaquine: preferential inhibition of protein biosynthesis in Bacillus megaterium. Mode of action of primaquine: preferential inhibition of protein biosynthesis in Bacillus megaterium  study deals with the action of primaquine, a lysosomotropic agent, on EGF-receptor complexes (EGF-RC). By the  etic analysis of primaquine inhibition indicates that its point of action is at an early step in the vesicular transport mechanism. P Kinetic analysis of primaquine inhibition indicates that its point of action is at an early step in the vesicular transport mechanism. n explored. Recently, new primaquine-based hybrids as new molecules with potential multi-acting anti-malarial activity were reported and two hybrids of primaquine linked to quinoxaline 1,4-di-N-oxide (PQ-QdNO) were identified as the most active against erythrocytic, exoerythrocytic and sporogonic stages.METHODS: To further understand the anti-malarial mode of action (MA) of these hybrids, hepg2-CD81 were infected with Plasmodium yoelii 17XNL and treated with PQ-QdNO hybrids during 48\u00a0h. After were evaluated the production of ROS, the mitochondrial depolarization, the total glutathione content, the DNA damage and proteins related to oxidative stress and death cell.RESULTS: In a preliminary analysis as tissue schizonticidals, these hybrids showed a mode of action dependent on peroxides production, but independent of the activation of transcription factor p53, mitochondrial depolarization and arrest cell cycle.CONCLUSIONS: Primaquine-quinoxaline 1,4-di-N-oxide hybrids exert their antiplasmodial activity in the exoerythrocytic phase by generating high levels of oxidative stress which promotes the increase of total glutathione levels, th Primaquine blocks transport by inhibiting the formation of functional transport vesicles. Studies in a cell-free assay of protein transport through the Golgi apparatus. Primaquine-quinoxaline 1,4-di-N-oxide hybrids with action on the exo-erythrocytic forms of Plasmodium induce their effect by the production of reactive oxygen species. In addition to illuminating the mechanism of action of primaquine, this study suggests that the selective action of this agent will make it a useful tool in the study of the formation of transport vesicles."}
{"id":"6221209b3a8413c653000074","question":"Proteins in the karyopherin family (Kaps) are associated with what cellular process?","long_answer":"Nuclear translocation of large proteins is mediated through specific protein carriers, collectively named karyopherins (importins, exportins and adaptor proteins)","answer":"nuclear transport","context":"Nuclear translocation of large proteins is mediated through specific protein carriers, collectively named karyopherins (importins, exportins and adaptor proteins). Karyopherins mediate the macromolecular transport between the cytoplasm and the nucleus and participate in cancer progression. Transportin-1 (Trn1), also known as karyopherin-\u03b22 (Kap\u03b22), is probably the best-characterized nuclear import receptor of the karyopherin-\u03b2 family after Importin-\u03b2 Karyopherin alpha 2 (KPNA2), a member of the nuclear transporter family, is elevated in multiple human cancers and accelerates carcinogenesis. Nuclear import of proteins relies on nuclear import receptors called importins\/karyopherins (Kaps), whose functions were reported in yeasts, fungi, plants, and animal cells, including cell cycle control, morphogenesis, stress sensing\/response, and also fungal pathogenecity.  In eukaryotic cells, nucleocytoplasmic trafficking of macromolecules is largely mediated by Karyopherin \u03b2\/Importin (KPN\u03b2 or Imp\u03b2) nuclear transport factors, and they import and export cargo proteins or RNAs via the nuclear pores across the nuclear envelope, consequently effecting the cellular signal cascades in response to pathogen attack and environmental cues.  The nuclear-cytoplasmic distribution of these proteins is controlled by proteins in the karyopherin family of nuclear transport factors (Kaps). We show here that the import of histone H2A and H2B is mediated by several members of the karyopherin (Kap; importin) family. Small molecules can freely exchange through the NPC, but macromolecules larger than ~40 kDa must be aided across by transport factors, most of which belong to a related family of proteins termed karyopherins (Kaps). Exportin-5, a novel karyopherin, mediates nuclear export of double-stranded RNA binding proteins. We show here that nuclear import of TBP is mediated by a new karyopherin (Kap) (importin) family member, Kap114p. The karyopherin (Kap) family of nuclear transport factors facilitates macromolecular transport through nuclear pore complexes (NPCs). ear-cytoplasmic distribution of these proteins is controlled by proteins in the karyopherin family of nuclear transport factors (Kaps). Recent Human karyopherin alpha2 (KPNA2), a member of the karyopherin alpha family, plays a key role in the nuclear import of proteins with a classical nuclear localization signal (NLS). K ystematically manipulating the amounts, types, and affinities of Kaps and cargos, we show that import rates in vivo are simply governed by the concentrations of Kaps and their cargo and the affinity between them. These Proteins in the karyopherin-\u03b2 family mediate the majority of macromolecular transport between the nucleus and the cytoplasm. The alpha- and beta-karyopherins (Kaps), also called importins, mediate the nuclear transport of proteins. Karyopherins interact with nucleoporins, proteins that form the nuclear pore complex, to promote the translocation of their cargos into the nucleus. Studies have also suggested that karyopherins might participate in histones deposition into nucleosomes. When binding to histones, karyopherins not only function as nuclear import receptors but also as chaperones, protecting histones from non-specific interactions in the cytoplasm, in the nuclear pore and possibly in the nucleus. In yeast there are at least 14 members of the beta-karyopherin protein family that govern the movement of a diverse set of cargoes between the nucleus and cytoplasm. The Karyopherin proteins are involved in nucleo-cytoplasmic trafficking and are critical for protein and RNA subcellular localization. The Karyopherin (Kap) family of nuclear transport receptors enables trafficking of proteins to and from the nucleus in a precise, regulated manner. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. BACKGROUND: Karyopherin \u03b1-2 (KPNA2) is a member of karyopherin family, which is proved to be responsible for the import or export of cargo proteins."}
{"id":"5fe1fc84a43ad31278000036","question":"What percentage of human genes have no introns?","long_answer":"Intronless genes (IGs) constitute approximately 3% of the human genome.","answer":"3%","context":"Intronless genes (IGs) constitute approximately 3% of the human genome. Intronless genes (IGs) fraction varies between 2.7 and 97.7% in eukaryotic genomes.  608 of these genes have intronless human orthologs Intronless genes, which constitute 3 percent of the human genome, differ from intron-containing genes in evolution and function."}
{"id":"61f563f7882a024a10000006","question":"What is caused by biallelic variants in PCDHGC4?","long_answer":"Biallelic variants in PCDHGC4 cause a novel neurodevelopmental syndrome with progressive microcephaly, seizures, and joint anomalies.","answer":"A novel neurodevelopmental syndrome with progressive microcephaly, seizures, and joint anomalies","context":"Biallelic variants in PCDHGC4 cause a novel neurodevelopmental syndrome with progressive microcephaly, seizures, and joint anomalies. We show that biallelic variants in PCDHGC4 are causing a novel autosomal recessive neurodevelopmental disorder and link PCDHGC4 as a member of the clustered PCDH family to a Mendelian disorder in humans."}
{"id":"5fe31316a43ad31278000043","question":"What induces downstream of gene (DoG) readthrough transcription?","long_answer":"Stress-induced transcriptional readthrough generates very long downstream of gene containing transcripts (DoGs), which may explain up to 20% of intergenic transcription. Massive induction of transcriptional readthrough generates downstream of gene-containing transcripts (DoGs) in cells under stress condition. Ca2+ signaling mediates reduced transcription termination in response to certain stress conditions. This reduction allows readthrough transcription, generating a highly inducible and diverse class of downstream of gene containing transcripts (DoGs) that we have recently described.","answer":"stress conditions","context":"Readthrough activation of early adenovirus E1b gene transcription Using the rigorous methodology Cap-Seq, we demonstrated that DoGs result from transcriptional readthrough, not de novo initiation.  Rather it is, as we originally demonstrated, transcriptional readthrough that leads to the formation of DoGs. Previous studies demonstrated that massive induction of transcriptional readthrough generates downstream of gene-containing transcripts (DoGs) in cells under stress condition  Importantly, Ca2+ signaling mediates reduced transcription termination in response to certain stress conditions. This reduction allows readthrough transcription, generating a highly inducible and diverse class of downstream of gene containing transcripts (DoGs) that we have recently described. Finally, we examine genomic features of readthrough transcription and observe a unique chromatin signature typical of DoG-producing regions, suggesting that readthrough transcription is associated with the maintenance of an open chromatin state. We recently discovered that stress-induced transcriptional readthrough generates very long downstream of gene containing transcripts (DoGs), which may explain up to 20% of intergenic transcription. DoGs are induced by osmotic stress at the level of transcription by a mechanism that depends on calcium release from the endoplasmic reticulum mediated by IP3 receptors.  Furthermore, the readthrough response to stress has thus far not been investigated outside of mammalian species, and the occurrence of readthrough in many physiological and disease conditions remains to be explored We further demonstrate the use of the DoGFinder software package on a new publically available RNA-seq dataset, and discover DoG induction in human PME cells following hypoxia - a previously unknown readthrough inducing stress type."}
{"id":"6206b5a8c9dfcb9c0900003a","question":"What is the effect of rHDL-apoE3 on endothelial cell migration?","long_answer":"rHDL-apoE3 has been shown to promote endothelial cell migration.","answer":"Promotion","context":"These novel insights into the rHDL-apoE3 functions suggest a potential clinical use to promote re-endothelialization and retard development of atherosclerosis. The capacity of rHDL-apoE3 to stimulate EC migration was assessed by wound healing and transwell migration assays. The contribution of MEK1\/2, PI3K and the transcription factor ID1 in rHDL-apoE3-induced EC migration and activation of EC migration-related effectors was assessed using specific inhibitors (PD98059: MEK1\/2, LY294002: PI3K) and siRNA-mediated gene silencing, respectively.  In addition, rHDL-apoE3 stimulated migration of HCAEC and EA.hy926 cells, and the migration was markedly attenuated in the presence of PD98059 or LY294002."}
{"id":"61f5ee57882a024a10000012","question":"Hampton\u2019s hump is characteristic to which disease?","long_answer":"Hampton\u2019s hump is characteristic to pulmonary embolism.","answer":"pulmonary embolism","context":"Hampton's hump in a patient with endocarditis and septic emboli. We discuss a case of a 20-year-old woman presenting with chest pain found to have a Hampton's hump on chest x-ray and corresponding wedge infarct on computed tomographic scan. Contrary to our suspicion that this febrile and tachycardic patient had a pulmonary embolism, she was later determined to have a septic embolus secondary to endocarditis.  Chest radiograph showed a peripheral-based opacity in the right lower zone, which was not seen in a previous study done three months ago, suggestive of Hampton's hump. The D-dimer level was raised. Computed tomography pulmonary angiography confirmed the diagnosis of pulmonary embolism in a right lower lobe segmental branch, with adjacent collapsed lung, consistent with lung infarction.  We discuss a case of a 20-year-old woman presenting with chest pain found to have a Hampton's hump on chest x-ray and corresponding wedge infarct on computed tomographic scan. emia (the Westermark sign), prominent central pulmonary artery (the Fleischner sign), pleural-based area of increased opacity (the Hampton hump), vascular redistribution, pleural effusion, elevated diaphragm, and enlarged hilum were also poor predictors of PE.CONC ferent from that in patients without PE. Oligemia (the Westermark sign), prominent central pulmonary artery (the Fleischner sign), pleural-based area of increased opacity (the Hampton hump), vascular redistribution, pleural effusion, elevated diaphragm, and enlarged hilum were also poor predictors of PE.CONCLUSION: Although chest radiographs are essential in the investigation of suspected PE, their main value is to exclude diagnoses that clinically mimic PE and to aid in "}
{"id":"6217d9493a8413c653000022","question":"What is the activity of Indoleamine 2,3-dioxygenase 1.","long_answer":"Indoleamine 2,3-dioxygenase 1 (IDO1), a known immunosuppressive enzyme that catalyzes the rate-limiting step in the oxidation of tryptophan (Trp) to kynurenine (Kyn), has received increasing attention as an attractive immunotherapeutic target for cancer therapy.","answer":"Immunosuppressive activity","context":"Indoleamine 2,3-dioxygenase 1 (IDO1), a known immunosuppressive enzyme that catalyzes the rate-limiting step in the oxidation of tryptophan (Trp) to kynurenine (Kyn), has received increasing attention as an attractive immunotherapeutic target for cancer therapy.  Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzing the conversion of tryptophan (Trp) to kynurenine (Kyn) in kynurenine pathway (KP) is involved in the immunosuppression in pancreatic cancer (PC), but the value of IDO1 as an independent prognostic marker for PC is uncertain.  Indoleamine 2,3-dioxygenase 1 (IDO1), which is negatively regulated by the BIN1 proto-oncogene, is an interferon (IFN)-\u03b3-inducible mediator of immune tolerance.  Indoleamine 2,3-dioxygenase 1 (IDO1) is a normal endogenous mechanism of acquired peripheral immune tolerance and may therefore be tumor-promoting. "}
{"id":"62211ebc3a8413c653000071","question":"What is the purpose of  Macropinocytosis?","long_answer":"Macropinocytosis is an endocytic process, which involves the engulfment of extra-cellular content in vesicles known as macropinosomes.","answer":"transport across an external cell membrane","context":"Macropinocytosis defines a series of events initiated by extensive plasma membrane reorganization or ruffling to form an external macropinocytic structure that is then enclosed and internalized.  Macropinocytosis is a form of endocytosis that accompanies cell surface ruffling. Modified LDLs are internalized by macrophages in part via macropinocytosis. Macropinocytosis results from the closure of lamellipodia generated by membrane ruffling, thereby reflecting cortical actin dynamics.  Gonococcal entry into primary human urethral epithelial cells (HUEC) can occur by macropinocytosis. Macropinocytosis as a mechanism of entry into primary human urethral epithelial cells by Neisseria gonorrhoeae. Macropinocytosis is a normal cellular process by which cells internalize extracellular fluids and nutrients from their environment and is one strategy that Ras-transformed pancreatic cancer cells use to increase uptake of amino acids to meet the needs of rapid growth Macropinocytosis is a regulated form of endocytosis that mediates the nonselective uptake of nutrients to support growth under nutrient-deprived conditions Macropinocytosis is an ancient mechanism that allows cells to harvest nutrients from extracellular media, which also allows immune cells to sample antigens from their surroundings. Macropinocytosis refers to the non-specific uptake of extracellular fluid, which plays ubiquitous roles in cell growth, immune surveillance, and virus entry. D Macropinocytosis has emerged as an important nutrient supply pathway that sustains cell growth of cancer cells within the nutrient-poor tumor microenvironment Macropinocytosis is a prevalent and essential pathway in macrophages where it contributes to anti-microbial responses and innate immune cell functions Macropinocytosis is an actin-driven process of large-scale and non-specific fluid uptake used for feeding by some cancer cells and the macropinocytosis model organism Dictyostelium discoideum In Dictyostelium, macropinocytic cups are organized by 'macropin Macropinocytosis-the large-scale, non-specific uptake of fluid by cells-is used by Dictyostelium discoideum amoebae to obtain nutrients. Macropinocytosis has received increasing attention in recent years for its various roles in nutrient acquisition, immune surveillance, and virus and cancer pathologies.  Macropinocytosis is an evolutionarily-conserved, large-scale, fluid-phase form of endocytosis that has been ascribed different functions including antigen presentation in macrophages and dendritic cells, regulation of receptor density in neurons, and regulation of tumor growth under nutrient-limiting conditions. Macropinocytosis is an evolutionarily conserved form of endocytosis that mediates non-selective uptake of extracellular fluid and the solutes contained therein. The primary function of macropinocytosis in amoebae and some cancer cells is feeding, but the conserved processing pathway for macropinosomes, which involves shrinkage and the retrieval of membrane to the cell surface, has been adapted in immune cells for antigen presentation. Macropinocytosis is induced by many pathogens to enter host cells, but other functions for macropinocytosis in virus replication are unknown. Macropinocytosis is a means by which eukaryotic cells ingest extracellular liquid and dissolved molecules. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. Macropinocytosis refers to the formation of primary large endocytic vesicles of irregular size and shape, generated by actin-driven evaginations of the plasma membrane, whereby cells avidly incorporate extracellular fluid. Macropinocytosis is exploited by many pathogens for entry into cells. This suggests that macropinocytosis is necessary for mTORC1-dependent growth of metazoan cells, both as a route for delivery of amino acids to sensors associated with lysosomes and as a platform for growth factor-dependent signalling to mTORC1 via phosphatidylinositol 3-kinase (PI3K) and the Akt pathway. Macropinocytosis is a form of endocytosis which provides an effective way for non-selective uptakes of extracellular proteins, liquids, and particles. Macropinocytosis is important in a range of physiological processes, including antigen presentation, nutrient sensing, recycling of plasma proteins, migration and signalling. Macropinocytosis is increasingly recognized for its versatile adaptations and functions as a highly conserved, ubiquitous pathway for the bulk uptake of fluid, particulate cargo, and membranes. In tumour cells, macropinocytosis functions as an amino acid supply route and supports cancer cell survival and proliferation. Macropinocytosis is an evolutionarily conserved endocytic pathway that permits the internalization of extracellular fluid via large endocytic vesicles known as macropinosomes. Recently, macropinocytosis has been determined to function as a nutrient-scavenging pathway in Ras-driven cancer cells."}
{"id":"5eb422150d431b5f73000009","question":"Which was the first species in which a de novo gene emergence (\"gene birth\") was reported?","long_answer":"New genes can arise through duplication of a pre-existing gene or de novo from non-coding DNA, providing raw material for evolution of new functions in response to a changing environment. A prime example is the independent evolution of antifreeze glycoprotein genes (afgps) in the Arctic codfishes and Antarctic notothenioids to prevent freezing.","answer":"the Arctic codfish","context":"de novo gene birth remains poorly understood, mainly because translation of sequences devoid of genes, or 'non-genic' sequences, is expected to produce insignificant polypeptides rather than proteins with specific biological functions. Testing this model at the genome scale in Saccharomyces cerevisiae, we detect translation of hundreds of short species-specific open reading frames (ORFs) located in non-genic sequences.  We identify ~1,900 candidate proto-genes among S. cerevisiae ORFs and find that de novo gene birth from such a reservoir may be more prevalent than sporadic gene duplication Although the origin of such \"orphan\" genes remains unclear, they are thought to be involved in species-specific adaptive processes. Here, we analyzed seven orphan genes (MoSPC1 to MoSPC7) prioritized based on in planta expressed sequence tag data in the rice blast fungus, Magnaporthe oryzae. Based on these results, the four orphan genes may be products of de novo gene birth processes, and their adaptive potential is in the course of being tested for retention or extinction through natural selection. NCYM is the first de novo evolved protein known to act as an oncopromoting factor in human cancer, and suggest that de novo evolved proteins may functionally characterize human disease. De novo gene-birth contributes to shorter exons, longer introns, and higher exon-density in species-specific genes relative to conserved genes. The phenomenon of de novo gene birth from junk DNA is surprising, because random polypeptides are expected to be toxic. These targets regulated diverse biological processes including nutrient sensing and the DNA damage response, and implicated Vts1 in de novo gene \"birth.\" Many modern analysis pipelines use significant sequence similarity scores (p- or E-values) and the ranked order of BLAST matches to test a wide range of hypotheses concerning homology, orthology, the timing of de novo gene birth\/death and gene family The Majority of Novel Protein-Coding Genes Identified with Phylostratigraphy Are Old Genes or Recent Duplicates. Using a combination of synteny information and sequence similarity searches, I show that \u223c60% of the remaining 381 putative de novo genes share homology with genes from other vertebrates, originated through gene duplication, and\/or share no synteny information with nonrodent mammals. We find hundreds of open reading frames that are translated and that show no evolutionary conservation or selective constraints.  The AQP2 gene consists of four exons, but the alternative AQP2 gene lacks the fourth exon and instead has a longer third exon that includes the original third exon and a part of the original third intron. Nonetheless we identified 35 de novo genes: 16 human-specific; 5 human and chimpanzee specific; and 14 that originated prior to the divergence of human, chimpanzee, and gorilla and are found in all three genomes De novo gene evolution of antifreeze glycoproteins in codfishes revealed by whole genome sequence data. New genes can arise through duplication of a pre-existing gene or de novo from non-coding DNA, providing raw material for evolution of new functions in response to a changing environment. A prime example is the independent evolution of antifreeze glycoprotein genes (afgps) in the Arctic codfishes and Antarctic notothenioids to prevent freezing."}
{"id":"620c28d03a8413c653000007","question":"Which type of cancer has been suggested as a strategy for potential small-molecule inhibition of METTL3?","long_answer":"Small-molecule inhibition of METTL3 is a strategy against myeloid leukaemia. Targeting of RNA-modifying enzymes represents a promising avenue for anticancer therapy.","answer":"myeloid leukaemia","context":"Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Here we present the identification and characterization of STM2457, a highly potent and selective first-in-class catalytic inhibitor of METTL3, and a crystal structure of STM2457 in complex with METTL3-METTL14. Treatment of tumours with STM2457 leads to reduced AML growth and an increase in differentiation and apoptosis. These cellular effects are accompanied by selective reduction of m6A levels on known leukaemogenic mRNAs and a decrease in their expression consistent with a translational defect. We demonstrate that pharmacological inhibition of METTL3 in vivo leads to impaired engraftment and prolonged survival in various mouse models of AML, specifically targeting key stem cell subpopulations of AML. Collectively, these results reveal the inhibition of METTL3 as a potential therapeutic strategy against AML, and provide proof of concept that the targeting of RNA-modifying enzymes represents a promising avenue for anticancer therapy."}
{"id":"621b54f03a8413c65300003b","question":"Where are the PUX proteins found?","long_answer":"PUX proteins specifically associate with the nucleoskeleton underneath the INM.","answer":"PUX proteins specifically associate with the nucleoskeleton underneath the INM.","context":" These PUX proteins specifically associate with the nucleoskeleton underneath the INM and physically interact with CDC48 proteins to negatively regulate INM protein degradation in plants.  plant UBX-containing (PUX) proteins The activity and targeting of CDC48 are controlled by adaptor proteins, of which the plant ubiquitin regulatory\u00a0X\u00a0(UBX) domain-containing (PUX) proteins constitute the largest family. Emerging knowledge on the structure and function of PUX proteins highlights that these proteins are versatile factors for plant homeostasis and adaptation that might inspire biotechnological applications."}
{"id":"6024a6871cb411341a0000a4","question":"Which substance use is associated with Brodifacoum poisoning?","long_answer":"Brodifacoum poisoning was linked to marijuana use.","answer":"marijuana","context":"Brodifacoum Poisoning Linked to Synthetic Marijuana Use in Wisconsin. INTRODUCTION: Recent outbreaks of brodifacoum-induced coagulopathy resulting from the use of synthetic cannabinoids represents a growing public health concern. Brodifacoum is a commonly used and commercially available rodenticide that has anticoagulant properties. As new, unregulated synthetic cannabinoids enter the market, the potential for further outbreaks continues to rise.CASE PRESENTATION: We report a case of severe bleeding secondary to inhalation of synthetic cannabinoids contaminated with brodifacoum.  CONCLUSION: While hemorrhaging after exposure to synthetic cannabinoids has been reported previously, we use this case to increase awareness of the potentially deadly exposures to brodifacoum from synthetic cannabinoids use in Wisconsin.  Disseminated Intravascular Coagulopathy Secondary to Unintentional Brodifacoum Poisoning via Synthetic Marijuana. Recent evidence demonstrates a rising epidemic of unintentional brodifacoum poisoning associated with synthetic cannabinoid use. We present a rare case of severe coagulopathy and cardiac arrest secondary to synthetic cannabinoid use complicated by brodifacoum toxicity. Brodifacoum Poisoning Linked to Synthetic Marijuana Use in Wisconsin Recent evidence demonstrates a rising epidemic of unintentional brodifacoum poisoning associated with synthetic cannabinoid use ently, brodifacoum-contaminated synthetic marijuana has led to multiple deaths and morbidity throughout the USA from severe coagulopathy associated with use of this strain of the drug (brodifacoum is a rodenticide and potent Vitamin K antagonist\/anticoagulant). We Brodifacoum-contaminated synthetic marijuana: clinical and radiologic manifestations of a public health outbreak causing life-threatening coagulopathy. INTRODUCTION: Recent outbreaks of brodifacoum-induced coagulopathy resulting from the use of synthetic cannabinoids represents a growing public h CONCLUSIONS Brodifacoum-laced synthetic marijuana toxicity can lead to potentially lethal complications if not recognized and treated in a timely manner. Brodifacoum intoxication with marijuana smoking. Brodifacoum use is authorized as rodenticide in many countries worldwide, but has been reported as cause of severe coagulopathies in humans, both intentional or involuntary, even consumed as a contaminant of herbal drugs, such as cannabis. We report the case of a 17-year-old boy with a significant history of drug and alcohol abuse, which included smoking marijuana mixed with brodifacoum. se effects. There have been sporadic reports of co-consumption of illicit drugs with rodenticides such as warfarin and brodifacoum (BFC) over the past 20 years but recently, hundreds of people have been reported to have been poisoned with a mixture of synthetic cannabino Recently, brodifacoum-contaminated synthetic marijuana has led to multiple deaths and morbidity throughout the USA from severe coagulopathy associated with use of this strain of the drug (brodifacoum is a rodenticide and potent Vitamin K antagonist\/anticoagulant). binoid use. Preliminary tests of patient serum samples and drug samples revealed that brodifacoum, an anticoagulant, was the likely adulterant.METHODS: We reviewed physician-reported data from patients admitted to Saint Francis Medical Center in Peoria, Illinois, between March 28 and April 21, 2018, and included in a case series adult patients who met the criteria used to diagnose synthetic cannabinoid-ass"}
{"id":"621b4a223a8413c65300003a","question":"What is Alphafold?","long_answer":"AlphaFold is a novel machine learning approach that incorporates physical and biological knowledge about protein structure, leveraging multi-sequence alignments, into the design of the deep learning algorithm.","answer":"Highly accurate protein structure prediction approoach","context":"Highly accurate protein structure prediction with AlphaFold. AlphaFold is a novel machine learning approach that incorporates physical and biological knowledge about protein structure, leveraging multi-sequence alignments, into the design of the deep learning algorithm. Using novel deep learning, AF2 predicted the structures of many difficult protein targets at or near experimental resolution.  Using the neural network-based method AlphaFold2, 3D structures of almost the entire human proteome have been predicted and made available (https:\/\/www.alphafold.ebi.ac.uk)."}
{"id":"61f5847b882a024a10000008","question":"Which receptor is targeted by Spesolimab?","long_answer":"Spesolimab is a novel anti-interleukin-36 receptor antibody.","answer":"interleukin-36","context":"A prior Phase I proof-of-concept study showed rapid improvements in skin and pustule clearance with a single intravenous dose of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients presenting with an acute GPP flare. The objectives of this study were to evaluate the safety and efficacy of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients with PPP. Directing treatment at neutrophil recruitment and activation by targeting IL-36 with spesolimab fits well in the pathogenic concept of HS and clinical phase II trial results are pending. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results.  In a proof-of-concept clinical trial, treatment with spesolimab, an anti-IL-36 receptor antibody, resulted in rapid skin and pustular clearance in patients presenting with GPP flares. Recently, specific inhibitors of the IL-36 pathway have been evaluated in GPP and PPP, including spesolimab, an IL-36 receptor inhibitor which has shown promising results in GPP.  Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. In a proof-of-concept clinical trial, treatment with spesolimab, an anti-IL-36 receptor antibody, resulted in rapid skin and pustular clearance in patients presenting with GPP flares. Therefore, blockage of the IL-36 pathway has become a new treatment target in PPP, and three studies are currently evaluating the use of monoclonal antibodies that block the IL-36 receptor in PPP: ANB019 and spesolimab (BI 655130). Recently, specific inhibitors of the IL-36 pathway have been evaluated in GPP and PPP, including spesolimab, an IL-36 receptor inhibitor which has shown promising results in GPP. h PPP. The objectives of this study were to evaluate the safety and efficacy of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients wit 6 pathway have been evaluated in GPP and PPP, including spesolimab, an IL-36 receptor inhibitor which has shown promising results in GPP. The emerging drugs for pustular psoriasis  ares. A prior Phase I proof-of-concept study showed rapid improvements in skin and pustule clearance with a single intravenous dose of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients presenting with an acute GPP f IL-36 pathway has become a new treatment target in PPP, and three studies are currently evaluating the use of monoclonal antibodies that block the IL-36 receptor in PPP: ANB019 and spesolimab (BI 655130). In this review, we explore  ent at neutrophil recruitment and activation by targeting IL-36 with spesolimab fits well in the pathogenic concept of HS and clinical phase II trial results are pending. In contrast to is (GPP). In a proof-of-concept clinical trial, treatment with spesolimab, an anti-IL-36 receptor antibody, resulted in rapid skin and pustular clearance in patients presenting with GPP asis (GPP). In a proof-of-concept clinical trial, treatment with spesolimab, an anti-IL-36 receptor antibody, resulted in rapid skin and pustular clearance in patients presenting with GPP flares.OBJECTIVE: We sought to compare the molecular profiles of lesional and nonlesional skin from patients with GPP or palmoplantar pustulosis (PPP) with skin from healthy volunteers, and to investigate the molecular changes after spesolimab treatment in the skin and blood of patients with GPP flares.METHODS: Pre- and post-treatment skin and blood samples were collected from patients with GPP who participated in a si"}
{"id":"62058198c9dfcb9c09000030","question":"What is the effect of grapefruit juice on CYP3A4?","long_answer":"Grapefruit juice inhibits CYP3A4 activity.","answer":"Inhibitory","context":"The inhibition of CYP3A by grapefruit juice was significantly attenuated by processing particularly with \u03b3CD. The encapsulation of BG and DHBG by \u03b3CD and the resulting attenuation of the inhibition of CYP3A activity by grapefruit juice may be applicable to juice processing for preventing drug-grapefruit juice interactions."}
{"id":"61f81857882a024a10000040","question":"Which is the major clinical feature observed in FDXR-associated disease?","long_answer":"FDXR-associated disease is a phenotypically heterogeneous disorder with retinal dystrophy being a major clinical feature observed in this cohort.","answer":"Retinal dystrophy","context":"FDXR-associated disease is a phenotypically heterogeneous disorder with retinal dystrophy being a major clinical feature observed in this cohort. In addition, we hypothesize that a number of factors are likely to drive the pathogenesis of optic atrophy, retinal degeneration, and perhaps the associated systemic manifestations."}
{"id":"6217da133a8413c653000026","question":"Where is the the protein perforin localized?","long_answer":"Perforin are stored inside the leukocytes in secretory granules.","answer":"In secretory granules","context":" a family of pore-forming proteins (PFPs), known as perforin like proteins (PLPs) cytotoxic granules (granzyme B, granulysin, and perforin) Granzyme B and perforin are stored inside the leukocytes in secretory granules. T cells produce effector molecules that are either directly cytotoxic, such as granzymes, perforin"}
{"id":"621ecf1a3a8413c653000061","question":"What is an exosome?","long_answer":"Exosomes are a type of cell-derived extracellular nanovesicle.","answer":"extracellular nanovesicle","context":"Exosomes are a type of cell-derived extracellular nanovesicle. Exosomes are small extracellular vesicles released to the extracellular milieu through fusion of multivesicular bodies with the plasma membrane. Exosomes are natural products released from many sources and play a role in antigen presentation, immunoregulation, and signal transduction.  Exosomes, cell-derived vesicles encompassing lipids, DNA, proteins coding genes and noncoding RNAs (ncRNAs) are present in diverse body fluids. Exosomes are 60-80 nm vesicles of endocytic origin. Exosomes are small membrane vesicles, secreted by most cell types from multivesicular endosomes, and thought to play important roles in intercellular communications. Exosomes are extracellular vesicles first described as such 30\u00a0years ago and since implicated in cell-cell communication and the transmission of disease states, and explored as a means of drug discovery. Exosomes are extracellular vesicles released upon fusion of multivesicular bodies(MVBs) with the cellular plasma membrane. Exosomes are small vesicles with an average diameter of 100 nm that are produced by many, if not all, cell types. The exosome, a molecular machine for controlled RNA degradation in both nucleus and cytoplasm. Exosomes are part of the endocytic system,which is tightly regulated and able to respond to several stimuli that lead to alterations in the composition of its sub-compartments. Exosomes were shown to contain selectively sorted functional proteins, lipids, and RNAs, mediating cell-to-cell communications and hence playing a role in the physiology of the healthy and diseased organism. Exosomes are nano-sized vesicles of endocytic origin released into the extracellular space upon fusion of multivesicular bodies with the plasma membrane. Exosomes are small membrane vesicles that are secreted by a multitude of cell types as a consequence of fusion of multivesicular late endosomes\/lysosomes with the plasma membrane. Exosomes are extracellular vesicles released by the vast majority of cell types both in vivo and ex vivo, upon the fusion of multivesicular bodies (MVBs) with the cellular plasma membrane. An exosome (30-150 nm size) is a cell-derived vesicle. Exosomes are a subtype of vesicles released by cells of both healthy and neoplastic origin. PURPOSE: Exosomes are small membrane vesicles (30-100nm in diameter) secreted by cells into extracellul Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology. Exosomes are the newest family member of 'bioactive vesicles' that function to promote intercellular communication. Exosomes are nanosized membrane vesicles released by fusion of an organelle of the endocytic pathway, the multivesicular body, with the plasma membrane. Exosomes are nano-sized membrane vesicles (50-120\u00a0nm), which are released from a wide variety of cells. Exosomes are small extracellular vesicles (EVs) secreted by many cell types in both normal and pathogenic circumstances. Exosomes are nanovesicles originating from late endosomal compartments and secreted by most living cells in ex vivo cell culture conditions. Exosomes are nanosized membrane particles that are secreted by cells that transmit information from cell to cell. he exosome is a promising biomarker carrying many kinds of membrane proteins with huge heterogeneity, so the sensitive and multiplex analysis of exosomes is very significant for diseas The RNA exosome is an evolutionarily conserved 3'-5' exoribonucleolytic protein complex involved in processing and degradation of different classes of nuclear and cytoplasmic RNAs, and, therefore, important for the posttranscriptional control of gene expression."}
{"id":"62190bac3a8413c653000034","question":"Which disease is associated with X-linked recessive TLR7 deficiency?","long_answer":"X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of critical COVID-19 pneumonia, in about 1.8% of male patients below the age of 60 years.","answer":"critical COVID-19 pneumonia","context":"X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Overall, X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of critical COVID-19 pneumonia, in about 1.8% of male patients below the age of 60 years. Human TLR7 and pDCs are essential for protective type I IFN immunity against SARS-CoV-2 in the respiratory tract."}
{"id":"6206cfd5c9dfcb9c09000040","question":"Which one was the first chromone in clinical use?","long_answer":"The first chromone in clinical use, khellin.","answer":"Khellin","context":"The first chromone in clinical use, khellin, was extracted from the seeds of the plant Ammi visnaga, and had been used for centuries as a diuretic and as a smooth muscle relaxant. "}
{"id":"605fb19794d57fd879000038","question":"Which resource is used for visualisation of non-covalent contacts?","long_answer":"The Protein Contacts Atlas is an interactive resource of non-covalent contacts from over 100,000 PDB crystal structures. The Protein Contacts Atlas enables researchers from different disciplines to investigate diverse questions in the framework of non-covalent contacts, including the interpretation of allostery, disease mutations and polymorphisms, by exploring individual subunits, interfaces, and protein-ligand contacts and by mapping external information. The Protein Contacts Atlas is available at http:\/\/www.mrc-lmb.cam.ac.uk\/pca\/ and also through PDBe.","answer":"Protein Contacts Atlas","context":"Visualization and analysis of non-covalent contacts using the Protein Contacts Atlas. We present the Protein Contacts Atlas, an interactive resource of non-covalent contacts from over 100,000 PDB crystal structures. We developed multiple representations for visualization and analysis of non-covalent contacts at different scales of organization: atoms, residues, secondary structure, subunits, and entire complexes. The Protein Contacts Atlas enables researchers from different disciplines to investigate diverse questions in the framework of non-covalent contacts, including the interpretation of allostery, disease mutations and polymorphisms, by exploring individual subunits, interfaces, and protein-ligand contacts and by mapping external information. The Protein Contacts Atlas is available at http:\/\/www.mrc-lmb.cam.ac.uk\/pca\/ and also through PDBe."}
{"id":"60234dc61cb411341a000094","question":"Which disease is treated with Emapalumab?","long_answer":"Emapalumab is a human monoclonal antibody directed against interferon-\u03b3 (IFN-\u03b3) that was approved by the Food and Drug Administration for primary hemophagocytic lymphohistiocytosis (HLH).","answer":"primary hemophagocytic lymphohistiocytosis","context":"All patients who received the complement blocker eculizumab in addition to the interferon gamma blocker emapalumab had complete resolution of their TMA and survived.  Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. CONCLUSIONS: Emapalumab was an efficacious targeted therapy for patients with primary hemophagocytic lymphohistiocytosis.  Emapalumab for the treatment of hemophagocytic lymphohistiocytosis. Emapalumab-Igsz (Gamifant) is a human monoclonal antibody directed against interferon-\u03b3 (IFN-\u03b3), and the first Food and Drug Administration (FDA)-approved therapy for primary hemophagocytic lymphohistiocytosis (HLH). Emapalumab is approved for treatment of primary HLH that is refractory, recurrent, progressing or intolerant to current HLH treatments in both adult and pediatric patients. FDA approval was based on the results of a phase II\/III clinical trial evaluating the safety and efficacy of emapalumab in 34 pediatric patients with primary HLH, 27 of whom were refractory to current therapies.  Emapalumab, a fully human anti-IFN\u03b3 monoclonal antibody, has been approved in the US as second-line treatment of primary hemophagocytic lymphohistiocytosis (HLH) patients and has shown promise in patients with graft failure (GF) requiring a second allogeneic hematopoietic stem cell transplantation (HSCT). Emapalumab is a fully human immunoglobulin G1 monoclonal antibody directed against interferon-\u03b3 (IFN-\u03b3), which in November 2018 received the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to HLH therapy. Available data support the use of emapalumab for treatment of pHLH patients with refractory, recurrent or progressive disease, or intolerance to conventional therapy, recently, leading to FDA approval of the drug for these indications. Emapalumab, a monoclonal antibody directed against IFN-\u03b3, is the first target therapy approved for primary HLH with refractory, recurrent or progressive disease or intolerance to conventional therapy. RT OPINION: Emapalumab is an effective treatment for HLH with a good safety profile. Its Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis. Recently, the therapeutic potential of IFN-\u03b3 inhibition has been documented; emapalumab, an anti-IFN-\u03b3 monoclonal antibody, has been approved in the United States for treatment of primary HLH that is refractory, recurrent or progressive, or in patients with intolerance to conventional therapy. Emapalumab, a fully human anti-IFN\u03b3 monoclonal antibody, has been approved in the US as second-line treatment of primary hemophagocytic lymphohistiocytosis (HLH) patients and has shown promise in patients with graft failure (GF) requiring a second allogeneic hematopoietic stem cell transplantation (HSCT). The  role. Emapalumab, a monoclonal antibody directed against IFN-\u03b3, is the first target therapy approved for primary HLH with refractory, recurrent or progressive disease or intolerance to conventional ther Emapalumab is a fully human immunoglobulin G1 monoclonal antibody directed against interferon-\u03b3 (IFN-\u03b3), which in November 2018 received the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to HLH therapy. This Emapalumab-Igsz (Gamifant) is a human monoclonal antibody directed against interferon-\u03b3 (IFN-\u03b3), and the first Food and Drug Administration (FDA)-approved therapy for primary hemophagocytic lymphohistiocytosis (HLH). HLH , the therapeutic potential of IFN-\u03b3 inhibition has been documented; emapalumab, an anti-IFN-\u03b3 monoclonal antibody, has been approved in the United States for treatment of primary HLH that is refractory, recurrent or progressive, or in patients with intolerance to conventional therapy. Moreover, r a disorder characterized by hypercytokinemia in the setting of unbridled immune activation, and emapalumab represents the first therapeutic developed to address the underlying pathophysiology of HLH. Emapal Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis ember 2018, emapalumab received its first global approval in the USA, for the treatment of paediatric (newborn and older) and adult patients with primary HLH, who have refractory, recurrent or progressive disease or intolerance to conventional HLH therapy. Emapalumab use of emapalumab for treatment of pHLH patients with refractory, recurrent or progressive disease, or intolerance to conventional therapy, recently, leading to FDA approval of the drug for these indications. Additional data are needed to Emapalumab is approved for treatment of primary HLH that is refractory, recurrent, progressing or intolerant to current HLH treatments in both adult and pediatric patients. The novel agent, emapalumab (an anti-IFN-\u03b3 monoclonal antibody) can be used to treat EBV-HLH cases to avoid the risk of secondary malignancy due to etoposide. hogenic role. Emapalumab, a monoclonal antibody directed against IFN-\u03b3, is the first target therapy approved for primary HLH with refractory, recurrent or progressive disease or intolerance to conventional therapy.AREAS COVERED: We reviewed the pharmacological characteristics, safety, efficacy and Emapalumab is being developed by Novimmune and Swedish Orphan Biovitrum for the treatment of haemophagocytic lymphohistiocytosis (HLH). In November 2018, emapalumab received its first global approval in the USA, for the treatment of paediatric (newborn and older) and adult patients with primary HLH, who have refractory, recurrent or progressive disease or intolerance to conventional HLH therapy."}
{"id":"621fcaf93a8413c653000065","question":"What is the function of the protein encoded by PUMILIO1?","long_answer":"Pumilio is a member of the highly conserved PUF family of RNA-binding proteins that function as a developmental regulator in diverse animal species. Pumilio1 (Pum1) has been shown to play key roles in translational regulation of target mRNAs in many systems of diverse organisms.","answer":"developmental and translational regulator of RNA","context":"Human Pumilio (hPUM) is a structurally well-analyzed RNA-binding protein that has been used recently for artificial RNA binding. A family of RBPs, which is known as the Pumilio-FBF (PUF) family, is highly conserved among different species and has been associated with the undifferentiated and differentiated states of different cell lines  The RNA-binding domains of Pumilio\/fem-3 mRNA binding factors (PUF domains) are programmable RNA binding scaffolds used to engineer artificial proteins that specifically modulate RNAs Pumilio is a member of the highly conserved PUF family of RNA-binding proteins that function as a developmental regulator in diverse animal species.  Pumilio1 (Pum1) has been shown to play key roles in translational regulation of target mRNAs in many systems of diverse organisms.  Human PUMILIO1 (PUM1) and PUMILIO2 (PUM2) are members of the PUMILIO\/FBF (PUF) family that regulate specific target mRNAs posttranscriptionally. We previously showed that Pumilio1 (Pum1) is specifically involved in the translational control of cyclin B1 mRNA during Xenopus oocyte maturation, in cooperation with cytoplasmic polyadenylation element-binding protein (CPEB). Seeking to understand how post-translational modification of ATAXIN1 levels influences disease, we discovered that the RNA-binding protein PUMILIO1 (PUM1) not only directly regulates ATAXIN1 but also plays an unexpectedly important role in neuronal function. ilio-1 (PUM1) is an RNA binding protein whose regulatory role is by binding to the consensus 5'UGUANAUA3' sequence on the 3'UTR of the mRNA targets and post-transcriptionally repressing their expression. This stu ighly conserved RNA-binding protein Pumilio-1 (PUM1) regulates mouse growth and cell proliferation, propelling us to examine its role in cancer. We e previously showed that Pumilio1 (Pum1) is specifically involved in the translational control of cyclin B1 mRNA during Xenopus oocyte maturation, in cooperation with cytoplasmic polyadenylation element-binding protein (CPEB). It Pumilio is a sequence-specific RNA-binding protein that regulates translation from the relevant mRNA to understand how post-translational modification of ATAXIN1 levels influences disease, we discovered that the RNA-binding protein PUMILIO1 (PUM1) not only directly regulates ATAXIN1 but also plays an unexpectedly important role in neuronal function. Loss of P st-transcriptional repressor Pumilio-1 was identified as a potent limiter of PrPC expression through the degradation of PRNP mRNA. Because of its h Pumilio is a member of the highly conserved PUF family of RNA-binding proteins that function as a developmental regulator in diverse animal species. Mouse PUMILIO1 (PUM1) and PUMILIO2 (PUM2) belong to the PUF (Pumilio\/FBF) family, a highly conserved RNA binding protein family whose homologues play critical roles in embryonic development and germ line stem cell maintenance in invertebrates. Although the pumilio protein regulates the reproductive organ development in many species, its role in Schistosoma japonicum is unknown. Two Pumilio genes, Pum1 and Pum2, have been identified in mammals and are found to be involved in sperm development, neuron development as well as human diseases such as neurodegeneration. These data show that Pumilio1 can be used as a scaffold to engineer RNA-binding proteins with designed sequence specificity. To understand the role of these proteins in human ESCs (hESCs), we first assessed the influence of the silencing of PUM1 and PUM2 on pluripotency genes and found that the knockdown of Pumilio genes significantly decreased the OCT4 and NANOG mRNA levels and reduced the amount of nuclear OCT4, which suggests that Pumilio proteins play a role in the maintenance of pluripotency in hESCs."}
{"id":"6028f5851cb411341a0000ff","question":"What is the prevalence of the inactivating AKT variant p.Pro50Thr in the Finnish population?","long_answer":"A study identified a novel association between the coding variant (p.Pro50Thr) in AKT2 and fasting plasma insulin (FI), a gene in which rare fully penetrant mutations are causal for monogenic glycemic disorders. The low-frequency allele is associated with a 12% increase in FI levels. This variant is present at 1.1% frequency in Finns but virtually absent in individuals from other ancestries. Carriers of the FI-increasing allele had increased 2-h insulin values, decreased insulin sensitivity, and increased risk of type 2 diabetes (odds ratio 1.05). In cellular studies, the AKT2-Thr50 protein exhibited a partial loss of function.","answer":"1.1%","context":"To identify novel coding association signals and facilitate characterization of mechanisms influencing glycemic traits and type 2 diabetes risk, we analyzed 109,215 variants derived from exome array genotyping together with an additional 390,225 variants from exome sequence in up to 39,339 normoglycemic individuals from five ancestry groups. We identified a novel association between the coding variant (p.Pro50Thr) in AKT2 and fasting plasma insulin (FI), a gene in which rare fully penetrant mutations are causal for monogenic glycemic disorders. The low-frequency allele is associated with a 12% increase in FI levels. This variant is present at 1.1% frequency in Finns but virtually absent in individuals from other ancestries. Carriers of the FI-increasing allele had increased 2-h insulin values, decreased insulin sensitivity, and increased risk of type 2 diabetes (odds ratio 1.05). In cellular studies, the AKT2-Thr50 protein exhibited a partial loss of function. We extend the allelic spectrum for coding variants in AKT2 associated with disorders of glucose homeostasis and demonstrate bidirectional effects of variants within the pleckstrin homology domain of AKT2."}
{"id":"621ec0313a8413c65300005e","question":"What class of drugs is commonly associated with Drug-induced interstitial lung disease (DIILD)?","long_answer":"Cytotoxic drugs are the most common cause of toxic lung disease.","answer":"cytotoxic drugs","context":"The problem of the drug induced pulmonary toxicity (cytotoxic and non-cytotoxic drugs) is discussed. ulmonary drug toxicity is increasingly being diagnosed as a cause of acute and chronic lung disease. Numerous agents including cytotoxic and noncytotoxic drugs have the potential to cause pulmonary toxicity Cytotoxic agents may cause interstitial or eosinophilic pneumonitis, alveolar proteinosis, pulmonary venous occlusive disease, pulmonary fibrosis, pneumothorax, or pulmonary oedema The cytotoxic drugs which are most often implicated in causing this are bleomycin, methotrexate, cyclophosphamide and busulfan.  Cytotoxic drugs are the most common cause of toxic lung disease. er drugs, followed by rheumatology drugs, amiodarone and antibiotics, were the most common causes of DIILD. The Drug-induced interstitial lung disease (DIILD) is a serious side effect of chemotherapy in cancer patients with an extremely high mortality rate. Furthermore, in a subgroup analysis of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-induced interstitial lung disease (ILD), we observed seven candidate SNVs that were possibly associated with ILD (P < 0.00001). Drug-induced interstitial lung disease (DI-ILD) is a rare, yet life-threatening complication associated with tyrosine-kinase inhibitor (TKI) therapy. Thi Drug-induced interstitial lung disease associated with dasatinib coinciding with active tuberculosis s was added. It is known that drug-induced ILD and susceptibility to infection associated with dasatinib occur in a dose-dep INTRODUCTION: The study objective was to determine the incidence and characteristics of drug-induced interstitial lung disease (ILD) associated with an orally available small-molecule tyrosine kinase inhibitor, crizotinib, in a real-world clinic INTRODUCTION: Although gefitinib used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease (ILD), few case reports on erlotinib-induced ILD have Drug-induced interstitial lung disease (DILD) can be caused by chemotherapeutic agents, antibiotics, antiarrhythmic drugs, and immunosuppressive agents. INTRODUCTION: A rare but serious complication of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy is a lung injury syndrome commonly referred to as a drug-induced interstitial lung  BACKGROUND: Treatment of rheumatoid arthritis (RA)-related interstitial lung disease (ILD) is challenging, and many conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) have been associated with ILD development or  OBJECTIVE: To review published cases of induced or exacerbated interstitial lung disease (ILD) in rheumatoid arthritis (RA) associated with non-biologic disease-modifying antirheumatic drugs (nbDMARDs) and biologics and to discuss clinical implications in daily practice.METHODS: We performed a systematic literature review from 1975 to July 2013 using Medline, Embase, Cochrane, and abstracts from the ACR 2010-2012 and EULAR 2010-2 13 annual meetings. Case reports and series that suggest a causative role of nbDMARDs (methotrexate [MTX], leflunomide [LEF], gold, azathioprine [AZA], sulfasalazine [SSZ], and hydroxychloroquine [HCQ]) and biologic agents (TNF inhibitors [TNFi], rituximab [RTX], tocilizumab [TCZ], abatacept [ABA], and anakinra) in causing ILD or worsening a pre-existing ILD in RA pat Drugs that are more commonly associated with lung toxicity include nitrofurantoin, amiodarone, and chemotherapeutic agents such as bleomycin and methotrexate. Drug-induced interstitial lung disease (D-ILD) can be caused by various drugs, including antibiotics, amiodarone, antitumor, rheumatological and non-steroidal anti-inflammatory drugs."}
{"id":"6206b399c9dfcb9c09000039","question":"What pathological phenotype could potentially concomitant pomegranate juice and rosuvastatin use cause?","long_answer":"Concomitant use of rosuvastatin and pomegranate juice has been hypothesized to be associated with the development of rhabdomyolysis in a case report.","answer":"Rhabdomyolysis","context":"In conclusion, because both grapefruit and pomegranate juice are known to inhibit intestinal cytochrome P450 3A4, this report suggests that pomegranate juice may increase the risk of rhabdomyolysis during rosuvastatin treatment, despite the fact that rosuvastatin is not known to be metabolized by hepatic P450 3A4."}
{"id":"621911323a8413c653000038","question":"Which tool has been developed to discover VNTR-associated deletions?","long_answer":"\u03a4rfermikit is a software tool designed to detect deletions larger than 50\u2009bp occurring in Variable Number Tandem Repeats (VNTRs) using Illumina DNA sequencing reads. In such regions, it achieves a better trade-off between sensitivity and false discovery than a state-of-the-art structural variation (SV) caller, Manta, and complements it by recovering a significant number of deletions that Manta missed. trfermikit is based upon the fermikit pipeline, which performs read assembly, maps the assembly to the reference genome, and calls variants from the alignment.","answer":"trfermikit","context":"trfermikit: a tool to discover VNTR-associated deletions. We present trfermikit, a software tool designed to detect deletions larger than 50\u2009bp occurring in Variable Number Tandem Repeats (VNTRs) using Illumina DNA sequencing reads. In such regions, it achieves a better trade-off between sensitivity and false discovery than a state-of-the-art structural variation (SV) caller, Manta, and complements it by recovering a significant number of deletions that Manta missed. trfermikit is based upon the fermikit pipeline, which performs read assembly, maps the assembly to the reference genome, and calls variants from the alignment. RESULTS: We present trfermikit, a software tool designed to detect deletions larger than 50\u2009bp occurring in Variable Number Tandem Repeats (VNTRs) using Illumina DNA sequencing reads. RESULTS: We present trfermikit, a software tool designed to detect deletions larger than 50\u2009bp occurring in Variable Number Tandem Repeats (VNTRs) using Illumina DNA sequencing trfermikit is based upon the fermikit pipeline, which performs read assembly, maps the assembly to the reference genome, and calls variants from the alignment.AV RESULTS: We present trfermikit, a software tool designed to detect deletions larger than 50\u2009bp occurring in Variable Number Tandem Repeats (VNTRs) using Illumina DNA sequenci"}
{"id":"6020a8431cb411341a00007f","question":"Which CD38 antibody has been shown to be effective for Lupus Erythematosus?","long_answer":"Daratumumab, a human monoclonal antibody that targets CD38, has been used to treat Lupus Erythematosus.","answer":"Daratumumab","context":"Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. Daratumumab, a human monoclonal antibody that targets CD38, depletes plasma cells and is approved for the treatment of multiple myeloma. Long-lived plasma cells are implicated in the pathogenesis of systemic lupus erythematosus because they secrete autoantibodies, but they are unresponsive to standard immunosuppression. We describe the use of daratumumab that induced substantial clinical responses in two patients with life-threatening lupus, with the clinical responses sustained by maintenance therapy with belimumab, an antibody to B-cell activating factor.  This study was undertaken to evaluate the potential of targeting CD38 as a plasma cell\/plasmablast depletion mechanism by daratumumab in the treatment of patients with RA and SLE. CONCLUSION: These results indicate that CD38 may be a potential target for RA disease interception and daratumumab should be evaluated clinically for the treatment of both RA and SLE. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus addition, ligation of SLAMF7 with elotuzumab or of CD38 with daratumumab on SLE NK cells enhanced degranulation of both healthy and SLE NK cells and primed them to kill circulating plasma cells in an in vitro co-culture  In addition, ligation of SLAMF7 with elotuzumab or of CD38 with daratumumab on SLE NK cells enhanced degranulation of both healthy and SLE NK cells and primed them to kill circulating plasma cells in an in vitro co-culture system.  from patients with early RA. Most importantly, our data show for the first time that daratumumab effectively depletes plasma cells\/plasmablasts in PBMC from patients with SLE and RA in a dose-dependent manner ex vivo.CONCLUSION: These results indicate that CD38 may be a potential target for RA disease interception and daratumumab should be evaluated clinic osus (SLE). This study was undertaken to evaluate the potential of targeting CD38 as a plasma cell\/plasmablast depletion mechanism by daratumumab in the treatment of patients with RA and SLE.METHODS: RNA-sequencing analysis of synovial biopsies from various stages of RA disease progression, flow cytometry analysis of peripheral blood mononuclear cells (PBMC) from patients with RA or SLE and healthy donors, immunohistochemistry assessment (IHC) of synovial biopsies from patients with early RA, and ex vivo immune cell depletion assays using daratumumab (an anti-CD38 monoclonal antibody) were used to assess CD38 as a therapeutic target.RESULTS: We demonstrated that the plasma cell\/plasmablast-related genes CD38, XBP1, IRF4, PRDM1, IGJ and TNFSF13B are significantly up-regulated in synovial biopsies from patients with arthralgia, undifferentiated arthritis (UA), early RA and established RA as compared to healthy controls and control"}
{"id":"60853db94e6a4cf630000010","question":"What is a circRNA?","long_answer":"Circular RNAs (circRNAs) are a new class of non-coding RNA with a stable structure formed by special loop splicing.","answer":"Circular RNAs (circRNAs) are a new class of non-coding RNA with a stable structure formed by special loop splicing.","context":"Circular RNAs (circRNAs) are a new class of non-coding RNA with a stable structure formed by special loop splicing. Circular RNAs (circRNA) have been reported as regulators involved in hepatocellular carcinoma (HCC), but their mechanism of activity remains unknown.  Recent technological advances in RNA sequencing and analysis have allowed an increasingly thorough investigation of a previously unexplored class of transcripts, circular (circ)RNAs. Accumulating evidence suggests that circRNAs have unique functions which often rely on their association with microRNAs and RNA-binding proteins. Through these interactions, circRNAs have been implicated in major cellular processes and hence in the pathophysiology of a range of diseases. "}
{"id":"6211454a3a8413c65300000b","question":"Which one of the CYP450 enzymes is the second most frequently implicated in the metabolism of the drugs currently available on the market?","long_answer":"CYP3A4 and CYP2D6 are the most relevant since they metabolize about 50% and 30% of the drugs on the market, respectively.","answer":"CYP2D6","context":"Among CYP enzymes, CYP3A4 and CYP2D6 are the most relevant since they metabolize about 50% and 30% of the drugs on the market, respectively."}
{"id":"603534671cb411341a000153","question":"What is the msDNA?","long_answer":"msDNA is actually a complex of DNA, RNA, and probably protein. It is composed of a small, single-stranded DNA, linked to a small, single-stranded RNA molecule. The 5' end of the DNA molecule is joined to an internal guanosine residue of the RNA molecule by a unique 2'-5' phosphodiester bond. msDNA is produced in many hundreds of copies per cell, but its function remains unknown.","answer":"msDNA is actually a complex of DNA, RNA, and probably protein.","context":" msDNA is actually a complex of DNA, RNA, and probably protein. It is composed of a small, single-stranded DNA, linked to a small, single-stranded RNA molecule. The 5' end of the DNA molecule is joined to an internal guanosine residue of the RNA molecule by a unique 2'-5' phosphodiester bond. msDNA is produced in many hundreds of copies per cell, but its function remains unknown.  Retron is a prokaryotic genetic element that produces multicopy single-stranded DNA covalently linked to RNA (msDNA) by a reverse transcriptase. msDNAs are small, structurally unique satellite DNAs found in a number of Gram-negative bacteria. Composed of hundreds of copies of single-stranded DNA--hence the name multicopy single-stranded DNA--msDNA is actually a complex of DNA, RNA, and probably protein.  The multi-copy single-stranded DNA (msDNA) is yielded by the action of reverse transcriptase of retro-element in a wide range of pathogenic bacteria Multi-copy single-stranded DNA (msDNA) is composed of covalently bound single-stranded DNA and RNA, and synthesized by retron-encoded reverse transcriptase. "}
{"id":"621142713a8413c65300000a","question":"What percentage of currently available drugs are metabolized by CYP3A4?","long_answer":"CYP3A4 metabolizes approximately 50% of the drugs available today on the market.","answer":"50%","context":"Among CYP enzymes, CYP3A4 and CYP2D6 are the most relevant since they metabolize about 50% and 30% of the drugs on the market, respectively. "}
{"id":"61f810a5882a024a1000003e","question":"What is caused by bi-allelic loss-of-function variants in IPO8?","long_answer":"Bi-allelic loss-of-function variants in IPO8 cause a syndromic form of thoracic aortic aneurysm (TAA) with clinical overlap with Loeys-Dietz and Shprintzen-Goldberg syndromes.","answer":"A syndromic form of thoracic aortic aneurysm (TAA) with clinical overlap with Loeys-Dietz and Shprintzen-Goldberg syndromes","context":"A human importin-\u03b2-related disorder: Syndromic thoracic aortic aneurysm caused by bi-allelic loss-of-function variants in IPO8. Importin 8, encoded by IPO8, is a ubiquitously expressed member of the importin-\u03b2 protein family that translocates cargo molecules such as proteins, RNAs, and ribonucleoprotein complexes into the nucleus in a RanGTP-dependent manner. Current knowledge of the cargoes of importin 8 is limited, but TGF-\u03b2 signaling components such as SMAD1-4 have been suggested to be among them. Here, we report that bi-allelic loss-of-function variants in IPO8 cause a syndromic form of thoracic aortic aneurysm (TAA) with clinical overlap with Loeys-Dietz and Shprintzen-Goldberg syndromes."}
{"id":"6056fef294d57fd87900001f","question":"Which glands in the bee secretes royal jelly?","long_answer":"hypopharyngeal glands","answer":"hypopharyngeal glands","context":"The hypopharyngeal glands (HGs) of honey bee nurse workers secrete the major protein fraction of jelly, a protein and lipid rich substance fed to developing larvae, other worker bees, and queens. The first MRJP was identified in royal jelly, a secretion of the bees' hypopharyngeal glands that is used by young worker bees, called nurses, to feed developing larvae The nurse hypopharyngeal glands produce the protein fraction of the worker and royal jelly that is fed to developing larvae and queens. The hypopharyngeal glands (HPGs) of worker honeybees undergo physiological changes along with the age-dependent role change from nursing to foraging: nurse bee HPGs secrete mainly major royal jelly proteins, whereas forager HPGs secrete mainly \u03b1-glucosidase III, which converts the sucrose in the nectar into glucose and fructose."}
{"id":"621145c63a8413c65300000c","question":"When did FDA approve the first B-cell maturation antigen-targeted CAR-T cell therapy?","long_answer":"FDA approved the first B-cell maturation antigen-targeted CAR-T cell therapy on March 26, 2021.","answer":"26 March 2021","context":"The most recent US Food and Drug Administration approval of the first B-cell maturation antigen-targeted CAR-T cell therapy on March 26, 2021, has paved a path forward for the eventual evaluation of more of these investigational agents undergoing clinical trials."}
{"id":"6049173d1cb411341a00016b","question":"When is the drug Ivermectin used?","long_answer":"Ivermectin (IVM) has been well known for its role in the treatment of parasitic diseases, due to its effect on glutamate-gated chloride channels. These same channels are also present in the mosquito vector, and thus, research has focused on the insecticidal effects of this drug.","answer":"Ivermectin is used to treat parasitic diseases","context":"The aim of this study was to compare the economic revenue related to the use of low- or high-efficacy anthelmintic drugs within suppressive or strategic schemes of treatment in growing heifers. Heifers raised in a semi-intensive grazing system in southern Brazil were used. Levamisole and ivermectin were selected as the high- and the low-efficacy drugs, respectively, based on a previous efficacy test. Ivermectin (IVM) has been well known for its role in the treatment of parasitic diseases, due to its effect on glutamate-gated chloride channels. These same channels are also present in the mosquito vector, and thus, research has focused on the insecticidal effects of this drug.  Ivermectin is safe and widely used for treating helminth infections. It also kills arthropods feeding on treated subjects, including malaria vectors. "}
{"id":"6206b740c9dfcb9c0900003b","question":"What is the effect of rHDL-apoE3 on vascular permeability?","long_answer":"rHDL-apoE3 markedly improves vascular permeability as demonstrated by the reduced concentration of Evans Blue dye in tissues such as the stomach, the tongue and the urinary bladder and ameliorated hypercholesterolemia.","answer":"Improves","context":"Finally, administration of a single dose of rHDL-apoE3 in apoE KO mice markedly improved vascular permeability as demonstrated by the reduced concentration of Evans Blue dye in tissues such as the stomach, the tongue and the urinary bladder and ameliorated hypercholesterolemia.CONCLUSIONS: rHDL-apoE3 significantly enhanced EC migration in vitro, predominantly via overexpression of ID1 and subsequent activation of MEK1\/2 and PI3K, and their downstream targets ERK1\/2, AKT and p38 MAPK, respectively and improved vascular permeability in vivo. "}
{"id":"6217bf6a3a8413c65300001d","question":"What is inhibited by TH1579?","long_answer":"TH1579 is a best-in-class MTH1 inhibitor.","answer":"MTH1","context":"Previously, we showed cancer cells rely on the MTH1 protein to prevent incorporation of otherwise deadly oxidised nucleotides into DNA and we developed MTH1 inhibitors which selectively kill cancer cells. Recently, several new and potent inhibitors of MTH1 were demonstrated to be non-toxic to cancer cells, challenging the utility of MTH1 inhibition as a target for cancer treatment We demonstrate that in order to kill cancer cells MTH1 inhibitors must also introduce oxidized nucleotides into DNA. Furthermore, we describe TH1579 as a best-in-class MTH1 inhibitor, which we expect to be useful in order to further validate the MTH1 inhibitor concept."}
{"id":"606b32af94d57fd879000060","question":"What is the Versene Solution used for?","long_answer":"the Versene Solution is used for the detachment of stem cell sheets.","answer":"for the detachment of cells","context":" in 0.01 versene solution, containing 0.011% w\/v trypsin (Difco), 0.4 mg\/ml D-glucose, 0.17 mg\/ml KCl, 1.7 mg\/ml NaCl.  stem cell sheets detached by Versene solution  The object of study was follicular thyroid carcinoma cells suspension prepared with use of Versene solution and 0.25% trypsin solution."}
{"id":"621ebb733a8413c65300005c","question":"What is the indication for Favipiravir?","long_answer":"Favipiravir (FVP) has been used for treatment of COVID-19 in many countries.","answer":"Covid-19","context":". In the COVID-19 era, there has been a race for drugs to be effective against SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antivirals against virus  key repurposed drugs advocated to treat COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir and favipiravir),  : To compare the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19 patients Favipiravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19 treatments Favipiravir (FVP) has been used for treatment of COVID-19 in many countries.  To assess the efficacy of Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection. Favipiravir versus standard of care in patients with severe COVID-19 infections Favipiravir and Molnupiravir, orally available antivirals, have been reported to exert antiviral activity against SARS-CoV-2.  Molnupiravir\/Favipiravir in the treatment of COVID-19. Favipiravir, indicated for the treatment of new and re-emerging influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not yet fully validated. Comparing ICU admission rates of mild\/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir. We herein report the first case of a fever induced by favipiravir, a potential coronavirus disease 2019 therapeutic drug. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A\/California\/04\/2009 (H1N1) virus infections in mice. BACKGROUND: Favipiravir possesses high utility for treating patients with COVID-19. Favipiravir is active against a broad range of influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus. Favipiravir is approved in Japan for the treatment of influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with demonstrated efficacy in the type I interferon deficient mouse model. Favipiravir, an antiviral drug, is being used for COVID-19 treatment, and we currently have limited information regarding its efficacy and safety. Favipiravir is one such oral drug that was approved for new and reemerging pandemic influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-2. Favipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19. avipiravir, a novel antiviral drug which was mainly used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection. I  so far. Favipiravir is a repurposed antiviral agent in treatment of SARS-CoV-2 infection, and to meet the current need, pharmaceutical companies are working for manufacturing licensed generic favi  demonstrate that Favipiravir [T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus] inhibits in vitro murine norovirus replication. Tim The combination therapy of Lopinavir\/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19 vir, Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19. Recent Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study. AIM: Favipiravir and oseltamivir are antiviral compounds used for the treatment of influenza infec WHAT IS KNOWN AND OBJECTIVE: Favipiravir is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19) Favipiravir is expected to be an important therapeutic agent for severe influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available. Favipiravir, also known as T-705, is an antiviral drug that has been approved in 2014 in Japan to treat pandemic influenza virus infections. Favipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. With its unique mechanism of action and broad range of antiviral activity, favipiravir is a promising drug candidate for influenza and many other RNA viral diseases for which there are no approved therapies. Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza drug in Japan. Of note is that favipiravir shows anti-viral activities against other RNA viruses such as arenaviruses, bunyaviruses and filoviruses, all of which are known to cause fatal hemorrhagic fever. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections."}
{"id":"61f56284882a024a10000005","question":"Which syndrome is caused by pathogenic COL4A3-COL4A5 variants?","long_answer":"Massively parallel sequencing identifies pathogenic variants in the genes affected in Alport syndrome (COL4A3-COL4A5) in as many as 30% of individuals with focal and segmental glomerulosclerosis (FSGS), 10% of those with kidney failure of unknown cause, and 20% with familial immunoglobulin A (IgA) glomerulonephritis.","answer":"Alport syndrome","context":"Pathogenic Variants in the Genes Affected in Alport Syndrome (COL4A3-COL4A5) and Their Association With Other Kidney Conditions: A Review Massively parallel sequencing identifies pathogenic variants in the genes affected in Alport syndrome (COL4A3-COL4A5) in as many as 30% of individuals with focal and segmental glomerulosclerosis (FSGS), 10% of those with kidney failure of unknown cause, and 20% with familial immunoglobulin A (IgA) glomerulonephritis. The population frequencies for Alport syndrome are suggested by the frequencies of predicted pathogenic COL4A3-COL4A5 variants, but must be adjusted for the disease penetrance of individual variants and for the likelihood of already diagnosed disease and non-Gly substitutions. Disease penetrance may depend on other genetic and environmental factors. Massively parallel sequencing identifies pathogenic variants in the genes affected in Alport syndrome (COL4A3-COL4A5) in as many as 30% of individuals with focal and segmental glomerulosclerosis (FSGS), 10% of those with kidney failure of unknown cause, and 20% with familial immunoglobulin A (IgA) glomerulonephritis. FSGS ass"}
{"id":"61f52f22882a024a10000002","question":"Which disease do pathogenic NR2F1 variants cause?","long_answer":"Bosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS) is an autosomal-dominant disorder characterized by optic atrophy and intellectual disability caused by loss-of-function mutations in NR2F1.","answer":"Bosch-Boonstra-Schaaf optic atrophy syndrome","context":"Bosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS) is an autosomal-dominant disorder characterized by optic atrophy and intellectual disability caused by loss-of-function mutations in NR2F1."}
{"id":"6020b5681cb411341a000088","question":"Which mutation is targeted by Tepotinib?","long_answer":"MET Exon 14 Skipping Mutation is targeted by Tepotinib that is used for patients with non-small-cell lung cancer.","answer":"MET Exon 14 Skipping Mutation","context":"BACKGROUND: A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population. CONCLUSIONS: Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations. If type I MET inhibitors (crizotinib, capmatinib, tepotinib, savolitinib) drug resistance is developed, type II MET inhibitors (cabozantinib, glesatinib, merestinib) can be considered. Drugs targeting MET 14 exon skipping mutation bring new hope to patients. MET inhibitors that are currently on the market or are about to be marketed include: crizotinib, cabozantinib, savolitinib and tepotinib. At least five MET-targeted TKIs, including crizotinib, cabozantinib, capmatinib, tepotinib, and glesatinib, are being investigated clinically for patients with MET exon 14 altered-NSCLC.  Tepotinib hydrochloride is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations. hibitors for MET exon 14 skipping mutation such as capmatinib and tepotinib have elucidated their effectiveness. Only a few reports have suggested their efficacy ag Tepotinib is an oral MET inhibitor approved for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. ET exon 14 skipping mutation and poor performance status salvaged by marked leptomeningeal metastases response to tepotinib. We further provide measures of plasma\/cerebrospinal fluid concentrations of t Tepotinib is a key drug for cancer patients with mesenchymal-epithelial transition receptor tyrosine kinase proto-oncogene (MET) exon 14 skipping mutation. Herein, we report a case of a patient with metastatic lung adenocarcinoma harboring a MET exon 14 splice site mutation who has had prolonged disease control by a second-generation MET-TKI tepotinib. A 66-yr-old man was diagn Recently, in METex14-mutated NSCLC, multitarget tyrosine kinase inhibitors (TKIs), such as crizotinib and cabozantinib, as well as MET-selective TKIs, such as tepotinib and capmatinib, have demonstrated durable responses. Tepotinib is an oral MET inhibitor approved for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. Ex (NSCLC). The MET inhibitor tepotinib has demonstrated clinical efficacy in patients with MET exon 14 skipp ification (~14%). In 2020, the approval of two MET-tyrosine kinase inhibitors (TKIs), capmatinib and tepotinib, for NSCLCs carrying MET\u2206ex14 dawned a new era for ME Recently approved and highly specific small-molecule inhibitors of c-MET exon 14 skipping mutations (e.g., capmatinib, tepotinib) are a new and important therapeutic option for the treatment of non-small cell lung cancer (NSCLC) patients harbouring c-MET alterations. Seve , in METex14-mutated NSCLC, multitarget tyrosine kinase inhibitors (TKIs), such as crizotinib and cabozantinib, as well as MET-selective TKIs, such as tepotinib and capmatinib, have demonstrated durable responses. In this study tudies reported that NSCLC patients harboring a METex14del responded well to MET-tyrosine kinase inhibitors (TKIs), including tepotinib. Tepotinib  rgeted TKIs, including crizotinib, cabozantinib, capmatinib, tepotinib, and glesatinib, are being investigated clinically for patients with MET exon 14 altered-NSCLC. A further two compounds  Tepotinib is a key drug for cancer patients with mesenchymal-epithelial transition receptor tyrosine kinase proto-oncogene (MET) exon 14 skipping mutation.  . Several tyrosine kinase inhibitors for MET exon 14 skipping mutation such as capmatinib and tepotinib have elucidated their effect Tepotinib at this dose has obtained regulatory approval for the treatment of patients with non-small cell lung cancer harboring MET exon 14 skipping. Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation. Examining treatment-naive or tepotinib-resistant cells with MET amplification or METex14 skipping mutations identifies other receptor tyrosine kinases (RTKs) that co-exist in cells prior to tepotinib exposure and become more prominent upon tepotinib resistance."}
{"id":"602354e41cb411341a000098","question":"Nemolizumab has been shown to be effective for which disease?","long_answer":"Nemolizumab has been shown to be effective for atopic dermatitis.","answer":"atopic dermatitis","context":"Dupilumab, lebrikizumab, and nemolizumab demonstrate efficacy as agents producing improvement in clinical severity and pruritus. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. CONCLUSIONS: Nemolizumab resulted in rapid and sustained improvements in cutaneous signs of inflammation and pruritus in patients with AD, with maximal efficacy observed at 30\u00a0mg.  Lebrikizumab, tralokinumab, fezakinumab, nemolizumab, and GBR 830 lead to statistically significant improvements in disease severity and multiple endpoint outcome scores.  Tralokinumab, lebrikizumab, fezakinumab, nemolizumab, and GBR 830 are effective treatment options for adults with moderate-to-severe AD, but further large-scale studies are needed to confirm their efficacy as monotherapy in children with moderate-to-severe AD. CONCLUSIONS: Nemolizumab resulted in a greater reduction in pruritus and severity of skin lesions than placebo in patients with prurigo nodularis but was associated with adverse events. Larger and longer trials are needed to determine the durability and safety of nemolizumab for the treatment of prurigo nodularis. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis. CONCLUSIONS: In this 16-week trial, the use of subcutaneous nemolizumab in addition to topical agents for atopic dermatitis resulted in a greater reduction in pruritus than placebo plus topical agents.  Recent clinical trials have shown that the anti-IL-31RA antibody nemolizumab can successfully decrease pruritus in patients with atopic dermatitis and prurigo nodularis. Tralokinumab, lebrikizumab, and nemolizumab have also been confirmed to have significant efficacy against AD in phase III or IIb clinical trials. s showed nemolizumab could be another alternative therapy for moderate-to-severe AD with long-term efficiency and safety.CONCLU Nemolizumab is a humanized anti-interleukin-31 receptor A monoclonal antibody for treating atopic dermatitis, and it especially improves pruritus. ecently, Interleukin (IL)-31 and its receptor complex attracted significant interest, as clinical phase two studies demonstrated therapeutic efficacy of the neutralizing IL-31 receptor A (IL-31RA) antibody nemolizumab in patients suffering from atopic dermatitis or prurigo nodularis. IL-3 cal trials have shown that the anti-IL-31RA antibody nemolizumab can successfully decrease pruritus in patients with atopic dermatitis and prurigo nodularis. The IL-31  BACKGROUND: Nemolizumab, an anti-IL-31 receptor A\u00a0mAb, improved pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments in a phase II, 12-week, randomized, double-blind, placebo-controlled study (part A; NCT01986 ritus. Nemolizumab, a humanized monoclonal antibody against IL-31 receptor A, reduced pruritus in patients with AD after a 16-week administration p and nemolizumab have also been confirmed to have significant efficacy against AD in phase III or IIb clinical trials. Also, fezakinumab was effect n pruritus. Nemolizumab, a humanized monoclonal antibody against IL-31 receptor A, reduced pruritus in patients with AD after a 16-week administration period.OBJECTIVE: To examine the long-term effectiveness and safety of nemolizumab in patients aged \u226513 years with AD and inadequately controlled moderate-to-severe pruritus.METHODS: In two long-term phase III studies, nemolizumab 60 mg every 4 weeks (Q4W) was administered subcutaneously, concom BACKGROUND: Nemolizumab is a humanized anti-IL-31 receptor blocker in phase 3 for atopic dermatitis (AD).OBJECTIVE: Analyse onset of action of nemolizumab 30\u00a0mg and compare efficacy and safety vs placebo (SC q4wk plus loading dose) in moderate-to-severe AD.METHODS: Post hoc analysis of patients with Eczema Area and Severity Index (EASI) scores\u00a0\u2265\u00a016 from a phase 2b BACKGROUND: Nemolizumab, an anti-IL-31 receptor A\u00a0mAb, improved pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments in a phase II, 12-week, randomized, double-blind, placebo-controlled study (part A; NCT01986933).OBJECTIVE: We sought to assess the long-term efficacy and safety of nemolizumab injected subcutaneously every 4\u00a0weeks (Q4W) or every 8\u00a0weeks (Q8W) in a 52-week, double-blind extension (part B).METHODS: During part B, patients continued the previous nemolizumab dose (0.1, 0.5, or  d pruritus. We wanted to assess the efficacy and safety of nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A, in the treatment of atopic dermatitis.METHODS: In this phase 2, randomized, double-blind, placebo-controlled, 12-week trial, we assigned adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments to receive subcutaneous nemolizumab (at a dose of 0.1 mg, 0.5 mg, or 2.0 mg per kilogram of body weight) or placebo every 4 weeks or an exploratory dose of 2.0 mg of nemolizumab per ki BACKGROUND: Nemolizumab targets the IL-31 receptor \u03b1 subunit involved in atopic dermatitis (AD) pathogenesis.OBJECTIVE: We sought to evaluate a new dosing strategy of nemolizumab in patients with AD.METHODS: We performed a 24-week, randomized, double-blind, multicenter study of nemolizumab (10, 30, and 90\u00a0mg) subcutaneous injections every 4\u00a0weeks versus placebo, with topical corticosteroids in adults with moderate-to-severe AD, severe pruritus, and inadequate control w dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis.METHODS: In a 16-week, double-blind, phase 3 trial, we randomly assigned Japanese patients with atopic dermatitis and moderate-to-severe pruritus and an inadequate response to topical agents in a 2:1 ratio to receive subcutaneous nemolizumab (60 mg) or placebo every 4 weeks until week 16, with concom Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI\u00a0\u2265\u00a016) analysis of randomized phase 2B study. Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68\u00a0weeks: results from two phase III, long-term studies. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study.  maintained during the follow-up period. The long-term safety profile was consistent with previous studies, with no unexpected late-onset adverse events.CONCLUSIONS: Nemolizumab 60 mg Q4W with concomitant topical treatments in patients with AD and inadequately controlled moderate-to-severe pruritus produced a continuous improvement in pruritus, signs of AD, and quality of life"}
{"id":"603bc3181cb411341a00015c","question":"What is the mammalian version of arginine vasotocin?","long_answer":"Arginine vasopressin (AVP) is the mammalian homolog of arginine vasotocin (AVT).","answer":"Arginine vasopressin (AVP)","context":" Conopressin-T belongs to the vasopressin-like peptide family and displays high sequence homology to the mammalian hormone oxytocin (OT) and to vasotocin, the endogenous vasopressin analogue found in teleost fish, the cone snail's prey In particular, arginine vasopressin and its non-mammalian homolog, arginine vasotocin (AVT), have been implicated in regulating affiliative, reproductive, and aggressive behavior in many vertebrate species. Arginine vasotocin (AVT) is the non-mammalian homolog of arginine vasopressin (AVP) The nonapeptides isotocin (IT) and arginine vasotocin (AVT), along with their mammalian homologs oxytocin and arginine vasopressin, are well known regulators of social behaviors across vertebrate taxa. The avian homologs of arginine vasopressin (AVP) and oxytocin (OT) are arginine vasotocin (AVT) and mesotocin (MT), respectively. The neurohypophysial peptide arginine vasotocin, and its mammalian ortholog arginine vasopressin, influence a wide range of physiological and behavioral responses, including aspects of sexual and social behaviors, osmoregulation, stress response, metabolism, blood pressure, and circadian rhythms. Here,  ic neuropeptide arginine-vasotocin (AVT) and its mammalian homologue, arginine- vasopressin (AVP) are key modulators of social behavior across vertebrates. In this study, we  The nonapeptide arginine vasotocin (AVT) and its mammalian homologue arginine vasopressin are well known for their role in the modulation of several intraspecific social behaviours, such as social approach\/withdrawal and aggression. R The neuropeptide arginine vasotocin (AVT; non-mammals) and its mammalian homologue, arginine vasopressin (AVP) influence a variety of sex-typical and species-specific behaviors, and provide an integrational neural substrate for the dynamic modulation of those behaviors by endocrine and sensory stimuli. Alth The nonapeptide arginine vasotocin (AVT) and its mammalian homologue arginine vasopressin play a key role in the regulation of social behaviour across vertebrates.  The neuropeptide arginine vasotocin (AVT) and its mammalian homologue arginine vasopressin (AVP) are neuromodulators known to be steroid sensitive and associated with social behaviors in a number of vertebrate taxa. Ho Arginine vasotocin (VT), and its mammalian homologue arginine vasopressin (VP), are neuropeptides involved in the regulation of social behaviors and stress responsiveness. Pr Arginine vasotocin (AVT) and its mammalian homologue, arginine vasopressin (AVP), regulate a variety of social and reproductive behaviors, often with complex species-, sex- and context-dependent effects. Despit Among adult mammals arginine-vasotocin is replaced by arginine-vasopressin which has much less oxytocin activity. Arginine vasotocin (AVT) is the non-mammalian homolog of arginine vasopressin (AVP) and, like vasopressin, serves as an important modulator of social behavior in addition to its peripheral functions related to osmoregulation, reproductive physiology, and stress hormone release. Arginine vasotocin (VT), and its mammalian homologue arginine vasopressin (VP), are neuropeptides involved in the regulation of social behaviors and stress responsiveness. Arginine vasotocin (AVT) and its mammalian homologue, arginine vasopressin (AVP), regulate a variety of social and reproductive behaviors, often with complex species-, sex- and context-dependent effects. Arginine vasotocin (AVT) and the mammalian homologue, arginine vasopressin (AVP), modulate vertebrate social behaviors, including vocalizations in male anurans. The nonapeptide arginine vasotocin (AVT) and its mammalian homologue arginine vasopressin are well known for their role in the modulation of several intraspecific social behaviours, such as social approach\/withdrawal and aggression. Arginine vasotocin (AVT) and its mammalian homologoue arginine vasopressin (AVP) influence male sexual and aggressive behaviors in many species. Here we provide the first empirical evidence that arginine vasotocin (AVT), a non-mammalian homologue of arginine vasopressin (AVP), plays a critical role as moderator of interspecific behaviour in the best studied and ubiquitous marine cleaning mutualism involving the Indo-Pacific bluestreak cleaner wrasse Labroides dimidiatus. The neurohypophysial peptide arginine vasotocin (AVT) and its mammalian ortholog arginine vasopressin function in a wide range of physiological and behavioral events. The neurohypophysial peptide arginine vasotocin, and its mammalian ortholog arginine vasopressin, influence a wide range of physiological and behavioral responses, including aspects of sexual and social behaviors, osmoregulation, stress response, metabolism, blood pressure, and circadian rhythms. Arginine vasotocin (AVT) is a nonmammalian analog of the mammalian hormone arginine vasopressin (AVP). The nonapeptide arginine vasotocin (AVT) and its mammalian homologue arginine vasopressin play a key role in the regulation of social behaviour across vertebrates. The peptide hormone arginine vasotocin (AVT) and its mammalian homolog arginine vasopressin modulate a variety of social behaviors in vertebrates."}
{"id":"6206bf3cc9dfcb9c0900003d","question":"Which kinase does PD98059 inhibit?","long_answer":"PD98059 is a specific, reversible MEK inhibitor.","answer":"MEK","context":"An injectable microparticle formulation for the sustained release of the specific MEK inhibitor PD98059: in vitro evaluation and pharmacokinetics. PD98059 is a reversible MEK inhibitor that we are investigating as a potential treatment for neurochemical changes in the brain that drive neurohumoral excitation in heart failure. "}
{"id":"61f80e22882a024a1000003d","question":"What is caused by loss-of-function variants in BCAS3?","long_answer":"BCAS3 microtubule-associated cell migration factor (BCAS3) is a large, highly conserved cytoskeletal protein previously proposed to be critical in angiogenesis and implicated in human embryogenesis and tumorigenesis. Bi-allelic loss-of-function variants in BCAS3 cause a syndromic neurodevelopmental disorder.","answer":"A syndromic neurodevelopmental disorder","context":"Bi-allelic loss-of-function variants in BCAS3 cause a syndromic neurodevelopmental disorder. BCAS3 microtubule-associated cell migration factor (BCAS3) is a large, highly conserved cytoskeletal protein previously proposed to be critical in angiogenesis and implicated in human embryogenesis and tumorigenesis. Here, we established BCAS3 loss-of-function variants as causative for a neurodevelopmental disorder. Bi-allelic loss-of-function variants in BCAS3 cause a syndromic neurodevelopmental disorder"}
{"id":"6217d8f03a8413c653000021","question":"What is the main use of ETD fragmentation?","long_answer":"Electron-based fragmentation methods have revolutionized biomolecular mass spectrometry, in particular native and top-down protein analysis.","answer":"Analysis of intact proteins","context":"Electron transfer dissociation (ETD) is an analytically useful tool for primary structure interrogation of intact proteins, but its utility is limited by higher-order reactions with the products.  Electron-based fragmentation methods have revolutionized biomolecular mass spectrometry, in particular native and top-down protein analysis.  nalyzed with less conventional mass spectrometry, i.e. using Electron Transfer Dissociation (ETD) for analyte fragmentation Using a longer than normal electron transfer dissociation (ETD) reaction time, we obtained enhanced coverage of peptide bonds that facilitated the localization of O-glycosites"}
{"id":"60329dc11cb411341a000147","question":"What is Congo red agar plates used for?","long_answer":"Congo red agar plates are used as a canonical indicator of biofilm-formation ability. Culture on Congo red agar plates in which slime-producing strains form black colonies, while nonslime-forming ones develop red colonies.","answer":"Assessment of bacterial biofilm-formation ability.","context":"Biofilm-forming ability was tested on Congo Red agar plates. The single MRSA isolate and 22 MSSA isolates were biofilm-producers on Congo red agar plates. , and rough morphotype on Congo red agar plates, indicating the formation of both curli fimbriae and cellulose.  Biofilm formation was evaluated by microtiter plate, tube method and Congo red agar method.  a canonical indicator of biofilm-formation ability, on Congo red agar plates.  by culture on Congo red agar plates in which slime-producing strains form black colonies, while nonslime-forming ones develop red colonies. Slime-forming ability was phenotypically tested on Congo red agar plates."}
{"id":"601db4ac1cb411341a000048","question":"What is the protein that is truncated to produce progerin?","long_answer":"Hutchinson Gilford progeria syndrome (HGPS) is a devastating accelerated aging disease caused by LMNA gene mutation. The truncated lamin A protein produced \"progerin\"","answer":"lamin-A","context":"Mutations in lamin A (LMNA) are responsible for a variety of human dystrophic and metabolic diseases. Here, we created a mouse model in which progerin, the lamin A mutant protein that causes Hutchinson-Gilford progeria syndrome (HGPS), can be inducibly overexpressed. Hutchinson-Gilford progeria syndrome (HGPS) is a rare laminopathy that produces a mutant form of prelamin A, known as Progerin Hutchinson Gilford progeria syndrome (HGPS) is a devastating accelerated aging disease caused by LMNA gene mutation. The truncated lamin A protein produced \"progerin The main cause of HGPS is a sporadic autosomal dominant point mutation in LMNA gene resulting in differently spliced lamin A protein known as progerin. Hutchinson-Gilford progeria syndrome (HGPS) is a rare premature aging disorder notably characterized by precocious and deadly atherosclerosis. Almost 90% of HGPS patients carry a LMNA p.G608G splice variant that leads to the expression of a permanently farnesylated abnormal form of prelamin-A, referred to as progerin.  Hutchinson-Gilford progeria syndrome (HGPS) is a progeroid disease characterized by the early onset of age-related phenotypes including arthritis, loss of body fat and hair, and atherosclerosis. Cells from affected individuals express a mutant version of the nuclear envelope protein lamin A (termed progerin) and have previously been shown to exhibit prominent histone modification changes.M Our approach involves expression of progerin, a truncated form of lamin A associated with premature aging. Progerin, a C-terminal truncated lamin A mutant, causes premature aging termed Hutchinson-Gilford Progeria Syndrome (HGPS). Hutchinson-Gilford progeria syndrome is a disorder of premature aging in children caused by de novo mutations in LMNA that lead to the synthesis of an internally truncated form of prelamin A (commonly called progerin). The production of progeri It is caused by a mutation in LMNA leading to expression of truncated prelamin A (progerin) in the nucleus. Mutations in the lamin A\/C (LMNA) gene that cause Hutchinson-Gilford progeria syndrome (HGPS) lead to expression of a protein called progerin with 50 amino acids deleted from the tail of prelamin A. In Hutchinson-Gilford progeria syndrome (HGPS) is a premature aging disorder, caused by mutation in the gene encoding lamin A\/C, which produces a truncated protein called progerin. In rly 90% of HGPS sufferers carry a G608G mutation within exon 11 of LMNA, producing a truncated form of prelamin A, referred to as \"progerin\". Here s mutation results in the deletion of 50 amino acids at the carboxyl-terminal tail of prelamin A, and the truncated protein is called progerin. Pr wide. The premature aging disease Hutchinson-Gilford syndrome (HGPS) is also caused by defined mutations in the LMNA gene resulting in activation of a cryptic splice donor site leading to a defective truncated prelamin A protein called prog mutation results in the deletion of 50 amino acids at the carboxyl-terminal tail of prelamin A, producing a truncated farnesylated protein called progerin. Lami PS is almost always caused by a de novo point mutation in the lamin A gene (LMNA) that activates a cryptic splice donor site, producing a truncated mutant protein termed \"progerin.\" WT  We sought to use splice-switching antisense oligonucleotides to produce a model of accelerated ageing by enhancing expression of progerin, translated from a mis-spliced lamin A gene (LMNA) transcript in human myogenic cells. HGPS arises from de novo mutations that activate a cryptic splice site in exon 11 of LMNA and result in progerin accumulation in tissues of mesodermal origin. Oligonucleotides that annealed within the 150 base region of exon 11 that is missing in the progerin transcript, as well as those that targeted the normal exon 11 donor site induced the LMNA \u0394150 transcript, but most oligonucleotides also generated variable levels of LMNA transcript missing the entire exon 11. This mutation results in the deletion of 50 amino acids at the carboxyl-terminal tail of prelamin A, producing a truncated farnesylated protein called progerin. This devastating incurable accelerated aging disease is caused by a silent mutation in the LMNA gene that generates a truncated lamin A protein \"progerin\" that exerts profound cellular toxicity and organismal decline. Accumulation of a truncated farnesylated prelamin A form, called progerin, is a hallmark of the severe premature ageing syndrome, Hutchinson-Gilford progeria. Hutchinson-Gilford progeria syndrome (HGPS) is a premature aging disorder, caused by mutation in the gene encoding lamin A\/C, which produces a truncated protein called progerin. Mutations in the lamin A\/C gene that cause Hutchinson-Gilford progeria syndrome lead to expression of a truncated, permanently farnesylated prelamin A variant called progerin. HGPS is almost always caused by a de novo point mutation in the lamin A gene (LMNA) that activates a cryptic splice donor site, producing a truncated mutant protein termed \"progerin.\" We have proposed that miR-9-mediated regulation of prelamin A in the brain could explain the absence of primary neurological disease in Hutchinson-Gilford progeria syndrome, a genetic disease caused by the synthesis of an internally truncated form of farnesyl-prelamin A (progerin). In this disease the lamin A, a protein participating (with others lamins) in the formation of the nuclear lamina and implicated in nuclear stability, chromatin structure and gene expression, is present in a truncated version called progerin. Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder because of a LMNA gene mutation that produces a mutant lamin A protein (progerin).  Progerin is a truncated form of lamin A. Hutchinson-Gilford progeria syndrome (HGPS) is caused by the production of a truncated prelamin A, called progerin, which is farnesylated at its carboxyl terminus."}
{"id":"602357ff1cb411341a00009a","question":"What treatment was studied in the KEYNOTE-522 trial?","long_answer":"KEYNOTE-522 trial studied adjuvant pembrolizumab for patients with triple-negative breast cancer.","answer":"pembrolizumab","context":"The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear.METHODS: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide.  CONCLUSIONS: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.). PURPOSE: In both the IMpassion 130 trial in the metastatic setting and in Keynote 522 in the neoadjuvant setting, patients with triple-negative breast cancer (TNBC) showed benefit from PD-1 axis immunotherapy.  Additionally, in light of the results of the KEYNOTE-522 study of adjuvant pembrolizumab in TNBC, evaluation of immunotherapy in the early disease setting is a subject of great interest.  Pembrolizumab plus chemotherapy may be an effective neoadjuvant treatment for triple-negative breast cancer. In the phase III KEYNOTE-522 trial, patients treated with the PD-1 inhibitor in combination with chemotherapy prior to surgery were more likely to have a pathologic complete response than patients who received chemotherapy alone, regardless of PD-L1 levels. Additionally, in light of the results of the KEYNOTE-522 study of adjuvant pembrolizumab in TNBC, evaluation of immunotherapy in the early disease setting is a subject of great interest.  in light of the results of the KEYNOTE-522 study of adjuvant pembrolizumab in TNBC, evaluation of immunotherapy in the early disease setting is a subject of great interest. This review a Pembrolizumab plus chemotherapy may be an effective neoadjuvant therapy in patients with early-stage triple-negative breast cancer: In an interim analysis of the phase III KEYNOTE-522 trial, patients treated with the combination had a higher pathologic complete response rate and trended toward better event-free survival than those who received chemotherapy alone."}
{"id":"6081b0b44e6a4cf630000009","question":"Which disease is associated with DNAJB1-PRKACA fusion gene?","long_answer":"Fibrolamellar carcinoma is distinctive at clinical and histologic levels. A novel DNAJB1-PRKACA fusion gene characterizes almost all cases.","answer":"Fibrolamellar carcinoma","context":"DNAJB1-PRKACA fusion gene found in sporadic fibrolamellar carcinomas, the presence of a characteristic DNAJB1-PRKACA fusion gene has been associated with FLC.  The fibrolamellar carcinoma-associated DNAJB1-PRKACA gene fusion transcript RNA codes for the catalytic domain of protein kinase A and, thus, overexpression of Aurora kinase A.  Fibrolamellar carcinoma is distinctive at clinical and histologic levels. A novel DNAJB1-PRKACA fusion gene characterizes almost all cases, distinguishes it from other hepatocellular neoplasms, and drives the pathogenesis of this unique tumor"}
{"id":"606b75c194d57fd87900006c","question":"When was dupilumab approved by EMA?","long_answer":"Dupilumab was approved fby the EMA in 2017.","answer":"2017","context":"This article covers etiology of the disease and summarizes dermatologic treatment standards of selected countries binding prior to the registration of dupilumab by both the European Medicines Agency (EMA) and Federal Drug Administration (FDA) in 2017. "}
{"id":"61f5914e882a024a1000000d","question":"Aducanumab can be used for treatment of which disease?","long_answer":"Aducanumab is approved for treatment of Alzheimer's disease.","answer":"Alzheimer's disease","context":"We highlight additional evidence consistent with the underwhelming efficacy of A\u03b2 oligomer-lowering agents, such as aducanumab, and of antioxidants, such as vitamin E, versus the so far isolated case report that DNase-I treatment for 2 months resulted in a severe AD patient's Mini-Mental State Exam score increasing from 3 to 18, reversing his diagnosis to moderate AD, according to the Mini-Mental State Exam. On 7 June 2021, aducanumab was granted accelerated approval for the treatment of Alzheimer disease (AD) by the FDA on the basis of amyloid-lowering effects considered reasonably likely to confer clinical benefit. This decision makes aducanumab the first new drug to be approved for the treatment of AD since 2003 and the first drug to ever be approved for modification of the course of AD. While the vast majority of immunotherapies have been developed for A\u03b2 and tested in Alzheimer's disease, the field has progressed to targeting other proteins including \u03b1Syn. Despite showing some remarkable results in animal models, immunotherapies have largely failed final stages of clinical trials to date, with the exception of Aducanumab recently licenced in the US by the FDA. The recent approval of aducanumab for Alzheimer's disease has heightened the interest in therapies targeting the amyloid hypothesis. Aducanumab (Aduhelm), the first new drug to treat Alzheimer's disease since 2003, has received accelerated approval from the Food and Drug Administration (FDA). Aducanumab is approved in the United States for the treatment of mild cognitive impairment or mild-dementia stage of AD. On the one hand, aducanumab is the first drug to be approved for the treatment of the disease since 2003 and is the first drug to act on the alleged pathophysiological mechanisms of AD. In June 2021, aducanumab received its first approval in the USA for the treatment of Alzheimer's disease. On June 7, 2021, the US Food and Drug Administration (FDA) approved aducanumab, a monoclonal amyloid targeting \u03b2-amyloid, for the treatment for Alzheimer's disease (AD). Aducanumab, a human monoclonal antibody that preferentially binds to aggregated amyloid-\u03b2 to reduce the number of amyloid plaques and slow disease progression, was approved to treat AD by the US Food and Drug Administration on June 7, 2021. The regulatory approval of the disease-modifying agent aducanumab has brought more attention to the complexity of the diagnosis, evaluation, and treatment of AD and the difficult decisions payers and policy makers will face over the next few years as innovation continues in this space. Based on the reduction of amyloid \u03b2 plaques, US FDA has recently approved Aducanumab as a disease modifying treatment for Alzheimer's disease (AD). Aducanumab is a human immunoglobulin G1 anti-amyloid beta (A\u03b2) antibody currently being evaluated for potential treatment of patients with early Alzheimer's disease. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease. Aducanumab, a human-derived antibody targeting amyloid-\u03b2 (A\u03b2), is in Phase 3 clinical trials for the treatment of Alzheimer's disease. Bi 2021, aducanumab received its first approval in the USA for the treatment of Alzheimer's disease. Accordin Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying treatment for Alzheimer's disease by the United States Food and Drug Administration (U.S. FDA). A Aducanumab (Aduhelm), the first new drug to treat Alzheimer's disease since 2003, has received accelerated approval from the Food and Drug Administration (FDA).Thi Based on the reduction of amyloid \u03b2 plaques, US FDA has recently approved Aducanumab as a disease modifying treatment for Alzheimer's disease (AD).  On June 7, 2021, the US Food and Drug Administration (FDA) approved aducanumab, a monoclonal amyloid targeting \u03b2-amyloid, for the treatment for Alzheimer's disease (AD). This  This article summarizes the milestones in the development of aducanumab leading to this first approval for Alzheimer's disease. Aducanumab, a human-derived antibody targeting amyloid-\u03b2 (A\u03b2), is in Phase 3 clinical trials for the treatment of Alzheimer's disease. INTRODUCTION: Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta, is being investigated as a disease-modifying treatment for Alzheimer's disease (AD).METHODS: This randomized, double-blind, placebo-controlled single ascending-dose study investigated the safety, tolerability, and pharmacokinetics (PK) of aducanumab in patients wi Clinical Development of Aducanumab, an Anti-A\u03b2 Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease. These results justify further development of aducanumab for the treatment of AD. BACKGROUND: Aducanumab is an anti-amyloid-\u03b2 (A\u03b2) antibody that achieved reduced amyloid pathology in Alzheimer's disease (AD) trials; however, it is controversial whether it also improved cognition, which has been suggested would require a sufficiently high cumulative dose of the antibody i Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer's disease (AD). [Aducanumab and Alzheimer's disease: a critical reflection.] Aducanumab's efficacy as a treatment for the cognitive dysfunction in Alzheimer's disease cannot be proven by clinical trials with divergent outcomes."}
{"id":"601efe051cb411341a00006a","question":"Covid-19 is though to have arisen from what species?","long_answer":"COVID-19 caused by SARS-CoV-2 most likely originated in bats and transmitted to humans through a possible intermediate host.","answer":"bats","context":"COVID-19 caused by SARS-CoV-2 most likely originated in bats and transmitted to humans through a possible intermediate host.  cent Findings: Based on high similarities in the genome sequences, the virus is thought to have arisen from SARS-like CoVs in bats but the lack of an intermediate species containing a CoV with even greater similarity has so far eluded discovery. T es of the conclusions of the different documents here assessed show that even considering the zoonotic hypothesis as the most likely, with bats and pangolins being possibly in the origin of the coronavirus, today's date the intermediate source species of SARS-CoV-2 has not been confirmed yet. On the othe Transmission rate of SARS-CoV-2 in the population is high, and the origin of this coronavirus appears to be related to some species of the bat. o other betacoronaviruses, SARS-CoV-2 appears to have crossed the species barrier, most likely from bats, clearly reinforcing the One Health concept. Veterinary"}
{"id":"6049080c1cb411341a000164","question":"Where are Goblet cells localized?","long_answer":"Goblet cells are found in the intestine, in the lungs, in the eyes etc. Goblet cells are localized in the epithelium.","answer":"Epithelium","context":"Goblet cells (GCs) and endocrine cells (ECs) play an important role in intestine physiology, Conjunctival goblet cells (CGCs) are specialized cells that produce and secrete soluble mucins to the tear film that bathes the ocular surface. goblet cells in the lungs The epithelial lining of the small intestine consists of multiple cell types, including Paneth cells and goblet cells, that work in cohort to maintain gut health.  goblet cell numbers are increased within the airway epithelium  The mucosa is lined with a stratified secretory epithelium rich in goblet cells that secrete neutral and acid mucins. "}
{"id":"601dbe101cb411341a00004c","question":"What is the brand name for erenumab?","long_answer":"Aimovig (erenumab; erenumab-aooe in the United States) is the only US Food and Drug Administration (FDA)-approved monoclonal antibody (mAb) therapy against the CGRP receptor (CGRPR) for the prevention of migraine.","answer":"Aimovig","context":"Aimovig (erenumab; erenumab-aooe in the United States) is the only US Food and Drug Administration (FDA)-approved monoclonal antibody (mAb) therapy against the CGRP receptor (CGRPR) for the prevention of migraine  Erenumab-aooe (erenumab, Aimovig\u00ae)-a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) receptor-is approved for the prevention of migraine in adults in a number of countries Purpose: Erenumab-aooe (erenumab, Aimovig\u00ae)-a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) receptor-is approved for the prevention of migraine in adults in a number of cou Amgen and Novartis are developing erenumab (AIMOVIG\u2122, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine. Aimovig (erenumab; erenumab-aooe in the United States) is the only US Food and Drug Administration (FDA)-approved monoclonal antibody (mAb) therapy against the CGRP receptor (CGRPR) for the prevention of migraine. Discovery of the Migraine Prevention Therapeutic Aimovig (Erenumab), the First FDA-Approved Antibody against a G-Protein-Coupled Receptor. In 2018, the United States Food and Drug Administration (FDA) approved Aimovig (erenumab) for the prevention of migraine. Purpose: Erenumab-aooe (erenumab, Aimovig\u00ae)-a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) receptor-is approved for the prevention of migraine in adults in a number of c"}
{"id":"606b7d6c94d57fd87900006f","question":"Which protein does capmatinib bind?","long_answer":"Capmatinib binds MET.","answer":"MET","context":"Capmatinib (Tabrecta\u2122) is an oral, small molecule mesenchymal-epithelial transition (MET) inhibitor being developed by Novartis Oncology, under a license from Incyte Corporation, for the treatment of lung cancer. Capmatinib targets and selectively binds to MET, including the mutant variant produced by exon 14 skipping, and inhibits cancer cell growth driven by the mutant MET variant. In May 2020, oral capmatinib received its first global approval in the USA for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that leads to MET exon 14 skipping, as detected by an FDA-approved test. "}
{"id":"6082f0ec4e6a4cf63000000e","question":"What is carboxyglutamate?","long_answer":"One of the important glutamic acid modifications is post-translationally modified 4-carboxyglutamate.","answer":"carboxyglutamateis a  a post-translational glutamic acidof","context":" One of the important glutamic acid modifications is post-translationally modified 4-carboxyglutamate. Vitamin K serves as an essential co-factor in the \u03b3-carboxylation of glutamate to \u03b3-carboxyglutamate (GLA), a post-translational modification mediated by gamma-glutamyl carboxylase (GGCX) and vitamin K oxidoreductases (VKORC1 or VKORC1L1). Vitamin K (VK) is an essential cofactor for the post-translational conversion of peptide-bound glutamate to \u03b3-carboxyglutamate."}
{"id":"606bff2194d57fd879000075","question":"Which company produces the HercepTest?","long_answer":"DAKO is the company producing the companion diagnostic HercepTest.","answer":"DAKO","context":"The FDA-Approved Breast Cancer HER2 Evaluation Kit (HercepTest; Dako) May Miss Some HER2-Positive Breast Cancers."}
{"id":"601ff4021cb411341a000075","question":"In what year did Gregor Mendel die?","long_answer":"Johann Gregor Mendel 1822-1884","answer":"1884","context":"Historical study: Johann Gregor Mendel 1822-1884. The life and personality of Johann Gregor Mendel (1822-1884) Gregor Mendel, OSA (1822-1884), founder of scientific genetics. The life and personality of Johann Gregor Mendel (1822-1884), the founder of scientific genetics, are reviewed against the contemporary background of his times."}
{"id":"61f60157882a024a1000001e","question":"What is the use of Atogepant?","long_answer":"Atogepant is used for preventive treatment of migraine.","answer":"preventive treatment of migraine","context":"Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. BACKGROUND: Atogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist for the preventive treatment of migraine. CONCLUSION: Atogepant demonstrated treatment benefits as early as the first full day after treatment initiation, and sustained efficacy across each 4-week interval during the 12-week treatment period. Atogepant (Qulipta\u2122) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine. In September 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults. The drug is also in phase 3 clinical development for the preventive treatment of migraine in various other countries.  This paper reviews the available data from RCTs to assess the clinical efficacy, safety, and tolerability profile of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine and atogepant for the prevention of migraine. Atogepant is a potent, selective, oral calcitonin gene-related peptide (CGRP) receptor antagonist in development for migraine prevention. Atogepant, a potent, selective antagonist of the calcitonin gene-related peptide receptor-in development for migraine prevention-is thus likely to be used by women taking oral contraceptives. Atogepant for the Preventive Treatment of Migraine ember 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults. The dr Atogepant for the Preventive Treatment of Migraine. Atogepant for the Preventive Treatment of Migraine. Atogepant (Qulipta\u2122) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine. BACKGROUND: Atogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist for the preventive treatment of migraine.METHODS: In the double-blind, phase 3 ADVANCE trial, participants with 4-14 migraine days\/month were randomized to atogepant 10\u2009mg, 30\u2009mg, 60\u2009mg, or placebo onc In September 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults. This article summarizes the milestones in the development of atogepant leading to this first approval for the preventive treatment of episodic migraine in adults."}
{"id":"6217e5433a8413c653000032","question":"What is the function of the protein SERT?","long_answer":"SERT is a Serotonin transporter.","answer":"Serotonin transporter","context":"serotonin and dopamine transporters (SERT and DAT).  the transporter proteins for serotonin (SERT)   serotonin transporter (SERT) serotonin transporter (SERT) serotonin receptor (SERT)  5-HT transporter (SERT) "}
{"id":"61f5fcb6882a024a1000001b","question":"What causes Ocular Thelaziasis?","long_answer":"Ocular Thelaziasis is caused by Thelazia callipaeda.","answer":"Thelazia callipaeda","context":"Human ocular thelaziasis caused by gravid Thelazia callipaeda - A unique and rare case report. We report the first case of human ocular thelaziasis in Nepal in a 6-month-old child from a Rukum district, Nepal. The infant presented with conjunctivitis, and his visual acuity and dilated fundal examination were normal. A total of 6 worms were removed for identification. Collected nematodes were identified based on morphological keys as Thelazia callipaeda. Thelaziasis is an arthropod-born disease of the eye and adnexa caused by Thelazia callipaeda, a nematode parasite transmitted by drosophilid flies to carnivores and humans.  Thelaziasis is an arthropod-born disease of the eye and adnexa caused by Thelazia callipaeda, a nematode parasite transmitted by drosophilid flies to carnivores and humans. BACKGROUND: Thelazia callipaeda is the main causative organism in thelaziasis, commonly infecting orbital cavities and associated tissues of carnivores. Thelaziasis is a zoonosis caused by\nnematodes of the genus Thelazia, parasites of the conjunctival bags or tear ducts of mammals and birds. Human ocular thelaziasis caused by gravid Thelazia callipaeda - A unique  BACKGROUND: Thelazia callipaeda is the main causative organism in thelaziasis, commonly infecting orbital cavities and associated tissues of Thelaziasis is an ocular infection of several mammals caused by nematodes of the genus Thelazia (Spirurida, Thelaziidae). Human thelaziasis is a zoonotic eye disease caused by a nematode parasite called Thelazia Thelaziasis is an ocular arthropod-borne, zoonotic disease of the eye infecting the conjunctival sac, lacrimal duct, and lacrimal gland caused by a nematode of the genus Thelazia."}
{"id":"6217d8973a8413c653000020","question":"What is the role of cytidine deaminase in healthy cells?","long_answer":"Activation-induced cytidine deaminase (AID) catalyses the deamination of deoxycytidines to deoxyuracils within immunoglobulin genes to induce somatic hypermutation and class-switch recombination.","answer":"deamination of deoxycytidines","context":"The AID\/APOBEC family of enzymes are cytidine deaminases that act upon DNA and RNA. APOBEC1 is a member of the AID\/APOBECs, a group of deaminases responsible for the editing of C>U in both DNA and RNA. The human genome contains 11 APOBEC (apolipoprotein B mRNA editing catalytic polypeptide-like) cytidine deaminases classified into four families. These proteins function mainly in innate antiviral immunity and can also restrict endogenous retrotransposable element multiplication.  Activation-induced cytidine deaminase (AID) catalyses the deamination of deoxycytidines to deoxyuracils within immunoglobulin genes to induce somatic hypermutation and class-switch recombination Efficient humoral responses rely on DNA damage, mutagenesis and error-prone DNA repair. Diversification of B cell receptors through somatic hypermutation and class-switch recombination are initiated by cytidine deamination in DNA mediated by activation-induced cytidine deaminase\u00a0(AID)1 and by the subsequent excision of the resulting uracils by uracil DNA glycosylase (UNG) and by mismatch repair proteins1-3. "}
{"id":"622628b03a8413c65300007d","question":"Through which pathway does the FTO-guided demethylation of GADD46 drive myogenesis?","long_answer":"FTO-mediated demethylation of GADD45B promotes myogenesis through the activation of p38 MAPK pathway.","answer":"p38 MAPK pathway","context":"FTO-mediated demethylation of GADD45B promotes myogenesis through the activation of p38 MAPK pathway. Our results indicate that the FTO-mediated m6A modification in GADD45B mRNA drives skeletal muscle differentiation by activating the p38 MAPK pathway, which provides a molecular mechanism for the regulation of myogenesis via RNA methylation. Moreover, the expression of GADD45B regulates the expression of\u00a0myogenic regulatory factors and peroxisome proliferator-activated receptor gamma coactivator 1 alpha by activating the p38 mitogen-activated protein kinase (MAPK) pathway."}
{"id":"621d02f33a8413c653000047","question":"What is the function of the protein PIEZO1?","long_answer":"Piezo1 is a key element of the  mechanotransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.","answer":"mechanotransduction process","context":"the mechanosensitive ion channel Piezo1  mechanosensitive Piezo1 channels mechanosensitive Piezo1 channels Mechanosensitive cation channel Piezo1 Piezo1 is a key element of the mechanotransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations."}
{"id":"622627103a8413c65300007c","question":"What is the most common N6-methyladenosine (m6A) methylation modification site of RUNX1T1?","long_answer":"The RRACH motif is the most common N6-methyladenosine (m6A) methylation modification site of RUNX1T1.","answer":"RRACH motif","context":"Of these SNPs only rs34269950 located in the 'RRACH' motif, the most common N6-methyladenosine (m6A) methylation modification site (recognized by FTO), was significantly associated with obesity risk and metabolic abnormalities. "}
{"id":"61f95f9f882a024a1000004e","question":"Which disorder is caused by biallelic mutations in G-Protein coupled receptor kinase 1 (GRK1)?","long_answer":"Biallelic mutations in G-Protein coupled receptor kinase 1 (GRK1) cause Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB).","answer":"Oguchi disease","context":"Biallelic mutations in G-Protein coupled receptor kinase 1 (GRK1) cause Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB)."}
{"id":"61f5fb64882a024a1000001a","question":"Which disease is treated with Tebentafusp?","long_answer":"Tebentafusp is used for treatment of Metastatic Uveal Melanoma.","answer":"Metastatic Uveal Melanoma","context":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma.  If approved, tebentafusp could become the standard of care for metastatic uveal melanoma-but only for those patients with a particular HLA allele. Recently, a randomized phase III trial reported an overall survival benefit for tebentafusp in patients with untreated metastatic uveal melanoma. The aim of this comprehensive review is to summarize evidence of Gp-100 as a therapeutic target in melanoma, and the preclinical and clinical development of tebentafusp as a novel therapeutic strategy for patients with uveal melanoma. Although UM metastases are less responsive than cutaneous melanoma to chemotherapy or immune checkpoint inhibitors, encouraging results have been reported with partial hepatectomy for solitary metastases, with percutaneous hepatic perfusion with melphalan or with tebentafusp. Several alternative systemic therapeutic approaches have been or are currently being investigated, including two agents that have been taken into registration-intent clinical trials: tebentafusp, a T cell redirecting agent, and IDE196, an oral protein kinase C inhibitor. Treatment of advanced uveal melanoma remains challenging, however, encouraging results from novel agents offer hope for improvement in the near future. melanoma received tebentafusp. Treatment efficacy, treatment-related adverse events, and biomarker assessments were performed for blood-derived and tumor biopsy samples obtained at baseline and on-treatment.RESULTS: Tebentafusp was generally well-tolerated and active in both patients with metastatic uveal melanoma and pati"}
{"id":"6222257e3a8413c653000077","question":"What are TAMs in cancer therapy?","long_answer":"TAMs are Tumor Associated Macrophages and are important in Cancer therapy.","answer":"Tumor Associated Macrophages","context":" tumor-associated macrophages (TAMs)  tumour-associated macrophages (TAMs)  tumor-associated macrophages (TAMs) tumor-associated macrophages (TAMs) However, endocrine therapy resistance mechanisms mediated through interactions between breast cancer cells and tumor-associated macrophages (TAMs) are still unclear. ntional cancer therapy also strengthens cancer-related inflammation by inducing massive tumor cell death that activate surrounding immune-infiltrating cells such as tumor-associated macrophages (TAMs). Mac Although M2-like tumor-associated macrophages (TAMs) have been considered as a vital therapeutic target in cancer therapy due to their role in promoting tumor progression and metastasis, very few compounds have been identified to inhibit M2-like polarization of TAMs. H Eliciting effective antitumor immune responses in patients who fail checkpoint inhibitor therapy is a critical challenge in cancer immunotherapy, and in such patients, tumor-associated myeloid cells and macrophages (TAMs) are promising therapeutic targets. We As CSCs depend on their specific niche, including tumor-associated macrophages (TAM), elucidating the network between CSCs and TAMs may help to effectively inhibit the progression and ADT resistance of prostate cancer.Experimental Design: The underlying intracellular mechanism that sustains the stem-like characteristics of CSCs in prostate cancer was assessed via RNA sequencing, co-immunoprecipitation, chromatin immunoprecipitation, and other assays. Tumor-associated macrophages (TAMs) is a promising therapeutic target for cancer immunotherapy, while TAMs targeting therapy using nano-sized drug delivery system (NDDS) is a great challenge. Tumor-associated macrophages (TAMs) play a crucial part in cancer evolution. Tumor-associated macrophages (TAMs) of M2 phenotype have mediated the immunosuppression in a tumor microenvironment, facilitating the escape of tumor cells from immunosurveillance. In this review, we outline the importance of tumor-associated macrophages (TAM), a major component of the TME, in the response of tumors to cancer therapy. In particular, tumor-associated macrophages (TAMs) are the most abundant leucocyte subset in many cancers and play a major role in the creation of a protective niche for tumor cells. These cells, known as tumor-associated macrophages (TAMs), play complex but pivotal roles in the outcome of photodynamic therapy (PDT) of malignant lesions. Tumor-associated macrophages (TAMs) represent the most abundant innate immune cells in tumors. Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the TME."}
{"id":"6200411cc9dfcb9c09000014","question":"Which java utility has been developed for class hidden markov models?","long_answer":"JUCHMME is an open-source software package in Java designed to fit arbitrary custom Hidden Markov Models (HMMs) with a discrete alphabet of symbols.","answer":"JUCHMME","context":"JUCHMME: a Java Utility for Class Hidden Markov Models and Extensions for biological sequence analysis. JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs) with a discrete alphabet of symbols. SUMMARY: JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs) with a discrete alphabet of symbols."}
{"id":"601eb3b61cb411341a000057","question":"Where is the body would the Peyer's patches be found","long_answer":"Peyer's patches (PPs) play a major role in intestinal mucosal immunity and are located in the gut.","answer":"gut","context":"Peyer's patches (PPs) play a major role in intestinal mucosal immunity The small intestine hosts specialized lymphoid structures, the Peyer's patches, that face the gut lumen and are overlaid with unique epithelial cells, called microfold (M) cells.  In the Peyer's patches of the small intestine, specialized epithelial cells, the membranous (M) cells, sample antigenic matter from the gut lumen and bring it into contact with cells of the immune system, which are then capable of initiating specific immune reactions A strong clustering of lymphoid cells originating from either twin was seen in the ileal Peyer's patches (IPPs). he gastrointestinal tract (GIT) is one of the largest immune organs in the body and contains multiple immune cells in the GIT-associated lymphoid tissue, Peyer's patches and elsewhere, which together have profound effects on local and systemic inflammation. The  During routine lower gastrointestinal endoscopy of children for suspected chronic inflammatory bowel disease, it is possible to visualize lymphoid follicles (Peyer's patches) in the last few centimeters of the terminal ileum. Bi ls responsible for local pIg production are initially stimulated in lymphoepithelial structures, particularly the Peyer's patches in the distal small intestine, from which they migrate as memory cells to exocrine tissues all over the body. Mucous mem During the course of their recirculation through the body, blood-borne lymphocytes specifically adhere to high endothelial venules (HEV) within secondary lymphoid organs such as peripheral lymph nodes (PN) and gut-associated Peyer's patches (PP). This this respect, Peyer's patches (PP), represent one of the most important immunological site of the body and the major component of the gut -associated lymphoid tissue. The a en-stimulated B and T lymphocytes are distributed from Peyer's patches and other gut-associated lymphoid tissue to exocrine glandular sites all over the body; this is the basis for local generation of SIgA antibodies with an enormous selection of specificities required for protection of the extensive mucosal surfaces. Regu Peyer's patch have been extensively studied as a major inductive site for mucosal immunity within the small intestine. nistration. The Peyer's patches have been considered an important structure of the gut associate lymphoid tissue (GALT) for the initiation of the immune response towards particulate or Peyer patches are the major entrance of Salmonella infection and antigen transportation in intestine. The early replication of certain prion strains within Peyer's patches in the small intestine is essential for the efficient spread of disease to the brain after oral exposure. Distribution of Peyer's patches in the distal ileum. The position of the Peyer's patches is unusual in that the first three Peyer's patches are on the right side of the small intestine whereas the penultimate and ultimate Peyer's patches are large, contain many lymphoid follicles and are in an anti-mesenteric position in the small intestine and sometimes in the large intestine (ultimate Peyer's patch). Peyer's patches in the small intestine are prominent, ranging from four to 13, and increase in size (surface area) with age. The jejunal Peyer's patches are devoid of CAP, persist in the adult animal, contain M cells with clusters of B cells in the follicle-associated epithelium, and have many CD4+ lymphocytes in the follicles and in the interfollicular areas. They were distributed in the whole small intestine and there were four distinct types of Peyer's patches: nodular, faviform, cup-shaped, and cystic form Peyer's patches. Oligoclonal Peyer's patch follicles in the terminal small intestine of cattle. In addition, the distribution density of Peyer's patches in ileum was the maximum, then was jejunum and duodenum. c acid, and transilluminated. Peyer's patches were counted, and the length, breadth, and distance from the ileocecal valve were recorded.RESULTS: Patches were most numerous in the terminal 10-1 Located in the small intestine, Peyer's patches (PP) are primary antigen sampling and mucosal immune response inductive sites. In this respect, Peyer's patches (PP), represent one of the most important immunological site of the body and the major component of the gut -associated lymphoid tissue. [Number and localization of Peyer's patches in the small intestine of the rabbit (Oryctolagus cuniculus)]. In the rabbit intestine Peyer's patches can easily be distinguished. Peyer's patches are gut-associated lymphoid tissue located throughout the intestinal wall. Peyer's patches consist of highly organized ovoid-shaped follicles, classified as non-encapsulated lymphatic tissues, populated with B cells, T cells, macrophages, and dendritic cells and function as an organism's intestinal surveillance. Rats had a significantly reduced number of Peyer's patches in the duodenum in comparison to either the jejunum or ileum. In summary, the gene expression pattern of Peyer's patches is influenced by intestinal location and may contribute to its role in that segment. Limited work compares the gene profiles of Peyer's patches derived from different intestinal regions. Using samples obtained from additional subjects (n\u2009=\u200910), we validated the novel gene expression patterns in Peyer's patches obtained from the three regions of the small intestine. In the current study, we first performed whole transcriptome analysis using RNAseq to compare duodenal and ileal Peyer's patches obtained from the small intestine of Long Evans rats."}
{"id":"61f60735882a024a10000022","question":"Which disease is treated with Risdiplam?","long_answer":"Risdiplam is approved for spinal muscular atrophy.","answer":"spinal muscular atrophy","context":"Furthermore, drug therapies including injectables such as onasemnogene abeparvovec-xioi (ZOLGENSMA\u00ae), nusinersen (SPINRAZA\u00ae), and an oral-solution, risdiplam (EVRYSDI\u2122), are medications that have been FDA-approved for the treatment of SMA. The phenotype of spinal muscular atrophy (SMA) has been changing with the recent availability of three FDA-approved treatments: intrathecal nusinersen, intravenous onasemnogene abeparvovec-xioi, and enteral risdiplam.  The United States' Food and Drug Administration's (FDA) approval of nusinersen, onasemnogene abeparvovec, and risdiplam for SMA has challenged existing treatment paradigms with multiple treatment options, a new natural history of the disease, and an emerging understanding of the importance of early and pre-symptomatic treatment. The discovery of small molecule splicing modifiers and the development of risdiplam for the treatment of spinal muscular atrophy (SMA) have firmly established proof of concept for this exciting new platform and transformed a scientific curiosity into a viable technology to target disease.  Risdiplam (Evrysdi\u2122) is an orally administered, survival motor neuron 2 (SMN2)-directed RNA splicing modifier being developed by Roche, PTC Therapeutics Inc and the SMA Foundation for the treatment of the spinal muscular atrophy. SION: Combination therapy with onasemnogene and risdiplam in patients with SMA appears to be well-tolerated. Furth Risdiplam is currently the only orally administered drug approved by the FDA for the treatment of SMA. Risdiplam is the first and only oral medication to be approved to treat SMA. Risdiplam was approved recently for the treatment of patients with SMA, aged\u00a0\u2265\u00a02\u00a0months in the United States, and is currently under Health Authority review in the EU. OBJECTIVE: Evaluation of ophthalmologic safety with focus on retinal safety in patients with spinal muscular atrophy (SMA) treated with risdiplam (EVRYSDI\u00ae), a survival of motor neuron 2 splicing modifier associated with retinal toxicity in monkeys. The discovery of small molecule splicing modifiers and the development of risdiplam for the treatment of spinal muscular atrophy (SMA) have firmly established proof of concept for this exciting new platform and transformed a scientific curiosity into a viable technology to target disease. Risdiplam is the first approved small-molecule splicing modulator for the treatment of spinal muscular atrophy (SMA) Risdiplam (Evrysdi) improves motor neuron function in patients with spinal muscular atrophy (SMA) and has been approved for the treatment of patients \u22652\u00a0months old. Ri  small-molecule splicing modifier, risdiplam, was also approved for the treatment of SMA, highlighting small molecules as important warheads in the arsenal for regulating RNA splicing. The cellular  Risdiplam (Evrysdi\u2122) is an orally administered, survival motor neuron 2 (SMN2)-directed RNA splicing modifier being developed by Roche, PTC Therapeutics Inc and the SMA Foundation for the treatment of the spinal muscular atrophy. The  ext. Very recently, an orally deliverable small molecule, risdiplam (Evrysdi\u2122), became the third approved therapy for SMA. i\u2122 (risdiplam), recently approved for the treatment of SMA, and related compounds promote exon 7 inclusion to generate full-length SMN2 mRNA and increase SMN protein levels. SMN\u03947 ty AIMS: Risdiplam (RG7916, RO7034067) is an orally administered, centrally and peripherally distributed, survival of motor neuron 2 (SMN2) mRNA splicing modifier for the treatment of spinal muscular atrophy (SMA).  United States' Food and Drug Administration's (FDA) approval of nusinersen, onasemnogene abeparvovec, and risdiplam for SMA has challenged existing treatment paradigms with multiple treatment options, a new natural history of the disease, and an emerging understanding of the importance of early and pre-symptomatic treatment. The profo The phenotype of spinal muscular atrophy (SMA) has been changing with the recent availability of three FDA-approved treatments: intrathecal nusinersen, intravenous onasemnogene abeparvovec-xioi, and enteral risdiplam. The ently, the primary therapeutic strategy for SMA is to increase the level of SMN via correcting SMN2 splicing (nusinersen and risdiplam). How he discovery of small molecule splicing modifiers and the development of risdiplam for the treatment of spinal muscular atrophy (SMA) have firmly established proof of concept for this exciting new platform and transformed a scientific curiosity into a viable technology to target disease. T s including injectables such as onasemnogene abeparvovec-xioi (ZOLGENSMA\u00ae), nusinersen (SPINRAZA\u00ae), and an oral-solution, risdiplam (EVRYSDI\u2122), are medications that have been FDA-approved for the treatment of SMA. This review discusses the current and  Risdiplam for the Use of Spinal Muscular Atrophy. Risdiplam in Type 1 Spinal Muscular Atrophy.  These studies indicate that drugs such as risdiplam will be optimally therapeutic when given as early as possible after diagnosis and potentially will be required for the life of an SMA patient AIMS: Risdiplam (RG7916, RO7034067) is an orally administered, centrally and peripherally distributed, survival of motor neuron 2 (SMN2) mRNA splicing modifier for the treatment of spinal muscular atrophy  Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA). n monkeys. Risdiplam was approved recently for the treatment of patients with SMA, aged\u00a0\u2265\u00a02\u00a0months in the United States, and is currently under Health Authority review in the EU.METHODS: Subjects included patients with SMA aged 2\u00a0months-60\u00a0years enrolled in the FIREFISH, SUNFISH, and JEWELFISH clinical t Additionally, we explore the recently FDA-approved small molecule regulator of RNA splicing, risdiplam, for treatment of spinal muscular atrophy. In August 2020, Evrysdi\u2122 (risdiplam) received its first approval in the USA for the treatment of spinal muscular atrophy in patients 2\u00a0months of age and older. OBJECTIVE: Evaluation of ophthalmologic safety with focus on retinal safety in patients with spinal muscular atrophy (SMA) treated with risdiplam (EVRYSDI\u00ae), a survival of motor neuron 2 splicing modifier associated with retinal toxicity  Evrysdi\u2122 (risdiplam), recently approved for the treatment of SMA, and related compounds promote exon 7 inclusion to generate full-length SMN2 mRNA and increase SMN protein levels."}
{"id":"6028fad21cb411341a000101","question":"When was galcanezumab approved by FDA?","long_answer":"Galcanezumab was approved by the FDA in September 2018.","answer":"September 2018","context":"Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. "}
{"id":"602356b81cb411341a000099","question":"Tofersen has been developed for treatment of which disease?","long_answer":"Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis is being studied for the treatment of amyotrophic lateral sclerosis due to SOD1 mutations.","answer":"amyotrophic lateral sclerosis","context":"BACKGROUND: Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis. Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations.METHODS: We conducted a phase 1-2 ascending-dose trial evaluating tofersen in adults with ALS due to SOD1 mutations.  CONCLUSIONS: In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks.  Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations.METHODS: We conducted a ph nthesis. Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to S ently, the results of a phase I\/II study using the antisense oligonucleotides Tofersen to treat familial amyotrophic lateral sclerosis with superoxide dismutase 1 mutation have been reported. In  synthesis. Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD Recently, the results of a phase I\/II study using the antisense oligonucleotides Tofersen to treat familial amyotrophic lateral sclerosis with superoxide dismutase 1 mutation have been reported.  mutations.METHODS: We conducted a phase 1-2 ascending-dose trial evaluating tofersen in adults with ALS du  synthesis. Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations.METHODS: We conducted a phase 1-2 ascending-dose trial evaluating tofersen in adults with ALS d"}
{"id":"606b2b1994d57fd87900005c","question":"What is the cause of lactose intolerance?","long_answer":"Lactose intolerance is a common condition caused by lactase deficiency and may result in symptoms of lactose malabsorption (bloating, flatulence, abdominal discomfort, and change in bowel habits).\nFour clinical subtypes of lactose intolerance may be distinguished, namely lactase deficiency in premature infants, congenital lactase deficiency, adult-type hypolactasia and secondary lactase intolerance.","answer":"Lactase deficiency","context":"Lactose intolerance is a common condition caused by lactase deficiency and may result in symptoms of lactose malabsorption (bloating, flatulence, abdominal discomfort, and change in bowel habits).   Adult lactose intolerance (ALI) significantly alters calcium intake and absorption, and thus may promote osteoporosis. ALI is a recessive condition with a geographical north-south gradient characterised by decreased levels of intestinal lactase. Considerations include recognizing that a substantial proportion of the world's adult population (65%-70%) exhibits lactase nonpersistence, a reduced ability to metabolize lactose to glucose and galactose.  Four clinical subtypes of lactose intolerance may be distinguished, namely lactase deficiency in premature infants, congenital lactase deficiency, adult-type hypolactasia and secondary lactase intolerance. Lactose intolerance (LI) is characterized by the presence of primarily gastrointestinal clinical signs resulting from colonic fermentation of lactose, the absorption of which is impaired due to a deficiency in the lactase enzyme. These clinical signs can be modified by several factors, including lactose dose, residual lactase expression, concurrent ingestion of other dietary components, gut-transit time, and enteric microbiome composition."}
{"id":"621b78e63a8413c65300003f","question":"What is the activity of a Oligosaccharyltransferases ?","long_answer":"oligosaccharyltransferases (OSTs), which catalyze the attachment of glycans to specific amino acid residues in target proteins","answer":"attachment of glycans to specific amino acid residues in target proteins","context":"Oligosaccharyltransferases (OSTs) mediate the en\u00a0bloc transfer of N-glycan intermediates onto the asparagine residue in glycosylation sequons (N-X-S\/T, X\u2260P).  Protein glycosylation, or the attachment of sugar moieties (glycans) to proteins, is important for protein stability, activity, and immunogenicity. However, understanding the roles and regulations of site-specific glycosylation events remains a significant challenge due to several technological limitations. A particular challenge is the synthesis of oligosaccharyltransferases (OSTs), which catalyze the attachment of glycans to specific amino acid residues in target proteins Lipid-linked oligosaccharides (LLOs) play an important role in the N-glycosylation pathway as the donor substrate of oligosaccharyltransferases (OSTs), which are responsible for the en bloc transfer of glycan chains onto a nascent polypeptide. Key to bioconjugation are a group of enzymes known as oligosaccharyltransferases (OTases) that transfer polysaccharides to engineered carrier proteins containing conserved amino acid sequences known as sequons. T"}
{"id":"601eb56c1cb411341a000058","question":"On what chromosome would the MKKS gene for McKusick-Kaufman(AKA Kaufman-McKusick) syndrome be found?","long_answer":"The MKKS gene is mapped to chromosome 20","answer":"20","context":"The syndrome is caused by mutations in the MKKS gene mapped onto chromosome 20p12 between D20S162 and D20S894 markers.  Both MKS and BBS can be caused by mutations in the MKKS or BBS6 gene on chromosome 20p12 and BBS is also associated with mutations in other genes (BBS1, BBS2, BBS4, and BBS7).  Both MKS and BBS can be caused by mutations in the MKKS or BBS6 gene on chromosome 20p12 and BBS is also associated with mutations in other genes (BBS1, BBS2, BBS4, and BBS7). can be caused by mutations in the MKKS or BBS6 gene on chromosome 20p12 and BBS is also associated with mutations in other genes (BBS1, BBS2, BBS4, and BBS7). To address this he ome is caused by mutations in the MKKS gene mapped onto chromosome 20p12 between D20S162 and D20S894 markers. Mutatio Genotyping with markers from the MKKS region confirmed homozygosity at 20p12 in both affected individuals."}
{"id":"601ef0571cb411341a000067","question":"What is another name for  keratomileusis?","long_answer":"Laser in situ keratomileusis  is also known as LASIK","answer":"LASIK","context":"Report the outcomes of laser in situ keratomileusis (LASIK) for high myopia correction after long-term follow-up laser in-situ keratomileusis (LASIK) Laser in situ keratomileusis (LASIK)  Currently laser-assisted in situ keratomileusis (LASIK) is indicated to correct myopia of up to -\u20098\u00a0D, hyperopia up to +\u20093\u00a0D and astigmatism up to 5\u00a0D. Photorefractive keratectomy (PRK) and laser epithelial keratomileusis (LASEK) are primarily recommended for myopia up to -\u20096\u00a0D and for greater refractive errors, phakic intraocular lenses (IOL) are the first choice (myopia greater than -\u20096\u00a0D and hyperopia greater than +\u20093\u00a0D). PURPOSE: Ectasia after laser in situ keratomileusis (LASIK) is a rare but serious complication. BACKGROUND: Laser epithelial keratomileusis (LASEK) is a new keratorefractive procedure for the correction of myopia and myopic astigmatism, which may combine advantages and eliminate disadvantages of photorefractive keratectomy (e.g. pain, corneal haze) and laser in situ keratomileusis (e.g. flap and interface complications, dry eye, keratecta Laser subepithelial keratomileusis (LASEK) is a relatively new refractive surgical technique that purportedly combines the advantages of laser in-situ keratomileusis (LASIK) and photorefractive keratectomy (PRK). Li PRK (photorefractive keratectomy), LASEK (laser epithelial keratomileusis) are good alternatives for glaucoma patients. BACKGROUND: LASIK (Laser in situ keratomileusis) is used in refractive surgery especially for correction of higher degree LASEK (laser subepithelial keratomileusis). Laser subepithelial keratomileusis (LASEK) is a relatively new refractive surgical technique that purportedly combines the advantages of laser in-situ keratomileusis (LASIK) and photorefractive keratectomy (PRK). The incorporation of a microkeratome in 1990 finally led to laser in situ keratomileusis-LASIK-as we know it today. Photorefractive keratectomy, laser epithelial keratomileusis (LASEK) and Epi-LASIK are all variants of a similar type refractive surgery involving laser on the surface of the cornea and differ mainly in management of the epithelium. Although laser in situ keratomileusis (LASIK) is currently the most popular form of refractive surgery, LASEK is the procedure of choice in some patients. A 33-year-old man who underwent uneventful laser in situ keratomileusis (LASIK) developed pressure-induced stromal edema resulting in an interface haze in both eyes and a pocket of fluid under the flap of the right eye 10 days after surgery, while receiving topical fluorometholone."}
{"id":"62260afb3a8413c65300007b","question":"In which motif of the RUNX1T1 protein is the rs34269950 SNP located?","long_answer":"The rs34269950 SNP of RUNX1T1 is located in the 'RRACH' motif.","answer":"RRACH motif","context":"Of these SNPs only rs34269950 located in the 'RRACH' motif, the most common N6-methyladenosine (m6A) methylation modification site (recognized by FTO), was significantly associated with obesity risk and metabolic abnormalities."}
{"id":"603bc2801cb411341a00015a","question":"Isotocin is an homolog of what hormone?","long_answer":"Isotocin is a homolog of oxytocin.","answer":"oxytocin","context":" comprising the vast majority of vertebrate species, remains unclear. To address this issue, we evaluated the involvement of an oxytocin homolog (isotocin, referred herein as oxt) However, in fishes, the effect of isotocin, the homologue of oxytocin, on social behaviour is less clear isotocin may have a homologous role to oxytocin  The present study examined the possible involvement of isotocin (Ist), an oxytocin-like neuropeptide,  The vasopressin homolog in non-mammalian vertebrates is vasotocin; and the oxytocin homolog is mesotocin in non-eutherian tetrapods, mesotocin and [Phe2]mesotocin in lungfishes, and isotocin in ray-finned fishes. The nonapeptides arginine vasopressin (AVP; including its non-mammalian homolog arginine vasotocin, AVT) and oxytocin (OT; including its non-mammalian homologs mesotocin, MT, and isotocin, IT) regulate social behavior, including aggression and reproduction, via receptors conserved across vertebrates. the current study, we focused on the comparative neuroendocrine functions and regulation of isotocin, the teleost homologue of mammalian oxytocin. Spe The present study using zebrafish as a model explores the role of isotocin, a homolog of oxytocin, in controlling ion regulatory mechanisms.  eost fishes possess vasopressin and oxytocin homologues known as arginine vasotocin (AVT) and isotocin (IT), respectively. The r Isotocin, which is homologous to oxytocin, is expressed early, in a simple pattern in the developing zebrafish brain. The present study using zebrafish as a model explores the role of isotocin, a homolog of oxytocin, in controlling ion regulatory mechanisms. Our study provides some of the first evidence of a pro-social effects of isotocin in a fish and suggests that in fishes, isotocin may have a homologous role to oxytocin, at least in promoting shoaling behaviour. However, in fishes, the effect of isotocin, the homologue of oxytocin, on social behaviour is less clear."}
{"id":"6052729c94d57fd879000011","question":"Fingolimod is a selective antagonist for which molecule?","long_answer":"Fingolimod is a selective S1P1 functional antagonist by induction of irreversible S1P1 internalization and degradation.","answer":"S1P1","context":"Pharmacologically, fingolimod was characterized as a non-selective agonist of all of the S1P receptors (S1PR), with the exception of S1P2, and in addition, as a selective S1P1 functional antagonist by induction of irreversible S1P1 internalization and degradation."}
{"id":"622118a43a8413c65300006a","question":"Telomestatin is derived from what organism?","long_answer":"Telomestatin is a natural macrocyclic compound derived from Streptomyces anulatus 3533-SV4","answer":"Streptomyces anulatus","context":"Telomestatin is a natural macrocyclic compound derived from Streptomyces anulatus 3533-SV4 Telomestatin is a natural macrocyclic compound derived from Streptomyces anulatus 3533-SV4. Telomestatin is a natural product isolated from Streptomyces anulatus 3533-SV4 and has been shown to be a very potent telomerase inhibitor. Telomestatin is a natural product isolated from Streptomyces anulatus 3533-SV4 and has been shown to be a very potent telomerase inhibitor through its G-quadruplex interaction. Telomestatin, a natural product isolated from Streptomyces anulatus, stabilizes telomeric DNA G-quadruplexes. A novel telomerase inhibitor, telomestatin, isolated from Streptomyces anulatus is the most potent telomerase inhibitor so far."}
{"id":"6206d06ec9dfcb9c09000041","question":"Which plant is khellin extracted from?","long_answer":"Khellin is extracted from the seeds of the plant Ammi visnaga.","answer":"Ammi visnaga","context":"The first chromone in clinical use, khellin, was extracted from the seeds of the plant Ammi visnaga, and had been used for centuries as a diuretic and as a smooth muscle relaxant. "}
{"id":"603219c21cb411341a000133","question":"What is vesiduction?","long_answer":"'Vesiduction' as a fourth mode of intercellular DNA transfer.","answer":"'Vesiduction' as a fourth mode of intercellular DNA transfer.","context":"Besides the canonical gene transfer mechanisms transformation, transduction and conjugation, DNA transfer involving extracellular vesicles is still under appreciated. However, this widespread phenomenon has been observed in the three domains of life. Here, we propose the term 'Vesiduction' as a fourth mode of intercellular DNA transfer. In this review, we first summarize the major pathways of HGT in bacteria, including conjugation, transformation, transduction and vesiduction. "}
{"id":"6026f0251cb411341a0000d6","question":"What is the route of administration of eptinezumab?","long_answer":"Eptinezumab is administered intravenously.","answer":"Intravenously","context":"Eptinezumab, delivered by intravenous (IV) administration, is being developed by Lundbeck Seattle BioPharmaceuticals for the prevention of migraine."}
{"id":"606b648394d57fd879000069","question":"What is the origin of  HEp-2 cells?","long_answer":"human larynx epidermoid carcinoma cell line (HEp-2)","answer":"human larynx epidermoid carcinoma cell line","context":"oropharyngeal carcinoma (HEp-2) oropharyngeal cancer cells (HEp-2)  human larynx epidermoid carcinoma cell line (HEp-2)  HEp-2 laryngeal cancer cells "}
{"id":"602c1b141cb411341a00011c","question":"What is another name for bimagrumab","long_answer":"Bimagrumab also goes by the name BYM338.","answer":"BYM338","context":"Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis."}
{"id":"6023501a1cb411341a000096","question":"What is the generic name of the Xofluza?","long_answer":"Baloxavir marboxi is the generic name of Xofluza. It is approved for influenza.","answer":"Baloxavir marboxi","context":"Baloxavir marboxil (Xofluza\u00ae; hereafter referred to as baloxavir), the prodrug of baloxavir acid, is a first-in-class, small molecule inhibitor of the polymerase acidic (PA) protein subunit of the influenza virus polymerase complex. Xofluza (baloxavir marboxil) for influenza approved in Japan under the SAKIGAKE Designation System is a good example of clinical trials including Japan. Arikayce (amikacin liposome inhalation suspension) for Mycobacterium avium complex lung disease; Xofluza (baloxavir marboxil) for acute uncomplicated influenza; and Nuzyra (omadacycline) for community-acquired bacterial pneumonia and\/or acute bacterial skin and skin structure infections. The latest approved antiviral is baloxavir marboxil (trade name, Xofluza) which targets the endonuclease function of the viral PA polymerase subunit and prevents the transcription of viral mRNA.  Baloxavir marboxil (Xofluza\u00ae), recently approved for clinical use, inhibits cap-snatching endonuclease. The latest approved antiviral is baloxavir marboxil (trade name, Xofluza) which targets the endonuclease function of the viral PA polymerase subunit and prevents the transcription of viral mRNA. Baloxavir marboxil (Xofluza\u00ae; hereafter referred to as baloxavir), the prodrug of baloxavir acid, is a first-in-class, small molecule inhibitor of the polymerase acidic (PA) protein subunit of the influenza virus polymerase complex. Bal he latest approved antiviral is baloxavir marboxil (trade name, Xofluza) which targets the endonuclease function of the viral PA polymerase subunit and prevents the transcription of viral mRNA. Th Baloxavir marboxil (Xofluza\u2122; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. Th se, from the innovation of to begin with antiviral medicate Idoxuridine in 1962 to the revelation of Baloxavir marboxil (Xofluza) that was FDA-approved in 2018, the hone of creating antivirals has changed significantly. In this art Arikayce (amikacin liposome inhalation suspension) for Mycobacterium avium complex lung disease; Xofluza (baloxavir marboxil) for acute uncomplicated influenza; and Nuzyra (omadacycline) for community-acquired bacterial pneumonia and\/or acute bacterial skin and skin struc Baloxavir marboxil (Xofluza), an antiviral flu treatment, has now been approved to prevent influenza.Pa Baloxavir marboxil (Xofluza), an antiviral flu treatment, has now been approved to prevent influenza.Patients should avoid taking calcium, aluminum, or magnesium products while receiving baloxavir as this will lead to a loss of antiviral efficacy. In any case, from the innovation of to begin with antiviral medicate Idoxuridine in 1962 to the revelation of Baloxavir marboxil (Xofluza) that was FDA-approved in 2018, the hone of creating antivirals has changed significantly."}
{"id":"6026d8641cb411341a0000cd","question":"What is the synonym of MK-1602?","long_answer":"MK-1602 is also named Ubrogepant.","answer":"ubrogepant","context":"Ubrogepant (MK-1602) is a novel, oral, calcitonin gene-related peptide receptor antagonist in clinical development with positive phase III outcomes for acute treatment of migraine. "}
{"id":"61f919cc882a024a10000048","question":"How many families did the 100,000 Genomes Pilot enrol?","long_answer":"The U.K. 100,000 Genomes Project is in the process of investigating the role of genome sequencing in patients with undiagnosed rare diseases after usual care and the alignment of this research with health care implementation in the U.K. National Health Service. Other parts of this project focus on patients with cancer and infection. A pilot study was conducted involving 4660 participants from 2183 families, among whom 161 disorders covering a broad spectrum of rare diseases were present.","answer":"2183","context":"The U.K. 100,000 Genomes Project is in the process of investigating the role of genome sequencing in patients with undiagnosed rare diseases after usual care and the alignment of this research with health care implementation in the U.K. National Health Service. Other parts of this project focus on patients with cancer and infection.METHODS: We conducted a pilot study involving 4660 participants from 2183 families, among whom 161 disorders covering a broad spectrum of rare diseases were present."}
{"id":"606bfeb494d57fd879000074","question":"What methodology does the Oncomine Dx target test use?","long_answer":"The Oncomine Dx target test uses the next generation sequencing methodology.","answer":"next generation sequencing","context":"FISH-positive samples were also analyzed with next-generation sequencing (Oncomine Dx Target Test Panel, Thermo Fisher Scientific)."}
{"id":"61f7d683882a024a10000036","question":"Which enzyme is inhibited by Aramchol?","long_answer":"Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression.","answer":"hepatic stearoyl-CoA desaturase 1","context":"Aramchol attenuates NASH in mouse models and decreases steatosis by downregulating the fatty acid synthetic enzyme stearoyl CoA desaturase 1 (SCD1) in hepatocytes.  Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents and reduced steatosis in an early clinical trial.  Although the primary end point of a reduction in liver fat did not meet the prespecified significance level with Aramchol 600\u2009mg, the observed safety and changes in liver histology and enzymes provide a rationale for SCD1 modulation as a promising therapy for NASH and fibrosis and are being evaluated in an ongoing phase 3 program. A number of phase 3 clinical trials are currently ongoing including Elafibranor, a dual PPAR \u03b1\/\u03b4 agonist, Cenicriviroc, a CCR2\/CCR5 chemokine antagonist, the nuclear bile acid receptor FXR agonist obeticholic acid, Aramchol, a fatty acid bile acid conjugate that modulates SCD-1, and Resmetrion, a liver-specific THR-\u03b2 agonist.  BACKGROUND: Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis.  Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents and reduced steatosis in an early clinical trial. Aramchol attenuates NASH in mouse models and decreases steatosis by downregulating the fatty acid synthetic enzyme stearoyl CoA desaturase 1 (SCD1) in hepatocytes. Aramchol downregulated stearoyl-CoA desaturase 1 (SCD1), a key enzyme involved in triglyceride biosynthesis whose loss enhances fatty acid \u03b2-oxidation. nclusions: Aramchol treatment improved steatohepatitis and fibrosis by 1) decreasing SCD1, and 2) increasing the flux through the transsulfuration pathway maintaining cellular redox homeostasis. W BACKGROUND: Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis. atherogenesis. The aim of the present study was to investigate whether inhibition of SCD by Aramchol, a fatty acid bile conjugate with known hypocholesterolemic effects, will affect atheroge BACKGROUND: Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatoh Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis stearoyl-CoA desaturase 1 (SCD1), a key enzyme involved in triglyceride biosynthesis whose loss enhances fatty acid \u03b2-oxidation. Aramchol increased the  epatitis (NASH). Aramchol attenuates NASH in mouse models and decreases steatosis by downregulating the fatty acid synthetic enzyme stearoyl CoA desaturase 1 (SCD1) d increased PPARG mRNA expression.Conclusions: Aramchol downregulates SCD1 and elevates PPARG in HSCs, reduci Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. g COL1A1 and ACTA2 mRNAs and COL1A1 secretion. These data suggest a direct inhibitory effect of Aramchol in HSCs through SCD1 inhibition, as part of a broader impact on both fibrogenic genes a  hepatocellular carcinoma. Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents an atitis and fibrosis in 0.1MCD fed mice. Aramchol downregulated stearoyl-CoA desaturase 1 (SCD1), a key enzyme involved in triglyceride biosynthesis wh sis. The aim of the present study was to investigate whether inhibition of SCD by Aramchol, a fatty acid bile conjugate with known hypocholesterolemic Aramchol, an oral stearoyl-coenzyme-A-desaturase-1 inhibitor, has been shown to reduce hepatic fat content in patients with primary nonalcoholic fatty liver disease (NAFLD); however, its effect in patients with human immunodeficiency virus (HIV)-associated NAFLD is unknown. BACKGROUND: Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of stea cing COL1A1 and ACTA2 mRNAs and COL1A1 secretion. These data suggest a direct inhibitory effect of Aramchol in HSCs through SCD1 inhibition, as part of a broader impact on both fibrogenic gene ich catalyses cholesterol synthesis. In phHeps, Aramchol also reduced SCD1 and increased PPARG mRNA expression.Conclusions: Aramchol downregulates SCD1 and elevates PPARG in HSCs, red"}
{"id":"622d17b83a8413c6530000a2","question":"What is the cause of the Diamond Blackfan Anemia?","long_answer":"Diamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome associated with ribosomal gene mutations that lead to ribosomal insufficiency.","answer":"Diamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome associated with ribosomal gene mutations that lead to ribosomal insufficiency.","context":"Diamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome associated with ribosomal gene mutations that lead to ribosomal insufficiency. Diamond-Blackfan anemia is an autosomal dominant syndrome, characterized by anemia and a predisposition for malignancies. Ribosomal proteins are responsible for this syndrome, and the incidence of colorectal cancer in patients with this syndrome is higher than the general population."}
{"id":"61f7d5a0882a024a10000035","question":"Which molecule is targeted by Fenebrutinib?","long_answer":"Fenebrutinib is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase (BTK).","answer":"Bruton's tyrosine kinase","context":"These inhibitors include four Syk inhibitors, Bay 61-3606, R406 (fostamatinib), entospletinib, TAK-659; four irreversible BTK inhibitors, ibrutinib, acalabrutinib, ONO-4059 (tirabrutinib), AVL-292 (spebrutinib); and four reversible BTK inhibitors, CG-806, BMS-935177, BMS-986195, and fenebrutinib.  However, an increasing number of trials instead addresses autoimmunity and inflammation in multiple sclerosis, rheumatoid arthritis, pemphigus and systemic lupus erythematosus with the use of either irreversibly binding inhibitors, e.g., evobrutinib and tolebrutinib, or reversibly binding inhibitors, like fenebrutinib.  OBJECTIVE: Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase (BTK). In contrast, no bleeding has been reported in clinical trials of other BTKi. These include the brain-penetrant irreversible tolebrutinib and evobrutinib (against multiple sclerosis), the irreversible branebrutinib, the reversible BMS-986142 and fenebrutinib (targeting rheumatoid arthritis and lupus erythematodes), and the reversible covalent rilzabrutinib (against pemphigus and immune thrombocytopenia). Bruton's tyrosine kinase (BTK) is crucial for Fc\u03b5RI-mediated mast cell activation and essential for autoantibody production by B cells in chronic spontaneous urticaria (CSU). Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU.  New therapeutics under investigation include IgG1 anti-IgE monoclonal antibodies (ligelizumab), chemoattractant rector-homologous molecule expressed on TH2 cells antagonists (AZD1981), Bruton tyrosine kinase inhibitors (fenebrutinib), anti-siglec-8 monoclonal antibody (AK002), and topical spleen tyrosine kinase inhibitors (GSK2646264).  Fenebrutinib (GDC-0853) is an orally administered small molecule inhibitor of Bruton's tyrosine kinase being investigated for treatment of rheumatoid arthritis in patients with inadequate responses to methotrexate (MTX). Absence of Pharmacokinetic Interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate. In efforts to develop additional series of reversible Btk inhibitors for chronic immune diseases, we sought to differentiate from our clinical stage inhibitor fenebrutinib using cyclopropyl amide isosteres of the 2-aminopyridyl group to occupy the flat, lipophilic H2 pocket. erapeutics under investigation include IgG1 anti-IgE monoclonal antibodies (ligelizumab), chemoattractant rector-homologous molecule expressed on TH2 cells antagonists (AZD1981), Bruton tyrosine kinase inhibitors (fenebrutinib), anti-siglec-8 monoclonal antibody (AK002), and topical spleen tyrosine kinase inhibitors (GSK2646264). We review the mechanisms of promising drugs that are currently under development for CU are a chemoattractant receptor-homologous molecule expressed on TH2 cell antagonist, a monoclonal antibody to Siglec-8 (AK002), Bruton tyrosine kinase inhibitors (fenebrutinib and Lou064), a spleen tyrosine kinase inhibitor, and dupilumab. Promising targets of future These inhibitors include four Syk inhibitors, Bay 61-3606, R406 (fostamatinib), entospletinib, TAK-659; four irreversible BTK inhibitors, ibrutinib, acalabrutinib, ONO-4059 (tirabrutinib), AVL-292 (spebrutinib); and four reversible BTK inhibitors, CG-806, BMS-935177, BMS-986195, and fenebrutinib. OBJECTIVE: Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase OBJECTIVE: To evaluate fenebrutinib, an oral and highly selective non-covalent inhibitor of Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthrit PURPOSE: Fenebrutinib (GDC-0853), a Bruton's tyrosine kinase (BTK) inhibitor was investigated in a Phase 2 clinical trial in patients with rheumatoid arthritis  Fenebrutinib (GDC-0853) is an orally administered small molecule inhibitor of Bruton's tyrosine kinase being investigated for treatment of rheumatoid arthritis in patients with inadequate responses to methotrexate (MTX). T OBJECTIVE: Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine ki PURPOSE: Fenebrutinib (GDC-0853), a Bruton's tyrosine kinase (BTK) inhibitor was investigated in a Phase 2 clinical trial in patients with rheumatoid arthri OBJECTIVE: To evaluate fenebrutinib, an oral and highly selective non-covalent inhibitor of Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arth utinib 200 mg twice daily. By week 48, patients treated with fenebrutinib had reduced levels of a BTK-dependent plasmablast RNA signature, anti-double-stranded DNA autoantibodies, total IgG, and IgM, as well as increased complement C4 level OBJECTIVE: To evaluate fenebrutinib, an oral and highly selective non-covalent inhibitor of Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthritis (RA).METHODS: Patients with RA and inadequate response to methotrexate (cohort 1, n=480) were randomized to fenebrutinib (50 mg once daily, 150 mg once daily, 200 mg twice daily), 40 mg adalimumab every oth Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. essants; however, additional treatments are needed. New therapeutics under investigation include IgG1 anti-IgE monoclonal antibodies (ligelizumab), chemoattractant rector-homologous molecule expressed on TH2 cells antagonists (AZD1981), Bruton tyrosine kinase inhibitors (fenebrutinib), anti-siglec-8 monoclonal antibody (AK002), and top brutinib 200 mg twice daily. By week 48, patients treated with fenebrutinib had reduced levels of a BTK-dependent plasmablast RNA signature, anti-double-stranded DNA autoantibodies, total IgG, and IgM, as well as increased complement C4 levels, all relative to placebo.CONCLUSION: While fenebrutinib had an acceptable safety profile, the primary end point, SRI-4 response, was not met despi"}
{"id":"6237a8343a8413c6530000b2","question":"Which protein family is epiregulin a member of?","long_answer":"EREG (epiregulin), a member of the epidermal growth factor (EGF) family.","answer":"epidermal growth factor family","context":"EREG (epiregulin), a member of the epidermal growth factor (EGF) family, plays a role in inflammation, wound healing, normal physiology and malignancies. However, little is known about its function on hair growth."}
{"id":"622d1ed13a8413c6530000a3","question":"What is the Daughterless gene?","long_answer":"The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined.","answer":"The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined.","context":"As the only class I helix-loop-helix transcription factor in Drosophila, Daughterless (Da) has generally been regarded as a ubiquitously expressed binding partner for other developmentally regulated bHLH transcription factors.  The daughterless (da) gene in Drosophila encodes a broadly expressed transcriptional regulator whose specific functions in the control of sex determination and neurogenesis have been extensively examined.  The daughterless (da) gene in Drosophila functions in the regulation of at least three significant developmental pathways: sex determination, neurogenesis and oogenesis. "}
{"id":"6237a8a33a8413c6530000b3","question":"What is amphiregulin a ligand of?","long_answer":"Amphiregulin (AREG) is an epidermal growth factor receptor (EGFR) ligand.","answer":"epidermal growth factor receptor","context":"Amphiregulin (AREG) is an epidermal growth factor receptor (EGFR) ligand."}
{"id":"623dfd2ef0baec9a1b000004","question":"What is the function of the protein calreticulin?","long_answer":"Calreticulin (CALR) is an endoplasmic reticulum (ER)-resident protein involved in a spectrum of cellular processes. In healthy cells, CALR operates as a chaperone and Ca2+ buffer to assist correct protein folding within the ER.","answer":"chaperone and Ca2+ buffer to assist correct protein folding within the ER","context":"Subsequently, the N-glycosylated nascent proteins enter the folding step, in which N-glycans contribute largely to attaining the correct protein fold by recruiting the lectin-like chaperones, calnexin, and calreticulin.  The lectin chaperones calnexin (CNX) and calreticulin (CRT) localized in the endoplasmic reticulum play important roles in glycoprotein quality control.  Calreticulin (CRT), an endoplasmic reticulum-resident protein generally overexpressed in cancer cells, is associated with radiation resistance. Calreticulin (CALR) is an endoplasmic reticulum (ER)-resident protein involved in a spectrum of cellular processes. In healthy cells, CALR operates as a chaperone and Ca2+ buffer to assist correct protein folding within the ER."}
{"id":"6237ab873a8413c6530000b6","question":"What is the effect of epiregulin on leptin secretion?","long_answer":"Epiregulin induces leptin secretion.","answer":"induction","context":"Epiregulin induces leptin secretion and energy expenditure in high-fat diet-fed mice.  EREG increased leptin production and secretion in a dose-dependent manner in iAb fat explants via the EGFR\/MAPK pathway.  Our data revealed a new role of EREG in induction of leptin secretion leading to the energy expenditure state. "}
{"id":"6202f600c9dfcb9c0900002b","question":"Which JASPAR release is JASPAR 2022?","long_answer":"JASPAR (http:\/\/jaspar.genereg.net\/) is an open-access database containing manually curated, non-redundant transcription factor (TF) binding profiles for TFs across six taxonomic groups. In JASPAR 2022, JASPAR's 9th release, the CORE collection was expanded with 341 new profiles (148 for plants, 101 for vertebrates, 85 for urochordates, and 7 for insects), which corresponds to a 19% expansion over the previous release.","answer":"9th","context":"JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. JASPAR (http:\/\/jaspar.genereg.net\/) is an open-access database containing manually curated, non-redundant transcription factor (TF) binding profiles for TFs across six taxonomic groups. In this 9th release, we expanded the CORE collection with 341 new profiles (148 for plants, 101 for vertebrates, 85 for urochordates, and 7 for insects), which corresponds to a 19% expansion over the previous release. We added 298 new profiles to the Unvalidated collection when no orthogonal evidence was found in the literature. All the profiles were clustered to provide familial binding profiles for each taxonomic group. Moreover, we revised the structural classification of DNA binding domains to consider plant-specific TFs. This release introduces word clouds to represent the scientific knowledge associated with each TF. We updated the genome tracks of TFBSs predicted with JASPAR profiles in eight organisms; the human and mouse TFBS predictions can be visualized as native tracks in the UCSC Genome Browser. Finally, we provide a new tool to perform JASPAR TFBS enrichment analysis in user-provided genomic regions. All the data is accessible through the JASPAR website, its associated RESTful API, the R\/Bioconductor data package, and a new Python package, pyJASPAR, that facilitates serverless access to the data."}
{"id":"622deabc3a8413c6530000a6","question":"What is the SPRTN protein function?","long_answer":"The protease SPRTN emerged as the essential enzyme for DNA-protein crosslink proteolysis repair.","answer":"DNA-protein crosslink proteolysis repair","context":"we explored the role of Spartan (SPRTN), a metalloprotease associated with DNA replication, which removes proteins forming DPCs. Repair of covalent DNA-protein crosslinks (DPCs) by the metalloprotease SPRTN prevents genome instability, premature aging and carcinogenesis. The protease SPRTN emerged as the essential enzyme for DNA-protein crosslink proteolysis repair Covalent DNA-protein crosslinks (DPCs) have emerged as pervasive sources of genome instability. DPCs are targeted for repair by DNA-dependent proteases of the Wss1\/SPRTN family."}
{"id":"6238a0033a8413c6530000b8","question":"What part of the body is associated with Cauda equina","long_answer":"The cauda equina is the sack of nerve roots (nerves that leave the spinal cord between spaces in the bones of the spine to connect to other parts of the body) at the lower end of the spinal cord.","answer":"spine","context":"the right pedicle of L4, moved inside the vertebral canal (bridging the cauda equina) stopping just in front of the body of S2.  Thermoesthesia-and-algesthesia status in the dermatomes of cauda equina roots in patients with lumbar spine osteochondrosis Thermoesthesia-and-algesthesia disorders have been registered in the dermatomes of cauda equina roots of patients with lumbar spine osteochondrosis in all the cases.   Magnetic resonance images of the lumbar spine showed an intradural cystic lesion displacing and compressing the lower cord and cauda equina. Cauda equina syndrome is a well described state of neurologic compromise due to lumbosacral root compression. Acute cauda equina syndrome secondary to a lumbar synovial cyst INTRODUCTION: Schwannoma is a relatively common benign spinal cord and\/or cauda equina tumor; however, giant cauda equina schwannoma with extensive scalloping of the lumbar vertebral body is a rare pathology, and the treatment strategy, including the use of surgical procedures, is controversial. In this report, we present a rare case of a giant lumbar schwannoma of the cauda equina with extremely large scalloping of the vertebral body, and we discuss the surgical strategy we used to treat this pathology. In contrast, the caudal cord of Rana is reduced to a filum terminale consisting of little more than an ependymal tube; spinal nerves to all caudal myotomes leave the cord in the sacral region and reach their motor targets via a cauda equina and caudal plexus. The spinal cords of other teleosts, the sun-fish and angler, also are abbreviated and possess a filum terminale and cauda equina. Penetrating spinal cord injury with foreign body included or myelography stop or showing cauda equina syndrome should be operated on. Cauda Equina Conduction Time Determined by F-Waves in Normal Subjects and Patients With Neurogenic Intermittent Claudication Caused by Lumbar Spinal Stenosis After spinal cord injury, electrical stimulation of the roots inside the spinal column at the level of the cauda equina is a safe and effective way to regain some degree of control over lower body function, e.g. bladder and bowel management and leg movement.  Malignant spinal cord compression(MSCC)is defined as a compression of the spinal cord or cauda equina with neuropathy caused by tumor spreading to the vertebral body.  nction of the cauda equina, the collection of ventral and dorsal lumbar, sacral and coccygeal nerve roots that surround the filum terminale. This most INTRODUCTION: Schwannoma is a relatively common benign spinal cord and\/or cauda equina tumor; however, giant cauda equina schwannoma with extensive scalloping of the lumbar vertebral body is a rare pathology, and the treatment strategy, including the use of surgical procedures, is controversial Cauda equina syndrome is a relatively uncommon condition typically associated with a large, space-occupying lesion within the canal of the lumbosacral spine. Cauda equina syndrome refers to dysfunction of the cauda equina, the collection of ventral and dorsal lumbar, sacral and coccygeal nerve roots that surround the filum terminale. The involvement of intrinsic spinal cord neurons in the compression-induced cauda equina syndrome includes anterograde, retrograde and transneuronal degeneration in the lumbosacral segments. Single or double-level compression of the lumbosacral nerve roots located in the dural sac results in a polyradicular symptomatology clinically diagnosed as cauda equina syndrome. The cauda equina is an anatomic structure located in the lower part of the spinal canal consisting of multiple lumbar and sacral nerve roots."}
{"id":"62265b4a3a8413c653000083","question":"What does RUNX1T1 stand for?","long_answer":"RUNX1T1 stands for runt-related transcription factor 1.","answer":"runt-related transcription factor 1","context":"Runt-related transcription factor 1 (RUNX1T1) isoforms are involved in adipogenesis."}
{"id":"62265c953a8413c653000084","question":"Is METTL3 an m6A writer, reader or eraser?","long_answer":"The methyltransferase METTL3 is an m6A writer.","answer":"Writer","context":"Here we report decreased expression of the m6A \"writer\" METTL3 in tumor-infiltrating NK cells, and a positive correlation between protein\u00a0expression levels of METTL3 and effector molecules in NK cells."}
{"id":"622dfb133a8413c6530000a8","question":"What is the drug  gantenerumab targeting?","long_answer":"Gantenerumab significantly reduced amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 and attenuated increases of neurofilament light chain.","answer":"Gantenerumab significantly reduced amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 and attenuated increases of neurofilament light chain.","context":"Gantenerumab significantly reduced amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 and attenuated increases of neurofilament light chain.  The late-stage agents with positive clinical or biomarker data include four antibodies that engage A\u03b2 oligomers (aducanumab, lecanemab, gantenerumab, and donanemab) and ALZ-801, an oral agent that fully blocks the formation of A\u03b2 oligomers at the clinical dose. Reduction in Amyloid Burden with Subcutaneous Gantenerumab. These results demonstrate that prolonged gantenerumab treatment, at doses up to 1200 mg, reduces amyloid plaque levels below the amyloid positivity threshold. "}
{"id":"622b99f73a8413c653000093","question":"Which protein is targeted by Herceptin?","long_answer":"Her2 is targeted by Herceptin.","answer":"Her2","context":"HER2-targeting agents such as Herceptin\u00ae, Kadcyla\u00ae and ENHERTU\u00ae have been approved by the FDA for the treatment of breast cancer,  Herceptin toward ErbB2-positive breast cancer cells"}
{"id":"622668b13a8413c653000088","question":"What does PCAT6 stand for?","long_answer":"PCAT6 stands for prostate cancer-associated transcript 6.","answer":"rostate cancer-associated transcript 6","context":"In this work, we investigated the role and regulatory mechanism of lncRNA prostate cancer-associated transcript 6 (PCAT6) in breast cancer progression."}
{"id":"622b9d593a8413c653000095","question":"What organ is associated with a Gleason pattern or Gleason Score?","long_answer":"The Gleason score is an important parameter for clinical outcome in prostate cancer patients.","answer":"prostate","context":"The Gleason score is an important parameter for clinical outcome in prostate cancer patients Gleason score 8 prostate cancer patients. Gleason score 8 prostate cancer patients.  Men with Gleason score 9-10 prostate cancer have worse outcomes compared to those with Gleason 8 disease. OBJECTIVES: Most adenocarcinomas of the prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic extension and a high risk of progression. Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading. eason score (GS) and predominant Gleason pattern were determined in prostate biopsies and in prostate tissue specimens, crosschecked by two uro-pathologists.RE In conclusion, cribriform growth in Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate cancer at radical prostatectomy. Accurate recognition of Gleason pattern 5 (GP5) prostate adenocarcinoma (PCa) on core biopsy (NBX) is critical because it is associated with disease progression and the worst clinical outcome.  the first time that reelin is expressed in prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly with increasing of single Gleason patterns. This suggests reelin may b ne of the recent important modifications in the Gleason grading system recommended from the International Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate needle biopsy and radical prostatectomy cases with Gleason score 7 prostatic adenocarcinoma. Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue The Gleason score of prostate adenocarcinomas is an important preoperative predictor of cancer behavior, and is used to help guide treatment.  frequently found in high Gleason score prostate cancers, we explored whether reelin expression is influenced by single Gleason patterns. While Gleason 3 patt  of prostate cancer would occur within Gleason scores 3 to 10 even though higher scores are usually considered more aggressive forms of prostate cancers. Since our study is based upon a very li 3 + 4 = 7 and Gleason score 4 + 3 = 7. Gleason score 4 + 3 = 7 showed an overall correlation with pathological stage (organ confined, focal extraprostatic extension, nonfocal extraprostatic extension, seminal vesicle inva We compared the Gleason scores found on needle biopsy with the grade and stage (organ-confined, extra-prostatic extension, positive seminal vesicles or lymph nodes) at radical prostatectomy. Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma. OBJECTIVES: Most adenocarcinomas of the prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic extension and a high risk of  Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. A were similar in normal prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for prostate cancer. These variations showed "}
{"id":"621e59ce3a8413c65300004c","question":"Which tool has been developed to identify the glycan shielding of glycosylated proteins?","long_answer":"GLYCO (GLYcan COverage) is an in silico approach to quantify the glycan shielding of a protein surface. The software provides insights into glycan-dense\/sparse regions of the entire protein surface or a subset of the protein surface. GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.","answer":"GLYCO","context":"GLYCO: a tool to quantify glycan shielding of glycosylated proteins. Here, we developed an in silico approach, GLYCO (GLYcan COverage), to quantify the glycan shielding of a protein surface. The software provides insights into glycan-dense\/sparse regions of the entire protein surface or a subset of the protein surface. GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics."}
{"id":"6237a5513a8413c6530000b0","question":"What does the gene symbol EREG stand for?","long_answer":"The gene symbol EREG stands for the gene epiregulin.","answer":"epiregulin","context":"We found that epidermal growth factor (EGF)-deficient cells exhibited lower basal ERK activity than the cells deficient in heparin-binding EGF (HBEGF), transforming growth factor alpha (TGF\u03b1) or epiregulin (EREG), but all cell lines deficient in a single EGFR ligand retained the ERK activation waves."}
{"id":"62005e02c9dfcb9c09000018","question":"Which tool has been developed for proteome-wide detection of membrane lipid-binding proteins?","long_answer":"MBPpred is a profile Hidden Markov Model based method capable of detecting Membrane Binding Proteins (MBPs) from information encoded in their amino acid sequence.","answer":"MBPpred","context":"MBPpred: Proteome-wide detection of membrane lipid-binding proteins using profile Hidden Markov Models. Here we report a profile Hidden Markov Model based method capable of detecting Membrane Binding Proteins (MBPs) from information encoded in their amino acid sequence, called MBPpred. The method identifies MBPs that contain one or more of the Membrane Binding Domains (MBDs) that have been described to date, and further classifies these proteins based on their position in respect to the membrane, either as peripheral or transmembrane. MBPpred is available online at http:\/\/bioinformatics.biol.uoa.gr\/MBPpred. This method was applied in selected eukaryotic proteomes, in order to examine the characteristics they exhibit in various eukaryotic kingdoms and phyla."}
{"id":"61f7c883882a024a10000026","question":"What disease can be treated with Avacopan?","long_answer":"Avacopan is effective for ANCA-associated vasculitis.","answer":"ANCA-associated vasculitis","context":"Current therapies are often effective in inducing and maintaining remission but are associated with a range of toxicities. Several new therapies are in development for ANCA vasculitis. Avacopan, an orally administered inhibitor of the complement fragment 5a (C5a) receptor, has been assessed in a phase 3 clinical trial and may play a role in reducing the cumulative glucocorticoid dose.  New treatment approaches, such as the C5a receptor inhibitor avacopan could enable a\u00a0minimized steroid treatment in the future. GPA\/MPA INDUCTION OF REMISSION: \u2002As demonstrated in the ADVOCATE-trial avacopan allows for a substantial reduction of glucocorticoid (GC) use during induction of remission. A future role of avacopan in the treatment of GPA and MPA is likely. Avacopan has shown significant promise in ANCA-associated vasculitis as part of a glucocorticoid-free induction regimen in a recently completed phase 3 trial. In ANCA-associated vasculitis, avacopan was superior to prednisone taper for sustained remission SOURCE CITATION: Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599-609. 33596356. Avacopan for the Treatment of ANCA-Associated Vasculitis. BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. CONCLUSIONS: In this trial involving patients with ANCA-associated vasculitis, avacopan was noninferior but not superior to prednisone taper with respect to remission at week 26 and was superior to prednisone taper with respect to sustained remission at week 52.  Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. tly, new molecules are being developed and some of them have already demonstrated clinical efficacy, such as avacopan (C5aR blocker) in ANCA vasculitis. As for k ber 2021, avacopan received its first approval in Japan for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), the two most common forms of ANCA-associated vasculitis, where it is being commercialized by Kissei Pharmaceutical through a partnership with Vifor Pharma. In October 20 Avacopan for the treatment of ANCA-associated vasculitis Avacopan for the Treatment of ANCA-Associated Vasculitis Avacopan in the treatment of ANCA-associated vasculitis In ANCA-associated vasculitis, avacopan was superior to prednisone taper for sustained remission.  avacopan was approved in the USA as an adjunctive treatment in adults for severe active ANCA-associated vasculitis (specifically MPA and GPA) in combination with standard therapy including glucocorticoids (avacopan does not eliminate glucocorticoid use). Avacopan has rece Avacopan (TAVNEOS\u2122) is a complement 5a receptor (C5aR) antagonist developed by ChemoCentryx for the treatment of autoimmune diseases including anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. The  al will evaluate if avacopan replaces the need for chronic glucocorticoids in the treatment of ANCA-associated vasculitis.OBJECTI Avacopan for the treatment of ANCA-associated vasculitis. Avacopan in the treatment of ANCA-associated vasculitis. OBJECTIVE: This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in addition to standard-of-care (SOC) treatment with glucocorticoids with cyclophosphamide or rednisone.CONCLUSIONS: In this trial involving patients with ANCA-associated vasculitis, avacopan was noninferior but not superior to prednisone tap Avacopan (TAVNEOS\u2122) is a complement 5a receptor (C5aR) antagonist developed by ChemoCentryx for the treatment of autoimmune diseases including anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. In September 2021, avacopan received its first approval in Japan for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), the two most common forms of ANCA-associated vasculitis, where it is being commercialized by Kissei Pharmaceutical through a partnership with Vifor Pharma. In October 2021, avacopan was approved in the USA as an adjunctive treatment in adults for severe active ANCA-associated vasculitis (specifically MPA and GPA) in combination with standard therapy including glucocorticoids (avacopan does not eliminate glucocorticoid use). BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.METHODS: In this randomized, controlled trial, we assigned patients with ANCA-associated vasculitis in a 1:1 ratio to receive oral avacopan at a dose of 30 mg twice daily or oral prednisone on OBJECTIVE: This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in addition to standard-of-care (SOC) treatment with glucocorticoids with cyclophosphamide or rituximab.METHODS: In this randomized 12-week study, twice daily avacopan (10 mg or 30 mg) plus SOC was assessed versus SOC only in patients with newly diagnosed\/relapsing ANCA-as onephritis. This trial will evaluate if avacopan replaces the need for chronic glucocorticoids in the treatment of ANCA-associated vasculitis.OBJECTIVE: The aim of this study is to determine the proportions of patients in remission at week 26 and with sustained remission at week 52, defined as Birmingham Vasculitis Activity Score=0, and not taking glucocorticoids within the 4 weeks before week 26 and week 52, respectively.METHODS: The Avacopan Development in Vasculitis to Obtain Corticosteroid elimination and Therapeutic Efficacy study is a randomized, double-blind, active-comparator (prednisone), 2-arm study evaluating the safety and efficacy of avacopan versus prednisone, administered in combination with "}
{"id":"622b9e743a8413c653000097","question":"What disease is also known as Bechterew's Disease?","long_answer":"Ankylosing spondylitis (Bechterew's disease) is the most typical form of axial SpA whereby sacroiliitis can be found on X-rays of the SI joints.","answer":"Ankylosing spondylitis","context":"Ankylosing spondylitis (Bechterew's disease) is the most typical form of axial SpA whereby sacroiliitis can be found on X-rays of the SI joints. [Special considerations in therapy of injuries of the cervical spine in ankylosing spondylitis (Bechterew disease)] Ankylosing spondylitis (AS) or Bechterew disease is a chronic, usually progressive, systemic inflammatory joint disease, which predominantly affects the spine and sacroiliac joints. In  iagnosis and therapy of axial spondyloarthritis including ankylosing spondylitis (Bechterew's disease)]. Hyperplasia of the coronoid process in patients with ankylosing spondylitis (Bechterew disease) pecial considerations in therapy of injuries of the cervical spine in ankylosing spondylitis (Bechterew disease)] irected cloning of the HLA-B27 gene isolated from a patient with ankylosing spondylitis (Bechterew's disease)]. Bechterew's syndrome (ankylosing spondylitis). Ankylosing spondylitis (AS) or Bechterew disease is a chronic, usually progressive, systemic inflammatory joint disease, which predominantly affects the spine and sacroiliac joints. [Ankylosing spondylitis (Bechterew's disease)--a current review (author's transl)]. The distribution of clinical findings in Bechterew's syndrome (ankylosing spondylitis) suggests distinct genetic subgroups. Hyperplasia of the coronoid process in patients with ankylosing spondylitis (Bechterew disease). [Surgical management of ankylosing spondylitis (Bechterew's disease)]. [Diagnosis and therapy of axial spondyloarthritis including ankylosing spondylitis (Bechterew's disease)]. Ankylosing spondylitis (AS) or else Bechterews\u00a0or Marie-Str\u00fcmpells\u00a0disease is a\u00a0chronic inflammatory autoimmune disease affecting preferentially the spine in the form of sacroileitis and spondylitis [1,2]. Although involvement of the temporomandibular joint in patients with ankylosing spondylitis (AS, Bechterew disease) has been described previously"}
{"id":"6237ac143a8413c6530000b7","question":"Through which pathway does epiregulin promote leptin secretion?","long_answer":"EREG increased leptin production and secretion in a dose-dependent manner in iAb fat explants via the EGFR\/MAPK pathway.","answer":"EGFR\/MAPK pathway","context":"EREG increased leptin production and secretion in a dose-dependent manner in iAb fat explants via the EGFR\/MAPK pathway. "}
{"id":"61f7c60c882a024a10000025","question":"What is the target of Sotorasib?","long_answer":"Sotorasib is a KRASG12C inhibitor.","answer":"KRASG12C","context":"Encouragingly, the KRASG12C inhibitor AMG510 (sotorasib), which has been approved for treating NSCLC and CRC recently, makes directly targeting KRAS the most promising strategy for cancer therapy.  Finally, we show that a selective PI4KA inhibitor augments the antineoplastic activity of the KRASG12C inhibitor\u00a0sotorasib, suggesting a clinical path to exploit this pathway.  However, clinical candidates targeting the KRAS G12C protein have recently been developed. MRTX849 and recently approved Sotorasib are covalent binders targeting the mutated cysteine 12, occupying Switch II pocket. Sotorasib with efficacy in kRAS-G12C mutation of NSCLC Two such inhibitors, sotorasib (AMG 510) and adagrasib (MRTX849), were recently evaluated in phase I-III trials for the treatment of non-small cell lung cancer with KRAS-G12C mutations, heralding a new era of precision oncology.  The findings, along with data on the KRASG12C inhibitor sotorasib, were presented at the 2021 European Society for Medical Oncology Congress. The FDA has approved the first KRAS-targeted therapy, sotorasib, for patients with previously treated non-small cell lung cancer with KRASG12C mutations. In 2021, the Food and Drug Administration (FDA) approved the use of Sotorasib (Lumakras) for the treatment of adult patients with KRAS-G12C mutated locally advanced or metastatic NSCLC, following at least one prior systemic therapy. The KRASG12C inhibitor sotorasib continues to impress in non-small cell lung cancer: In the phase II CodeBreak 100 trial, the agent elicited responses in more than a third of patients and led to a median progression-free survival of almost 7 months. Based on these result Sotorasib is a first-in-class small molecule that irreversibly inhibits KRAS G12C, locking it in an inactive state, inhibiting oncogenic signaling, and inducing a proinflammatory microenvironment. Sotorasib is a first-in class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mutation. In the nonclinical to Recently, novel KRAS G12C inhibitors, such as sotorasib and adagrasib, are being developed in clinical trials and have revealed promising results in metastatic NSCLC. We evaluated the clinical validity of Guardant360 CDx as a companion diagnostic for sotorasib for detection of KRAS p.G12C, an important oncogenic NSCLC driver mutation. Until the recent approval of sotorasib, a KRAS G12C inhibitor, lack of targeted therapy for KRAS has resulted in poor prognosis of patients with tumors harboring KRAS mutations. Sotorasib is a first-in-class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KR Sotorasib is a first-in class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mut Nonclinical Safety Profile of Sotorasib, a KRASG12C-Specific Covalent Inhibitor for the Treatment of KRAS p.G12C t efforts to produce subtype specific inhibitors have been more successful, and several KRASG12C inhibitors have reached clinical trials, including adagrasib and sotorasib, which have shown early evidence of efficacy in patients. L Sotorasib is a first-in-class small molecule that irreversibly inhibits KRAS G12C, locking it in an inactive state, inhibiting oncogenic signaling, and inducing a proinflammatory microenvironment. H phase I trial, the KRASG12C inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated. seven KRAS-G12C inhibitors are in clinical trials and sotorasib has become the first one to be granted FDA approval. Here, we re have been surprising advances in directly targeted drugs for KRAS, especially in KRAS (G12C) inhibitors, such as AMG510 (sotorasib) and MRTX849 (adagrasib), which have obtained encouraging results in clinical trials. Excitingly, AMG510 w gly, the KRASG12C inhibitor AMG510 (sotorasib), which has been approved for treating NSCLC and CRC recently, makes directly targeting KRAS the most promising strategy for cancer therapy. To bett Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.METHODS: We conducted a phase 1 trial of sotorasib in patients with esults of the nonclinical safety program support a high benefit\/risk ratio of sotorasib for the treatment of patients with KRAS p.G12C-mutated tumors. oved the first KRAS-targeted therapy, sotorasib, for patients with previously treated non-small cell lung cancer with KRASG12C mutations. In a phase I ered an \"undruggable\" target, can be targeted successfully in non-small cell lung cancer. In a phase I trial, the KRASG12C inhibitor sotorasib elicite er cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the  Sotorasib is a first-in-class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mutation. Sotorasib is a first-in class KRASG12C covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mutation. Encouragingly, the KRASG12C inhibitor AMG510 (sotorasib), which has been approved for treating NSCLC and CRC recently, makes directly targeting KRAS the most promising strategy for cancer therapy. Based on promising results in both preclinical and clinical trials, sotorasib, a novel KRASG12C inhibitor, was given conditional approval by the FDA in May 2021. Nonclinical Safety Profile of Sotorasib, a KRASG12C-Specific Covalent Inhibitor for the Treatment of KRAS p.G12C-Mutated Cancer. In a phase I trial, the KRASG12C inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated. Overall, the results of the nonclinical safety program support a high benefit\/risk ratio of sotorasib for the treatment of patients with KRAS p.G12C-mutated tumors. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors."}
{"id":"6226335d3a8413c653000082","question":"What is Luteolin?","long_answer":"Luteolin has been reviewed as a flavonoid possessing potential cardioprotective, anti-inflammatory, anti-cancer activities.","answer":"flavonoid","context":"Recently, many studies have reported the anticancer properties of flavonoid luteolin against a variety of tumors, but there is still a lack in the description of its mechanism of action Luteolin, a polyphenolic flavonoid, has potent anti-inflammatory properties.  Luteolin is a falconoid compound that has an antioxidant effect, but its mechanism in I\/R injury in vivo and in vitro is still under explored. Luteolin is a naturally occurring flavone that reportedly has anti-inflammatory effects. Luteolin is a flavonoid present in plants in the form of aglycone or glucosides. Luteolin, a naturally occurring flavonoid, possesses anti-cancer activities against several human cancers, but the exact molecular and biochemical mechanisms of above findings are not very clear, and its activity against head and neck squamous cell carcinoma (HNSCC) is seldom mentioned. In thi Luteolin is a flavonoid with antioxidant properties already demonstrated in studies related to inflammation, tumor, and cardiovascular processes; however, there are no available information regarding its antioxidant effects at the venous endothelial site. We  Luteolin (3',4',5,7-tetrahydroxyflavone) is a phytochemical found frequently in medicinal herbs. Luteolin is a dietary flavonoid commonly found in some medicinal plants. Luteolin (2-[3,4-dihydroxyphenyl]-5,7-dihydroxy-4-chromenone), is a naturally occurring flavonoid found in fruits and vegetables that exhibits many anticancer properties. Luteolin, 3',4',5,7-tetrahydroxyflavone, is a common flavonoid that exists in many types of plants including fruits, vegetables, and medicinal herbs. Luteolin is a common dietary flavonoid present in Chinese herbal medicines that has been reported to have important anti-inflammatory properties. Luteolin is a falconoid compound that is present in various types of plants and possesses remarkable potential as a chemopreventive agent. Luteolin is a natural flavonoid widely distributed in plants with anti-inflammatory effect. Luteolin is a plant flavonoid which exhibits anti-oxidative, anti-inflammatory and anti-tumor effects. Luteolin is an anti-inflammatory flavonoid and widely distributed in the plants. ucial in the pathogenesis of numerous brain disorders. Luteolin, a flavonoid compound, inhibits glutamate release, however, its ability to affect glut depression and endoplasmic reticulum stress. Luteolin is a flavonoid contained in many plants and with a variety of known pharmacological properties s  common multiple infection disease under 2 years old. Luteolin is a natural flavonoid widely distributed in plants with anti-inflammatory effect. This Luteolin is a naturally occurring flavonoid with diverse pharmacological properties such as anti-inflammatory, antioxidant and anticancer. BACKGROUND: Luteolin is a 3',4',5,7-tetrahydroxyflavone found in various fruits and Luteolin is a bioflavonoid that attenuates adipocyte-derived inflammatory responses via suppression of nuclear factor-\u03baB\/mitogen-activated protein kinases pathway. Background: Luteolin (3',4',5,7-tetrahydroxyflavone) is a flavone with a yellow crystalline appearance present in numerous plants such as broccoli, green chili, Luteolin is a flavone which occurs in medicinal plants as well as in some vegetables and spices. Luteolin, a flavonoid with potential for cancer prevention and therapy. I diabetes. Luteolin is a bioflavonoid with many beneficial properties such as antioxidant, antiproliferative, and anti-cancer.OBJECTIVES: To elucidate the potential anti-inflammatory response and the underlying mechanism of luteolin in 3T3-L1 adipocytes.MATERIALS AND METHODS: We stimulated 3T3-L1 adipocytes with the mixture of tumor necrosis factor-\u03b1, lipopolysaccharide, and interferon- Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Luteolin, an abundant dietary component is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis. Luteolin is a natural flavonoid with strong anti-oxidative properties that is reported to have an anti-cancer effect in several malignancies other than bladder cancer. Luteolin is a flavonoid found in abundance in celery, green pepper, and dandelions. BACKGROUND: Luteolin, a plant derived flavonoid, exerts a variety of pharmacological activities and anti-oxidant properties associated with its capacity to scavenge oxygen and nitro Luteolin, a naturally occurring flavonoid, is abundant in our daily dietary intake. The flavonoid luteolin shows therapeutic potential with low incidence of unwanted side effects. Luteolin is a flavonoid contained in many plants and with a variety of known pharmacological properties such as anti-inflammatory, anti-anxiety, and memory-improving effects, suggesting that luteolin penetrates into the brain."}
{"id":"621e63a43a8413c653000051","question":"Which is the literature-based database of phenotypes?","long_answer":"PheneBank is a Web-portal for retrieving human phenotype-disease associations that have been text-mined from the whole of Medline. This approach exploits state-of-the-art machine learning for concept identification by utilising an expert annotated rare disease corpus from the PMC Text Mining subset. Evaluation of the system for entities is conducted on a gold-standard corpus of rare disease sentences and for associations against the Monarch initiative data.","answer":"PheneBank","context":"PheneBank: a literature-based database of phenotypes. PheneBank is a Web-portal for retrieving human phenotype-disease associations that have been text-mined from the whole of Medline. Our approach exploits state-of-the-art machine learning for concept identification by utilising an expert annotated rare disease corpus from the PMC Text Mining subset. Evaluation of the system for entities is conducted on a gold-standard corpus of rare disease sentences and for associations against the Monarch initiative data."}
{"id":"61f7ce26882a024a1000002d","question":"Idecabtagene vicleucel can be used for treatment of which disease?","long_answer":"Idecabtagene vicleucel was shown to be effective for Relapsed and Refractory Multiple Myeloma.","answer":"Multiple Myeloma","context":"B-cell maturation antigen (BCMA) has become a key target for antibody-drug conjugates, bispecific antibodies, chimeric antigen receptor T-cell therapies, and other immunotherapies in multiple myeloma. Some of these agents such as belantamab mafodotin and idecabtagene vicleucel have already received regulatory approval in the United States.  These include isatuximab (also anti-CD38) and, in the past year, the antibody-drug conjugate (ADC) belantamab mafodotin and the chimeric antigen receptor (CAR) T-cell product idecabtagene vicleucel (ide-cel). Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748).  Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. CONCLUSIONS: Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients.  Here, we will discuss the preclinical and clinical development of idecabtagene vicleucel and its future role in the changing treatment landscape of relapsed and refractory multiple myeloma. After the recent publication of the results of a phase II trial confirming a notable efficacy and acceptable safety profile, idecabtagene vicleucel is the first CAR-T to gain regulatory US Food and Drug Administration approval to treat refractory multiple myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the last therapy. BACKGROUND AND OBJECTIVE: Registrational trials for ciltacabtagene autoleucel [cilta-cel]) and idecabtagene vicleucel [ide-cel] chimeric antigen receptor T-cell (CAR-T) therapies were single-arm studies conducted with relapse refractory multiple myeloma (MM) patients who were triple-class-exposed (TCE) or triple-class-refractory (TCR). BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma. Idecabtagene vicleucel (ide-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm phase 2 KarMMa clinical trial. Two ther BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple m The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. Idecabtagene vicleucel (ide-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm phase 2 KarMMa clinical trial. Idecabtagene vicleucel (ide-cel), a novel chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for relapsed and refractory multiple myeloma (RRMM) after multicenter trials have demonstrated unprecedented results in this difficult-to-treat subgroup of patients. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma.METHODS: In this phase 2 study, we sought to confirm the efficacy and safety of ide-cel in patients with relapsed an The bulk of CAR T-cell constructs currently in clinical development target the B-cell maturation antigen (BCMA) and to date only idecabtagene vicleucel (ide-cel) is approved by the Food and Drug Administration (FDA) for commercial use in adult patients with relapsed or refractory MM based on the promising clinical responses and positive safety record shown in the pivotal KarMMa study. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748)."}
{"id":"623345bf3a8413c6530000ab","question":"LINC00339 is a diagnostic, prognostic and treatment efficacy biomarker for what disease?","long_answer":"LINC00339 as a cancer diagnostic, prognostic and treatment efficacy biomarker.","answer":"cancer","context":"Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377-3p\/HOXC6 signaling pathway. Through microarray data, Linc00339 was identified as a candidate oncogenic lncRNA. PURPOSE: To investigate the role and mechanism of long non-coding (lnc) RNA LINC00339 in pancreatic cancer (PANC), and provided a potential target for its biological diagnosis and trea  showed that LINC00339 was significantly up-regulated in NSCLC tissue and cells, which indicated the poor prognosis of NSCLC patients. Loss-o (HCC). The lncRNA LINC00339 was reported to regulate the development of lung cancer or breast we demonstrated that LINC00339 was upregulated in glioma tissue as well as in glioma cell lines. The e LINC00339 promotes cell proliferation and metastasis in pancreatic cancer via miR-497-5p\/IGF1R axis Introduction: Accumulating evidence has indicated that long noncoding RNAs (lncRNAs) are pivotal regulators involved in the pathogenesis of cancer; however, the molecular mechanism of LINC00339 in colorectal cancer (CRC) remain vasion. Xenograft experiment was used to test tumor growth in vivo. Results: LINC00339 overexpression was correlated with an advanced stage, metastasis, and bad prognosis Endometriosis risk alleles at 1p36.12 act through inverse regulation of CDC42 and LINC00339 LINC00339 regulates ROCK1 by miR-152 to promote cell proliferation and migration in hepatocellular carcinoma Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377-3p\/HOXC6 signaling pathway ugh microarray data, Linc00339 was identified as a candidate oncogenic lncRNA. We   in vivo experiments, Linc00339 overexpression promoted triple-negative breast cancer (TNBC) proliferation, inhibited cell cycle arrest, and suppressed apoptosis. Silencing of Linc00339  pared the expression levels of Linc00339 in several breast cancer cell lines and normal mammary gland epithelial cell line. The  work identified a 5-lncRNA signature (ENSG00000206567, PCAT29, ENSG00000257989, LOC388282, and LINC00339) from TCGA training studies (n = 1,878). The identifie fects of Linc00339 on tumor progression were examined both in vitro and in vivo. 3-(4 LINC00339 expression in colorectal cancer tissues and adjacent colorectal sampleswas detected by Real-time PCR. Linc00339 was then found to play a critical role in Huaier-mediated cancer suppression. Conclusions: LINC00339 expression is upregulated in colorectal cancer tissues and correlated with patients' clinicopathological features. tween miR-152 and ROCK1. The role of LINC00339 in tumor formation and metastasis were explored thr PURPOSE: To investigate the role and mechanism of long non-coding (lnc) RNA LINC00339 in pancreatic cancer (PANC), and provided a potential target for its biological diagnosis and treatment.METHODS: Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of LINC00339 in PANC tissue specime LINC00339 promotes gastric cancer progression by elevating DCP1A expression via inhibiting miR-377-3p. Our findings highlight the importance of the LINC00339-miR-539-SOX9 pathway in gastric cancer pathogenesis and may point to novel targets for the diagnosis, prognosis, and\/or treatment of gastric cancer. LINC00339 promotes cell proliferation and metastasis in pancreatic cancer via miR-497-5p\/IGF1R axis. In conclusion, LINC00339 promotes gastric cancer progression by elevating DCP1A expression via inhibiting miR-377-3p. r transfected with miR-152 mimics. LINC00339 exerted oncogenesis effect on HCC progression by targeting miR-152\/ROCK1, and the expression of LINC00339 was negatively correlated with miR-152 expression and positively correlated with ROCK1  Long noncoding RNA LINC00339 promotes the oncogenicity of gastric cancer by regulating SRY-box 9 expression via sponging of microRNA-539. Long noncoding RNA LINC00339 promotes laryngeal squamous cell carcinoma cell proliferation and invasion via sponging miR-145. In conclusion, our results illuminated that the novel Linc00339\/miR-377-3p\/HOXC6 axis played a critical role in TNBC progression and might be a promising therapeutic target for TNBC treatment. Through in vitro and in vivo experiments, Linc00339 overexpression promoted triple-negative breast cancer (TNBC) proliferation, inhibited cell cycle arrest, and suppressed apoptosis. Linc00339 was increased in breast cancer cell lines compared with the normal epithelial cell. And miR-377-3p was involved in Linc00339-mediated TNBC proliferation through regulating HOXC6 expression. The SP1-Induced Long Noncoding RNA, LINC00339, Promotes Tumorigenesis in Colorectal Cancer via the miR-378a-3p\/MED19 Axis. We compared the expression levels of Linc00339 in several breast cancer cell lines and normal mammary gland epithelial cell line."}
{"id":"61f86c03882a024a10000044","question":"Which disease is caused by repeat expansion in VWA1?","long_answer":"An ancestral 10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy.","answer":"Recessive hereditary motor neuropathy","context":"An ancestral 10-bp repeat expansion in VWA1 causes recessive hereditary motor neuropathy. In summary, we estimate that biallelic variants in VWA1 may be responsible for up to 1% of unexplained hereditary motor neuropathy cases in Europeans. The detailed clinical characterization provided here will facilitate targeted testing on suitable patient cohorts. This novel disease gene may have previously evaded detection because of high GC content, consequential low coverage and computational difficulties associated with robustly detecting repeat-expansions. Reviewing previously unsolved exomes using lower QC filters may generate further diagnoses."}
{"id":"622a5a7c3a8413c653000090","question":"Is PPROM a condition that occurs in males or females?","long_answer":"Preterm premature rupture of fetal membranes (PPROM) occurs in pregnant females.","answer":"Females","context":"preterm premature rupture of fetal membranes (PPROM) To examine the effect of aspirin, an anti-inflammatory agent, on the prevalence of preterm prelabor rupture of membranes (PPRoMs).  preterm prelabor rupture of membranes (PPROM).  preterm premature rupture of membranes (PPROM)  focused on TTTS, preterm premature rupture of membranes (PPROM), pregnancy-induced hypertension (PIH), and fetal sex as possible causes of PTB.RE lts: Patients with the pregnancy complicated by OHSS, had a considerably higher rate of preterm labor, whether this was labor before gestation week 37 (56.0% vs. 30.5%) or before gestation week 34 (34.0% vs. 6.8%); significantly lower weight of newborns, as in the newborns with low body weight <2500g (45.6% vs. 25.0%) and specially in the newborn with very low body weight <1500 grams (19.1% vs. 3.8%), as well as preterm premature rupture of membranes (PPROM), (11.76% vs. 1.59%).Conc OBJECTIVES: Preterm premature rupture of membranes (PPROM) is defined as a rupture of the amniotic membranes occurring before 37 weeks of gestation and before the onse Preterm premature rupture of membranes (PPROM) occurs in 1% to 2% of births. Im Preterm premature rupture of membranes (PPROM) is defined as rupture of membrane that happens before the onset of labor and 37 weeks.  OBJECTIVES: Preterm premature rupture of membranes (PPROM) is defined as the rupture of fetal membranes befor Objective: To show that infants delivered prematurely because of preterm premature rupture of the membranes (PPROM) show a tendency for asymmetric intrauterine growth retardation (IUGR). A ported among preterm prelabor rupture of membranes (PPROM). Educating the ates with PC were significantly different from controls with regard to male prevalence ( P =0.002), rates of preterm premature rupture of membranes (PPROM) ( P =0.02), longer duration of antibiotic therapy ( P =0.01) and of ventilation ( P =0.02). The di premature rupture of membranes (PPROM) is a common condition in pregnant women and is associated with significant maternal and perinatal morbidity. Mo tory response to lipopolysaccharide (LPS). This heightened response could be a critical pathway in promoting premature rupture of membranes (PPROM) and may be associated with life long OBJECTIVES: Preterm premature rupture of membranes (PPROM) is defined as a rupture of the amniotic membranes occurring before 37 weeks of gestation and before the ons Objective: To show that infants delivered prematurely because of preterm premature rupture of the membranes (PPROM) show a tendency for asymmetric intrauterine growth retardation (IUGR). AIM: To determine whether preterm premature rupture of membranes (PPROM) before 24 weeks is an independent risk factor for poor outcome in preterm neonates.METHODS: A retrospective comparative cohort study was conducted, including viable premature infants born between 25 and 34-we PURPOSE: To assess prevalence and risk factors for posttraumatic stress disorder (PTSD) and depression in fathers after early preeclampsia (PE) or preterm premature rupture of membranes (PPROM).METHODS: Partners of patients hospitalized for PE or PPROM and partners of healthy controls completed PTSD (PSS-SR) and depression (BDI-II) questionnaires during pregnancy (t 1) and 6 weeks s and iatrogenic preterm delivery. In our high-risk cohort there was no gender difference for preeclampsia (RR 0.93, 95% CI 0.61 to 1.41, p\u202f=\u202f0.725) or preterm premature rupture of membranes (PPROM) (RR 1.14, 95% CI 0.86 to 1.50, p\u202f=\u202f0.384) CONCLUSIONS: In a high-risk cohort there was no significant increased risk of miscarriage, spontaneous or iatrogenic PTB, preecl Preterm premature rupture of membranes (PPROM) is a condition leading to an increased risk of maternal and neonatal morbidity and mortality in pregnant women. UNLABELLED: Preterm premature rupture of membranes (PPROM) occurs in 3% of pregnancies and is responsible for one third of all pre Preterm premature rupture of the membranes (PPROM) occurs in approximately 3% of all pregnancies, and accounts for one third of all preterm births."}
{"id":"61f7cc0c882a024a1000002a","question":"What is the target of Sutimlimab?","long_answer":"Sutimlimab is a novel humanized monoclonal antibody directed against classical pathway complement factor C1s.","answer":"C1s","context":"Beyond PNH, complement inhibition has also shown efficacy and safety in cold agglutinin disease (CAD), primarily with the C1s inhibitor of the classical complement pathway, sutimlimab, but also with pegcetacoplan.  The complement C1s inhibitor sutimlimab is an emerging option in the second line and may also find its place in the first line in specific situations. Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathway. Sutimlimab is a novel humanized monoclonal antibody directed against classical pathway complement factor C1s.  Therapeutic options for these complement-mediated disorders are limited and sutimlimab, a humanized monoclonal antibody directed against complement factor C1s, may be potentially useful for inhibition of the classical complement pathway. Sutimlimab is a novel humanized monoclonal antibody directed against classical pathway complement factor C1s. SIONS: In patients with cold agglutinin disease who received sutimlimab, selective upstream inhibition of activity in the classic complement pathway rapidly halted hemolysis, increased hemoglobin levels, and reduced fatigue. (Fund The complement C1s inhibitor sutimlimab is an emerging option in the second line and may also find its place in the first line in specific situations. C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro. In this study, we use BIVV009 (Sutimlimab), a clinical stage, humanized mAb that specifically inhibits the CP-specific serine protease C1s to evaluate the impact of upstream CP antagonism on activation and proliferation of normal and autoimmune human B cells. Novel treatment options that target the classical complement pathway are under development and appear very promising, and the C1s inhibitor sutimlimab is currently being investigated in two clinical Phase II and III trials. Of these, the anti-C1s monoclonal antibody sutimlimab has shown favorable activity in CAD, while the anti-C3 cyclic peptide pegcetacoplan appears to be promising in PNH as well as CAD, and may also have a therapeutic potential in wAIHA. t pathway. Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this ent options that target the classical complement pathway are under development and appear very promising, and the C1s inhibitor sutimlimab is currently being investigated in two clinical Phase II and III trials. These achie apeutic options for these complement-mediated disorders are limited and sutimlimab, a humanized monoclonal antibody directed against complement factor C1s, may be potentially useful for inhibition of the classical complement pathway. A ph is trial tested the hypothesis that the anti-C1s antibody sutimlimab would ameliorate hemolytic anemia.  s study, we use BIVV009 (Sutimlimab), a clinical stage, humanized mAb that specifically inhibits the CP-specific serine protease C1s to evaluate the impact of upstream CP antagonism on activation and proliferation of normal and autoimmune human B cells. We repor In this phase 1 trial, we evaluated the safety and activity of BIVV009 (sutimlimab, previously TNT009), a targeted C1s inhibitor, in 10 subjects with active or past bullous pemphigoid (NCT02502903).  and activity of BIVV009 (sutimlimab, previously TNT009), a targeted C1s inhibitor, in 10 subjects with active or past bullous pemphigoid (NCT02502903 and sutimlimab, a humanized monoclonal antibody directed against complement factor C1s, may be potentially useful for inhibition of the classical comp . Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathw . This trial tested the hypothesis that the anti-C1s antibody sutimlimab would ameliorate hemolytic anemia. Ten patients with cold agglutinin disease  cted therapies (ibrutinib, venetoclax, parsaclisib) and inhibitors of complement (sutimlimab, pegcetacoplan), spleen tyrosine kinases (fostamatinib),  nt pathway. Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathway.METHODS: We conducted a 26-week multicenter, open-label, single-group study to assess the efficacy and safety of intravenous sutimlimab in patients with cold agglutinin disease and a recent hi This trial tested the hypothesis that the anti-C1s antibody sutimlimab would ameliorate hemolytic anemia."}
{"id":"624c919ee764a53204000004","question":"Where is the protein \"Single-stranded DNA-binding protein\" found?","long_answer":"In the mitochondrion (mitochondrial single-stranded DNA binding protein, mtSSB) and its role is the regulation of mitochondrial DNA replication initiation in mammalian mitochondria.","answer":"Mitochondrion","context":"the mitochondrial single-stranded DNA-binding protein (mtSSB) We report a role for the mitochondrial single-stranded DNA binding protein (mtSSB) in regulating mitochondrial DNA (mtDNA) replication initiation in mammalian mitochondria.  SSB1, a Mitochondrial Single-Stranded DNA-Binding Protein The mitochondrial single-stranded DNA-binding protein (mtSSB)  mitochondrial single-stranded DNA-binding protein. "}
{"id":"626aed2fe764a53204000043","question":"For which indication has inotersen been approved?","long_answer":"Inoteresen has been approved for patients in stage 1 and stage 2 hereditary transthyretin amyloidosis polyneuropathy.","answer":"stage 1 and stage 2 hereditary transthyretin amyloidosis polyneuropathy","context":"Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis. A new drug named inotersen (brand name Tagsedi), also known as IONIS-TTRRX, has been approved by the United States Food and Drug Agency, Health Canada, and European Commission in 2018, and introduced to the market for patients in stage 1 and stage 2 hATTR polyneuropathy."}
{"id":"623e04e4f0baec9a1b000006","question":"Which disease is caused by mutations in the gene CALR?","long_answer":"Somatic mutations of calreticulin (CALR) have been identified as a main disease driver of myeloproliferative neoplasms,","answer":"myeloproliferative neoplasms","context":"JAK2, CALR, and MPL are myeloproliferative neoplasm (MPN)-driver mutations,  loss-of-function CALR mutations promote oncogenesis Myeloproliferative Neoplasms (MPN) are acquired clonal disorders of the hematopoietic stem cells and include Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis. MPN are characterized by mutations in three driver genes (JAK2, CALR and MPL) and by a state of chronic inflammation.  Classification of myeloproliferative neoplasms is based on hematologic, histopathologic, and molecular characteristics, including the BCR-ABL1 and JAK2 V617F or MPL and CALR.  AIMS: JAK2V617F (JAK2), calreticulin (CALR) and MPL515L\/K (MPL) mutations are important in essential thrombocythemia (ET) and may be associated with various clinical consequences of the disease.  Somatic mutations of calreticulin (CALR) have been identified as a main disease driver of myeloproliferative neoplasms,"}
{"id":"62005c68c9dfcb9c09000017","question":"Which tool has been developed for annotation of G\u03b1, G\u03b2 and G\u03b3 subunits of G-proteins?","long_answer":"GprotPRED is a tool that has been developed for annotation of G\u03b1, G\u03b2 and G\u03b3 subunits of G-proteins using profile Hidden Markov Models (pHMMs).","answer":"GprotPRED","context":"GprotPRED: Annotation of G\u03b1, G\u03b2 and G\u03b3 subunits of G-proteins using profile Hidden Markov Models (pHMMs) and application to proteomes. An online tool, GprotPRED, was developed that uses these six pHMMs. The sensitivity and specificity for all pHMMs were equal to 100% with the exception of the G\u03b2 case, where sensitivity equals to 100%, while specificity is 99.993%. In contrast to Pfam's pHMM which detects G\u03b1 subunits in general, our method not only detects G\u03b1 subunits but also classifies them into the appropriate G\u03b1-protein family and thus could become a useful tool for the annotation of G-proteins in newly discovered proteomes. GprotPRED online tool is publicly available for non-commercial use at http:\/\/bioinformatics.biol.uoa.gr\/GprotPRED and, also, a standalone version of the tool at https:\/\/github.com\/vkostiou\/GprotPRED."}
{"id":"623e02e0f0baec9a1b000005","question":"What is the KDEL retention signal?","long_answer":"the -KDEL retention signal sequence is characteristic of many proteins localized to the ER.","answer":"ER retention sequence (KDEL)","context":"By fusing the antibody with a KDEL retention signal, the interaction of antibodies and native membrane antigens occurs inside the endoplasmic reticulum during the process of protein secretion ER retention sequence (KDEL)  The KDEL retention signal led to the accumulation of PrP in the ER,  retained in the endoplasmic reticulum (ER) using a KDEL retention signal  These sequences are similar to the -KDEL retention signal sequence characteristic of many proteins localized to the ER."}
{"id":"626aef83e764a53204000044","question":"When was Vitravene approved in Brazil?","long_answer":"Vitravene was approved in Brazil in the summer of 1999.","answer":"1999","context":"In August 1998, the FDA approved the marketing of Vitravene for the local treatment of CMV retinitis [296420], [296780], and both European and Brazilian registration approval followed in the summer of 1999 [335238]."}
{"id":"623c8330f0baec9a1b000003","question":"What is the association between maternal and fetal alloantigens and RANTES production?","long_answer":"Maternal tolerance to fetal alloantigens may be induced by RANTES production.","answer":"induction of tolerance","context":"Induction of maternal tolerance to fetal alloantigens by RANTES production. we have investigated the role of RANTES in the induction of maternal-fetal tolerance. RANTES may be implicated in the local induction of a Th1-type response necessary for successful implantation. PROBLEM: Several studies indicate that RANTES (regulated on activation, normal T cell expressed and secreted) is able to downregulate T-cell responses which suggest it might be relevant for fetal tolerance induction. Induction of maternal tolerance to fetal alloantigens by RANTES production PROBLEM: Several studies indicate that RANTES (regulated on activation, normal T cell expressed and secreted) is able to downregulate T-cell responses which suggest it might be relevant for fetal tolerance ind PROBLEM: Several studies indicate that RANTES (regulated on activation, normal T cell expressed and secreted) is able to downregulate T-cell responses which suggest it might be relevant for fetal tolerance i Cytokines such as monocyte chemotactic peptide-1 (MCP-1), interleukin-8 (IL-8), RANTES (Regulated on Activation and Normally T-cells Expressed and presumably Secreted) and interleukin-10 (IL-10) are thought to play pivotal roles in immune recognition, acceptance of the fetal allograft, maintenance of pregnancy and parturition."}
{"id":"626ae803e764a5320400003c","question":"What is the half-life of epimutations across generations of C. elegans?","long_answer":"In C. elegans, epimutations typically have short half-lives of two to three generations. Nevertheless, some epimutations last at least ten generations.","answer":"Typically 2-3 generations. Sometimes >10 generations.","context":"We show that epimutations arise spontaneously at a rate approximately 25 times greater than DNA sequence changes and typically have short half-lives of two to three generations. Nevertheless, some epimutations last at least ten generations."}
{"id":"62507602e764a5320400000d","question":"What does temsirolimus inhibit?","long_answer":"Temsirolimus is a mTOR inhibitor","answer":"mTOR","context":"a clinically relevant mTOR inhibitor, temsirolimus, e mTOR-inhibitor temsirolimus  mTOR inhibitors: 23 everolimus and 21 temsirolimus; Temsirolimus is a mTOR inhibitor approved for the first-line treatment of advanced or metastatic renal cell carcinoma (a\/mRCC) with poor prognosis."}
{"id":"626aa929e764a53204000039","question":"What happens to the expression levels of piRNAs in the case of intracranial aneurysm rupture?","long_answer":"piRNAs showed a substantial decrease in RNA abundance that was sustained after IA rupture.","answer":"Decreased","context":"piRNAs and rRNAs showed a substantial decrease in RNA abundance that was sustained after IA rupture, whereas miRNAs were largely upregulated.  We used next-generation sequencing to analyze the expression of sRNAs in patients in the acute phase of IA rupture (first 72 h), in the chronic phase (3-15 months), and controls."}
{"id":"61f7c9ac882a024a10000028","question":"Lucio\u2019s Phenomenon is characteristic to which disease?","long_answer":"Lucio's phenomenon is a rare but distinctive skin eruption seen in patients with diffuse lepromatous leprosy.","answer":"leprosy","context":"Diffuse multibacillary leprosy patient with Lucio's phenomenon and positive anticardiolipin antibody misdiagnosed as lupus erythematosus panniculitis in the People's Republic of China. Lucio's phenomenon (LP) is a special reactional state associated with diffuse multibacillary leprosy; both exhibit a limitative global distribution mainly in Mexico and Central America.  Diffuse Multibacillary Leprosy of Lucio and Latap\u00ed with Lucio's Phenomenon, Peru. He also had Lucio's phenomenon, characterized by vascular thrombosis and invasion of blood vessel walls by leprosy bacilli, causing extensive skin ulcers. Lucio's phenomenon is a rare but distinctive skin eruption seen in patients with diffuse lepromatous leprosy.  Lucio's phenomenon is defined as a variant of type 2 leprosy reaction. Lucio's phenomenon is a rare manifestation among lepromatous patients with a rapid and severe evolution and high mortality. Lucio's phenomenon is a rare but distinctive skin eruption seen in patients with diffuse lepromatous leprosy.  Lucio's phenomenon is a rare but distinctive skin eruption seen in patients with diffuse lepromatous leprosy Lucio's phenomenon (LP) is a special reactional state associated with diffuse multibacillary leprosy; both exhibit a limitative global distribution mainly in Mexico and Central America. W BACKGROUND: Lucio's phenomenon is a rare manifestation of untreated leprosy which is seen almost exclusively in regions surrounding the Gul O Lucio's phenomenon is an uncommon type 2 reactional state occurring exclusively in patients with diffuse lepromatous leprosy (Lucio-Latapi leprosy). Lucio's phenomenon represents a serious cutaneous necrotizing reaction, which can occur with Lucio's leprosy and also in other forms of lepromatous leprosy. T BACKGROUND: Lucio's phenomenon is a rare leprosy reaction characterised by bizarrely-shaped, purpuric skin lesions and  Lucio's phenomenon (LPh) is considered a necrotizing panvasculitis and a variant of leprosy Type 2 reaction, clinically characterised by necrotic-haemorrhagic lesions on the extremities and trunk. LP estations. Ulcer is not a common feature in leprosy patients, except during reactional states, Lucio's phenomenon (LP), or secondary to neurop to the clinical and histopathological manifestations, leprosy reactions may be separated in 2 or 3 different variants: reverse reaction (type I), erythema nodosum leprosum (type II), erythema polymorphous (type II) and Lucio's phenomenon, mainly considered a type II reaction, but sometimes designated type III. Type I leprosy reac Lucio's phenomenon is a rare but distinctive skin eruption seen in patients with diffuse lepromatous leprosy. Lucio's phenomenon is characterized by necrotic ulcerations of the skin preferentially on the lower extremities usually in association with ongoing Lucio lepromatosis. Lucio's phenomenon\/erythema necroticans is a peculiar reaction pattern that occurs in untreated pure primitive diffuse lepromatous leprosy (PPDL) and\/or relapsing leprosy recognized as spotted leprosy of Lucio. BACKGROUND: Lucio's phenomenon is a rare and aggressive necrotising variant of erythema nodosum leprosum that classically occur in patients with undiagnosed, diffuse non-nodular lepromat io's phenomenon was suspected. A clinical diagnosis of Lucio's phenomenon occurring in the backdrop of lepromatous leprosy was made.CONCLUSION: Though leprosy is still a prevalent disease, it has manifestations that are "}
{"id":"62507520e764a5320400000c","question":"Where are the complexins expressed?","long_answer":"Complexins (CPLXs), initially identified in neuronal presynaptic terminals, are cytoplasmic proteins that interact with the soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNARE) complex to regulate the fusion of vesicles to the plasma membrane.","answer":"presynaptic terminal","context":"Complexins (CPLXs), initially identified in neuronal presynaptic terminals, are cytoplasmic proteins that interact with the soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNARE) complex to regulate the fusion of vesicles to the plasma membrane. Complexins (Cplxs) are small synaptic proteins that cooperate with SNARE-complexes in the control of synaptic vesicle (SV) fusion. Complexins are presynaptic proteins  Complexins are small \u03b1-helical proteins that modulate neurotransmitter release by binding to SNARE complexes during synaptic vesicle exocytosis. Complexins play a critical role in the regulation of neurotransmission by regulating SNARE-mediated exocytosis of synaptic vesicles."}
{"id":"6252f496e764a53204000020","question":"What is the gene ABCG1 encoding?","long_answer":"ABCG1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues.","answer":"ATP binding cassette (ABC) transporter","context":"ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1), ABCG1 is an ATP binding cassette (ABC) transporter that removes excess cholesterol from peripheral tissues.  ATP\u2011binding cassette sub\u2011family\u00a0G member\u00a01\u00a0(ABCG1) "}
{"id":"626aeab6e764a5320400003e","question":"When was Volanesorsen approved in the EU?","long_answer":"In May 2019, volanesorsen was approved in the EU for the treatment of adult patients with familial chylomicronemia syndrome.","answer":"May 2019","context":"In May 2019, volanesorsen was approved in the EU for the treatment of adult patients with FCS based on positive results from the multinational, phase\u00a0III APPROACH and COMPASS studies. "}
{"id":"6253307fe764a53204000024","question":"How many copies of LBX are found in teleosts?","long_answer":"In teleosts, that have undergone an additional genome duplication, 8 Lbx paralogons (three of which retain Lbx genes) were found.","answer":"8","context":"In teleosts, that have undergone an additional genome duplication, 8 Lbx paralogons (three of which retain Lbx genes) were found.   teleosts, that have undergone an additional genome duplication, 8 Lbx paralogons (three of which retain Lbx genes) were found. P  In teleosts, that have undergone an additional genome duplication, 8 Lbx paralogons (three of which retain Lbx genes) were foun  genes) in amniotes. In teleosts, that have undergone an additional genome duplication, 8 Lbx paralogons (three of which retain L"}
{"id":"6250787be764a5320400000e","question":"What is the drug Aduhelm approved for?","long_answer":"he Food and Drug Administration (FDA) granted approval for Aduhelm (aducanumab) for the treatment of Alzheimer's disease under its accelerated approval program","answer":"treatment of Alzheimer's disease","context":"According to the FDA, aducanumab (Aduhelm), the recently approved anti-Alzheimer drug, reduces the level of cerebral amyloid plaques-a hallmark finding in patients with Alzheimer's disease-and this will result in a reduction in clinical decline Aducanumab (aducanumab-avwa; Aduhelm\u2122) is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid \u03b2. It has been co-developed by Biogen and Eisai under license from Neurimmune for the treatment of Alzheimer's disease. Aducanumab (Aduhelm), the first new drug to treat Alzheimer's On June 7th 2021, the Food and Drug Administration (FDA) granted approval for Aduhelm (aducanumab) for the treatment of Alzheimer's disease under its accelerated approval program Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer's disease (AD). "}
{"id":"624c838ee764a53204000001","question":"What disease is presenilin involved in?","long_answer":"Loss-of-function mutations in PSEN1\/2 genes are the leading cause of familial Alzheimer's disease (fAD).","answer":"familial Alzheimer's disease","context":"The presenilin genes (PSEN1 and PSEN2) are mainly responsible for causing early-onset familial Alzheimer's disease, harboring ~300 causative mutations, and representing ~90% of all mutations associated with a very aggressive disease form.  Loss-of-function mutations in PSEN1\/2 genes are the leading cause of familial Alzheimer's disease (fAD).  Alzheimer's disease (AD) is the most frequent cause of dementia in the elderly. Few cases are familial (FAD), due to autosomal dominant mutations in presenilin-1 (PS1), presenilin-2 (PS2) or amyloid precursor protein (APP).  Mutations in the presenilin (PS\/PSEN) genes encoding the catalytic components of \u03b3-secretase accelerate amyloid-\u03b2 (A\u03b2) and tau pathologies in familial Alzheimer's disease (AD)."}
{"id":"62532ce6e764a53204000021","question":"In what part of the body is the masseter muscle located?","long_answer":"In human anatomy, the masseter is one of the muscles of mastication and is located in the jaw.","answer":"Jaw","context":"Intramuscular hemangiomas of the masseter muscle are uncommon tumors and therefore can be difficult to accurately diagnose preoperatively, due to the unfamiliar presentation and deep location in the lateral face. A case of intramuscular hemangioma of the masseter muscle in a 66-yearold woman is presented. As part of this study, a comparative analysis of the temporal and masseter muscle electrical activity at rest and during mandible excursion positions (protrusion, laterotrusion and maximal occlusion) was performed among patients aged 21 to 68 years.  Masticatory myofascial trigger points (TrP) are one of the major causes of nondental pain in the orofacial region. Intramuscular injections are considered the first-line treatment for myofascial TrPs. The objectives of this study were to evaluate and compare the effectiveness of local anesthesia (LA), botulinum toxin (BTX), and platelet-rich plasma (PRP) injections for the treatment of myofascial TrPs in the masseter muscle. The organ extends from below the zygomatic bone line to the middle of the mandible body, between the skin and the masseter muscle, on both sides of the animal. The reported lesions were located in cheek masseter muscle, parotid gland, upper neck, upper gingiva and body of mandibular. The enormous strength of jaw closure is in large part due to the pinnated arrangement of the muscle fibres in the masseter. orted lesions were located in cheek masseter muscle, parotid gland, upper neck, upper gingiva and body of mandibular. The clin e masseter muscle is the most frequent site and accounts for approximately 5% of all intramuscular vascular malformations in the head and neck region. M e relationship between the masseter muscle and the mandible, including its ramal and body components, was chosen as the model for study in nineteen human fetuses (ages 16 to 36 weeks). Cr Facial musculature is divided into masticatory muscles, i.e. M. masseter and M. buccalis, with bony insertions and smaller facial muscles involved in facial expression, which insert into bone and skin. T wo rigid bodies, the upper and lower jaws, including three dominant muscles, i.e. the masseter, the anterior portion of the temporalis and the lateral pterygoid. Static equilibrium Benign hypertrophy of the masseter muscle is an uncommon entity important in the differential diagnosis of head and neck masses, particularly a unilateral mass located in the cheek First, jaw opening that was produced by mechanically pulling down the mandible evoked an optical response, which reflects neural excitation, in two cortical regions: the most rostroventral part of the primary somatosensory cortex (S1) and the border between the ventral part of the secondary somatosensory cortex (S2) and the insular oral region (IOR) Masseter nerve stimulation initially excited the rostral part of the S2\/IOR region, and an adjacent region responded to jaw opening The caudal part of the region showing the maximum response overlapped with the region responding to jaw opening, whereas the rostral part overlapped with the region responding to electrical stimulation of the maxillary and mandibular molar pulps The masseter muscle is an integral part of the oral facial complex and one of the muscles of mastication  1% of cases. Masseter muscle localization is most common in head a Among the head and neck muscles, masseter muscle is the most common location, with the rate of 4.9%. Benign hypertrophy of the masseter muscle is an uncommon entity important in the differential diagnosis of head and neck masses, particularly a unilateral mass located in the cheek. ascular neoplasm Welsch and Hengerer, 1980 [4]. Of these 13.8% occur in the head and neck region, with the masseter muscle being the most common site, followed by the trapezi It was concluded that: 1) radiopaque muscle markers are a valuable tool for analysis of muscle growth and alteration of muscle location; 2) the masseter muscle in the rhesus monkey undergoes elongation, probably due to addition of sarcomeres at the fiber-tendon junctions; and 3) posterior migration of the masseter muscle relative to the corpus of the mandible, probably due to the nature of its periosteal attachment, results in a stability of the anteroposterior position of the masseter muscle despite the anterior displacement of the mandible. AIM: The masseter muscle is often exploited by craniofacial surgeons in transposition operations to correct facial palsy, benign masseteric hypertrophy; or neurectomy-induced atrophy of the mu The condition of a 36-year-old patient who applied to our clinic with the complaints of progressively increasing pain and progressively growing mass in the right cheek that appeared 1.5 years ago was diagnosed as arteriovenous malformation located in the masseter muscle. In the cattle, goat, sheep and Sika deer, the rostral layer of the masseter muscle arises from the facial crest with its fleshy portion and is inserted into the tubercle on the mandible through the strong tendinous sheet. Less than 1% of the vascular tumors are localized in a muscle, 15% of them are in the head and neck muscles"}
{"id":"6251a2ffe764a5320400001c","question":"What is the function of the protein SLC26A5?","long_answer":"SLC26A5 transporter prestin is fundamental for the higher hearing sensitivity and frequency selectivity of mammals. Prestin is a voltage-dependent transporter found in the cochlear outer hair cells responsible for their electromotility.","answer":"voltage-dependent transporter","context":"SLC26A5 transporter prestin is fundamental for the higher hearing sensitivity and frequency selectivity of mammals. Prestin is a voltage-dependent transporter found in the cochlear outer hair cells responsible for their electromotility.  The outer hair cell (OHC) membrane harbors a voltage-dependent protein, prestin (SLC26a5), in high density, whose charge movement is evidenced as a nonlinear capacitance (NLC). Prestin (SLC26A5) is responsible for acute sensitivity and frequency selectivity in the vertebrate auditory system. The voltage-dependent motor protein prestin (also known as SLC26A5) is responsible for the electromotive behaviour of outer-hair cells and underlies the cochlear amplifier1."}
{"id":"61f609d3882a024a10000024","question":"Bimekizumab is used for treatment of which disease?","long_answer":"Bimekizumab is used for psoriasis.","answer":"psoriasis","context":"In BE RADIANT, patients were randomised 1:1 to bimekizumab 320\u00a0mg every 4\u00a0weeks (Q4W) or secukinumab 300\u00a0mg (weekly until Week 4, then Q4W). Three items (itching, skin pain and scaling) of the P-SIM were electronically assessed throughout the trial and were scored from 0 to 10 (none to very severe signs\/symptoms\/impacts). CONCLUSIONS: In this review, we include a study of the new anti-IL-17 biological agents (secukinumab, ixekizumab, and bromalizumab) used for moderate-to-severe psoriasis and psoriatic arthritis treatment in clinical practice, as well as pivotal trials with bimekizumab.  Bimekizumab: the new drug in the biologics armamentarium for psoriasis. Due to its novel mechanism of action (dual inhibition of IL-17A and IL-17F), bimekizumab is considered a new therapeutic approach for the treatment of moderate-to-severe psoriasis. Bimekizumab has demonstrated superiority in all direct comparative clinical trials conducted, whether against ustekinumab (IL-12\/23 inhibitor), adalimumab (TNF inhibitor) or secukinumab (IL-17A inhibitor), and has shown very encouraging results for the treatment of psoriatic arthritis.  INTRODUCTION: Plaque psoriasis can significantly impact patients' quality of life. We assessed psychometric properties of the Psoriasis Symptoms and Impacts Measure (P-SIM), developed to capture patients' experiences of signs, symptoms and impacts of psoriasis.METHODS: Pooled, blinded, 16-week data from 1002 patients in the BE\u00a0VIVID and BE\u00a0READY bimekizumab phase\u00a03 trials were analysed.  Bimekizumab for the treatment of psoriatic disease.  of action (dual inhibition of IL-17A and IL-17F), bimekizumab is considered a new therapeutic approach for the treatment of moderate-to-severe psoriasis. Bimekizumab has demonstra Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis. Here we will discuss the safety and efficacy of bimekizumab in the treatment of moderate-to-severe plaque psoriasis. An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far. Long-term results and head-to-head trials comparing bimekizumab with other agents will be crucial to define the role of bimekizumab in the treatment of psoriatic disease. BACKGROUND: Bimekizumab is a monoclonal antibody that selectively inhibits both IL-17A and IL-17F, currently under investigation for moderate to severe plaque psoriasis. Maintenance dosing every 4 weeks is First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. igen-binding site of bimekizumab neutralizes both IL-17A and IL-17F; phase I, II, and III studies have demonstrated its efficacy and safety in psoriasis and psoriatic arthritis. Sonelok de alone. Bimekizumab is the first human monoclonal antibody to exert simultaneous specific inhibition of IL-17A and IL-17\u00a0F, and has been studied in several phase II\/III trials for psoriasi Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis. Bimekizumab for Moderate-to-Severe Plaque Psoriasis Bimekizumab for the Treatment of Psoriasis Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Bimekizumab for the Treatment of Psoriasis. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. Bimekizumab for Moderate-to-Severe Plaque Psoriasis. Bimekizumab is currently in clinical development for psoriasis, psoriatic arthritis, and ankylosing spondylitis, with promising results. ockade alone. Bimekizumab is the first human monoclonal antibody to exert simultaneous specific inhibition of IL-17A and IL-17\u00a0F, and has been studied in several phase II\/III trials for psoriasis and PsA.AREAS COVERED: Bimekizumab is no"}
{"id":"626aab13e764a5320400003b","question":"What is the rate of epimutations in C. elegans?","long_answer":"In C. elegans epimutations arise spontaneously at a rate approximately 25 times greater than DNA sequence changes.","answer":"25 times greater than DNA sequence changes","context":"We show that epimutations arise spontaneously at a rate approximately 25 times greater than DNA sequence changes and typically have short half-lives of two to three generations."}
{"id":"61f7d745882a024a10000038","question":"Which disease can be prevented with PfSPZ Vaccine?","long_answer":"PfSPZ Vaccine is used for prevention of malaria.","answer":"malaria","context":"BACKGROUND: A live-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria infection (CHMI) using homologous parasites (same P. falciparum strain as in the vaccine). CONCLUSIONS: Administering 4 stacked priming injections (multi-dose priming) resulted in 40% VE against heterologous CHMI, while dose escalation of PfSPZ using single-dose priming was not significantly protective.  Plasmodium falciparum sporozoite (PfSPZ) Vaccine (radiation-attenuated, aseptic, purified, cryopreserved PfSPZ) and PfSPZ-CVac (infectious, aseptic, purified, cryopreserved PfSPZ administered to subjects taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria infection (CHMI) in nonimmune adults.  The radiation-attenuated Plasmodium falciparum sporozoite (PfSPZ) vaccine provides protection against P. falciparum infection in malaria-na\u00efve adults.  BACKGROUND: A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously. The next step was to asses In this limited review, we focus on four approaches to malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S\/AS01), (2) whole sporozoite vaccines aimed at Pf pre-erythrocytic stages (PfSPZ Vaccine and PfSPZ-CVac), (3) prime boost vaccines that include recombinant DNA, viruses and bacteria, and protein with adjuvant aimed primarily at Pf pre-erythrocytic, but also asexual erythrocytic stages, and (4) recombinant protein with adjuvant vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages. In this limited review, we focus on four approaches to malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S\/AS01), (2) whole sporozoite vaccines aimed at Pf pre-erythrocytic stages (PfSPZ Vaccine and PfSPZ-CVac), (3) prime boost vaccines that include recombinant DNA, viruses and bacteria, and protein with adjuvant aimed primarily at Pf pre-erythrocytic, but also asexual erythrocytic stages, and (4) recombinant protein with adjuvant vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages. A live-attenuated malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo after final vaccination. No injectable malaria vaccine has demonstrated long Here, we aimed to investigate if P. falciparum sporozoite binding and invasion-inhibitory IgM antibodies are induced following immunization of malaria-preexposed volunteers with PfSPZ Vaccine. Immunization with attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown to be protective against malaria, but the features of the antibody response induced by this treatment remain unclear. T  of the candidate human malaria vaccines, which is based on human malaria sporozoites and called PfSPZ Vaccine, has been shown to protect a significant proportion of vaccine recipients from getting malaria. PfS BACKGROUND: A live-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria infection (CHMI) using homologous parasites (sa An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown. We asse BACKGROUND: Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive ind Sterile protection against human malaria by chemoattenuated PfSPZ vaccine PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, is administered by direct venous inoculation (DVI) for maximal efficacy against malaria. A cri nfections. The radiation attenuated sporozoite (PfSPZ) vaccine has been considered the gold standard for malaria vaccines because of its unparalleled CKGROUND: A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses admin  have demonstrated for the first time to our knowledge that PfSPZ Vaccine can protect against a 3-week heterologous CHMI in a limited group of malaria-naive adult subjects.  otective efficacy has been demonstrated in a small number of volunteers after intravenous (IV) inoculation of radiation-attenuated PfSPZ or in those who were exposed to live PfSPZ while on malaria chemoprophylaxis. These advance pared in vitro and in vivo activities of six CSP-specific mAbs derived from human recipients of a recombinant CSP vaccine RTS,S\/AS01 (mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria (mAbs 580 and 663). RTS,S mA Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. We are using controlled human malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) to try to reduce time and costs of developing PfSPZ Vaccine to prevent malaria in Africa An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown. CONCLUSIONS: We have demonstrated for the first time to our knowledge that PfSPZ Vaccine can protect against a 3-week heterologous CHMI in a limited group of malaria-naive adult subjects. Our findings suggest that PfSPZ Vaccine conferred durable protection to malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance protection. Collectively, these data suggest durable protection against homologous and heterologous Pf parasites can be achieved with PfSPZ Vaccine. A live-attenuated malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers sterile protection against controlled human malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine strain up to 14 mo after final vaccination. ON: PfSPZ Vaccine was well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria season.FUNDING: US National In BACKGROUND: A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously. BACKGROUND: Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive  We assessed immunization by direct venous inoculation of aseptic, purified, cryopreserved, non-irradiated PfSPZ ('PfSPZ Challenge') to malaria-naive, healthy adult volunteers taking chloroquine for antimalarial chemoprophylaxis (vaccine approach denoted as PfSPZ-CVac). Three doses of 5.12\u2009\u00d7\u2009104 PfSPZ of PfSPZ Challenge at 28-day intervals were well tolerated and safe, and prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria infection ten weeks after the last dose (group III)."}
{"id":"624d9492e764a53204000006","question":"What is MACE in the context of cardiotoxicity?","long_answer":"MACE is an acronym for Major Adverse Cardiovascular Events.","answer":"Major Adverse Cardiovascular Events.","context":"major adverse cardiovascular events (MACE) major cardiac adverse events (MACEs) major adverse cardiac events (MACE) Major adverse cardiovascular events (MACE) endpoint is defined as the occurrence of a major adverse cardiac event (MACE). The Objectives: The purpose of this study was to evaluate whether immune checkpoint inhibitors (ICIs) are associated with an\u00a0increased risk of major adverse cardiovascular events (MACE) compared with non-ICI therapies in patients with lung\u00a0cancer. BACKGROUND: Main adverse cardiac events (MACE) are essentially composite endpoints for assessing safety and efficacy of treatment processes of acute coronary syndrome (ACS)  Major adverse cardiac events (MACE) are common after renal transplant, especially in the perioperative period, leading to excess morbidity and mortality. Th aim of this study was to explore the predictive value of soluble osteoclast-associated receptor (sOSCAR) level for the major adverse cardiovascular events (MACE) occurring within 30\u00a0days after ACS. From J ciated with the occurrence of MACE, defined as a composite of cardiac death, congestive heart failure, and myocardial re-infarction (adjusted hazard ratio: 3.74; 95% confidence interval: 2.21 to 6.34). IS%LV \u226525% was  The study aimed to determine whether high sensitivity C-reactive protein to prealbumin (hs-CRP\/PAB) ratio could be used to predict in-hospital major adverse cardiac events (MACE) in patients with acute coronary syndrome (ACS). A  Objectives: The purpose of this study was to characterize major adverse cardiac events (MACE) in ICI-treated lung cancer patients based in a rural setting and to assess the utility of C-reactive protein (CRP) and neutrophil-lymphocyte ratio (NLR) in the diagnosis of iR OBJECTIVE: To evaluate whether LUTS severity can be considered as a significant risk factor of major adverse cardiac events (MACE) in the male populatio PATIENT SUMMARY: We evaluated whether the severity of lower urinary tract symptoms could be considered as a significant risk factor for major adverse cardiac events (MACE) in the male populatio CONTEXT: Percutaneous coronary intervention (PCI) is associated with excellent short-term improvements in ischemic symptoms, yet only three fifths of PCI patients at 5 years and one third of patients at 10 years remain free of major adverse cardiac events (MACE SES, n = 508; and PES, n = 576). Major adverse cardiac events (MACE) were defined as a composite of all-cause mortality, myocardial infarction, or target vessel revascularization (TVR).RESULTS: The patients treated with EES were older, presented more frequently with acute myocardial infarction, and had more  Therefore, the objectives of the present study were twofold: (1) to characterize the occurrence of and risk factors for major adverse cardiac events (MACEs: symptomatic heart failure and cardiac death) in a large contemporaneous population of adult patients treated with anthracyclines and (2) to test the value of LVEF and LV dimensions obtained using echocardiography in the prediction of MACE.  7, 30, and 90 days. Secondary outcomes included major adverse cardiac events (MACE; all-cause mortality, AMI, and revascularization) and the indivi Objectives: The purpose of this study was to evaluate whether immune checkpoint inhibitors (ICIs) are associated with an\u00a0increased risk of major adverse cardiovascular events (MACE) compared with non-ICI therapies in patients with lung\u00a0cancer.Background: ICIs activate the host immune system n be fatal. There have been few reports of iRC from a rural cancer population and few data for iRC and inflammatory biomarkers.Objectives: The purpose of this study was to characterize major adverse cardiac events (MACE) in ICI-treated lung cancer patients based in a rural setting and to assess the utility of C-reactive protein (CRP) and neutrophil-lymphocyte ratio (NLR) in the diagnosis of iRC.Methods: Patients with lung cancer treated with ICIs at Vidant Medical Center\/East Carolina University (VMC\/ECU) between 2015 and 2018"}
{"id":"626aeb2fe764a5320400003f","question":"Which clinical trials led to the first approval of Volanesorsen by the EU?","long_answer":"The approval of Volanesorsen by the EU was based on the positive results from the multinational, phase III APPROACH and COMPASS studies.","answer":"APPROACH and COMPASS","context":"In May 2019, volanesorsen was approved in the EU for the treatment of adult patients with FCS based on positive results from the multinational, phase\u00a0III APPROACH and COMPASS studies."}
{"id":"626aeba1e764a53204000040","question":"Which company developed Waylivra?","long_answer":"Waylivra is being developed by Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics.","answer":"Ionis Pharmaceuticals","context":"Volanesorsen (Waylivra\u00ae), an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics, to treat familial chylomicronemia syndrome (FCS), hypertriglyceridemia and familial partial lipodystrophy (FPL)."}
{"id":"625ebf76e764a53204000033","question":"What is the most frequent evolution (next stage) when Aortic intramural hematoma (IMH) is not treated?","long_answer":"Intramural hematoma IMH may progress to classic dissection, frank rupture, or aneurysmal dilation.","answer":"aortic dissection","context":"We consider that IMH may represent a part of a disease (aortic dissection), depicted by radiological images in a specific single instant of its clinical evolution. IMH may progress to classic dissection, frank rupture, or aneurysmal dilation; yet, IMH may also regress and be completely resorbed.  Type B acute aortic dissection (AAD) and intramural hematoma (IMH) can both present as potentially catastrophic lesions of the descending aorta. IMH is distinguished from AAD by the absence of an intimal tear and flap. With short-term outcomes being similar to type B AAD, IMH is treated identically to AAD in the corresponding segment of the aorta. Intramural hematomas (IMHs) are reported to dynamically evolve into different clinical outcomes ranging from regression to aortic rupture,   IMH displays a typical of dissection progress, and could be considered as a precursor of classic aortic dissection.  Aortic intramural hematoma (IMH) evolves very dynamically in the short-term to regression, dissection, or aortic rupture Intramural hematoma of the aorta is a condition increasingly observed in clinical practice. Uncertainty exists whether such lesions represent a different pathology or simply the precursors of classic dissecting aneurysm We stress that intramural hematoma of the ascending aorta has to be managed as an aortic type A dissection and that aggressive treatment is advisable. BACKGROUND: Aortic intramural hematoma (IMH) evolves very dynamically in the short-term to regression, dissection, or aortic rupture. LUSIONS: The most frequent long-term evolution of IMH is to aortic aneurysm or pseudoaneurysm. Com IMH also frequently leads to aortic emergency, which can be fatal unless rapidly diagnosed and treated. Aortic intramural hematoma (IMH) is an acute, potentially lethal disorder that is similar to but pathologically distinct from acute aortic dissection. BACKGROUND: It has been reported that early surgery should be required for patients with type A aortic intramural hematoma (IMH) because it tends to develop classic aortic dissection  BACKGROUND: Aortic intramural hematoma (IMH) evolves very dynamically in the short-term to regression, dissection, or aortic ome cases there is partial or complete regression of the hematoma under medical treatment, but most progress to dissection, aneurysmal dilatation or aortic rupture. The  ase evolution, IMH may progress to classic AD, frank rupture, or aneurysmal dilation; yet, IMH may also regress and be completely resorbed. However, since the nat CONCLUSIONS: The most frequent long-term evolution of IMH is to aortic aneurysm or pseudoaneurys  later developed pseudoaneurysm. At the end of follow-up, the IMH had regressed completely without dilatation in 17 patients (34%), progressed to classical dissection in 6 (12%), evolved to fusiform aneurysm in 11 (22%), evolved to saccular aneurysm in 4 (8%), and evolv"}
{"id":"625bb257e764a5320400002e","question":"When is lorlatinib used?","long_answer":"Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired ALK resistance mutations, including the solvent-front mutation G1202R.","answer":"In ALK-positive NSCLC","context":"Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired ALK resistance mutations, including the solvent-front mutation G1202R.  The study tested two medicines called lorlatinib and crizotinib in participants with untreated non-small cell lung cancer that had spread to other parts of their body. All those who took part\u00a0had changes in a gene called ALK, which is involved in cell growth.  In conclusion, we suggest molecular profiling of progressive tumor disease also for ALK-positive NSCLC to personalize treatment in a subgroup of ALK-positive patients."}
{"id":"62532ffee764a53204000023","question":"Ladybird homeobox (Lbx) transcription factors regulate the development of what body systems\/organs?","long_answer":"Ladybird homeobox (Lbx) transcription factors have crucial functions in muscle and nervous system development in many animals","answer":"muscle and nervous system","context":"Ladybird homeobox (Lbx) transcription factors have crucial functions in muscle and nervous system development in many animals. Lbx\/ladybird genes originated as part of the metazoan cluster of Nk homeobox genes. In all animals investigated so far, both the protostome genes and the vertebrate Lbx1 genes were found to play crucial roles in neural and muscle development. The Drosophila ladybird homeobox gene (lad) functions in founder cells of the segmental border muscle to promote myoblast fusion and muscle shaping. Our data reveal that ladybird not only contributes to the combinatorial code of transcription factors specifying the identity of muscle and cardiac precursors, but also regulates a large number of genes involved in setting cell shape, adhesion, and motility. A prior genetic analysis showed that during Drosophila muscle and heart development ladybird is required for the specification of a subset of muscular and cardiac precursors. The Hmx gene family is a new class of homeobox-containing genes defined by a conserved homeobox region and a characteristic pattern of expression in the central nervous system that is more rostral than that of the Hox genes. Ladybird (Lbx) homeodomain transcription factors function in neural and muscle development--roles conserved from Drosophila to vertebrates. LBX1 protein, a homeobox transcription factor that is orthologous to the Drosophila ladybird late gene, is involved in proper migration of muscle precursor cells, specification of cardiac neural crest cells, and neuronal determination in developing neural tubes.CONC Ladybird homeobox (Lbx) transcription factors have crucial functions in muscle and nervous system development in many animals.  Ladybird (Lbx) homeodomain transcription factors function in neural and muscle development--roles conserved from Drosophila to vertebrates.  yofibrils. The Drosophila ladybird homeobox gene (lad) functions in founder cells of the segmental border muscle to promote myoblast fusion and muscl re we show that the homeobox genes ladybird early and ladybird late are expressed in only one muscle progenitor and its progeny: the segmental border muscle founder cell and two precursors of adult muscles. T prior genetic analysis showed that during Drosophila muscle and heart development ladybird is required for the specification of a subset of muscular and cardiac precursors.  Homeobox genes are an evolutionarily conserved class of transcription factors that are critical for development of many organ systems, including the brain and eye. ladybird, a new component of the cardiogenic pathway in Drosophila required for diversification of heart precursors. he homeobox containing transcription factor ladybird homeobox 1 (Lbx1) is a central regulator of limb myoblast migration, null mutations of Lbx1 result in severe disruptions to limb muscle formation, particularly in the distal region of the limb in mice (Gross et al., 2000). As s Lbx1 has been hypothesized to control lateral migration of myoblasts into the distal limb anlage. It act that Lbx1 is differentially recruited to the developmental genetic program of inhibitory neurons both within a given tissue and between the DCN and cerebellum. The differential expr Phosphorylation of Lbx1 controls lateral myoblast migration into the limb Our data reveal that ladybird not only contributes to the combinatorial code of transcription factors specifying the identity of muscle and cardiac precursors, but also regulates a large number of genes involved in setting cell shape, adhesion, and motility Ladybird homeobox (Lbx) transcription factors have crucial functions in muscle and nervous system development in many animals The ladybird homeobox genes are essential for the specification of a subpopulation of neural cells. The Drosophila melanogaster genes, ladybird early (lbe) and ladybird late (lbl), encode transcriptional regulators, which play an important role in neurogenesis, myogenesis and cardiogenesis."}
{"id":"62587803e764a5320400002b","question":"When is the protein OAS1 activated?","long_answer":"OAS1 is a IFN-stimulated gene. Antiviral response.","answer":"IFN stimulated for antiviral resonse.","context":" encodes antiviral restriction enzyme activators (OAS1, OAS2 and OAS3) interferon-stimulating genes (ISG15, IFI6, IFI27, IFI44, and OAS1) IFN-stimulated genes (ISGs: ISG56, OAS1, MxA, and Mx2) OASs play critical roles in immune response against virus infection by polymerizing ATP into 2-5As, which initiate the classical OAS\/RNase L pathway and induce degradation of viral RNA. OAS1 gene in activation of innate immune response"}
{"id":"6278ca4a56bf9aee6f00000c","question":"Which is the protein-membrane interface of the Cholesterol-regulated Start protein 4 protein (STARD4)?","long_answer":"L124 is the protein-membrane interface of the Cholesterol-regulated Start protein 4 protein (STARD4).","answer":"L124","context":"Our results show that STARD4 interacts with anionic membranes through a surface-exposed basic patch and that introducing a mutation (L124D) into the Omega-1 (\u03a91) loop, which covers the sterol binding pocket, attenuates sterol transfer activity. w that STARD4 interacts with anionic membranes through a surface-exposed basic patch and that introducing a mutation (L124D) into the Omega-1 (\u03a91) loop, which covers the sterol binding pocket, attenuates sterol transfer activity. To gain insight int"}
{"id":"627a875a56bf9aee6f000023","question":"What causes the \"worst headache\" of a patient's life?","long_answer":"This is a classic description of a subarachnoid hemorrhage (SAH). The gold standard for the diagnostic evaluation of a SAH remains non-contrast head computed tomography (CT) followed by lumbar puncture if the CT is negative.","answer":"Subarachnoid hemorrhage (SAH)","context":"Aneurysmal subarachnoid hemorrhage (SAH) is associated with a mortality of more than 30%. Acute, severe headache, typically described as the worst headache of the patient's life, and meningismus are the characteristic manifestations of SAH. Computed tomog raphy (CT) reveals blood in the basal cisterns in the first 12 hours after SAH with approximately 95% sensitivity and specificity. If no blood is seen on CT, a lumbar puncture must be performed to confirm or rule out the diagnosis of SAH. Aneurysmal subarachnoid hemorrhage (SAH) is a neurological emergency with high risk of neurological decline and death. Although the presentation of a thunderclap headache or the worst headache of a patient's life easily triggers the evaluation for SAH, subtle presentations are still missed. The gold standard for diagnostic evaluation of SAH remains noncontrast head computed tomography (CT) followed by lumbar puncture if the CT is negative for SAH. Headache is the most common presenting symptom of subarachnoid hemorrhage (SAH), ranging from mild headache to the \"worst headache of my life\". Patients who survive an Aneurysmal Subarachnoid Haemorrhage or ASAH describe it as being the worst headache ever, multiplied one hundred-times over."}
{"id":"6278dfe956bf9aee6f000016","question":"Which disease phenotype has the worst prognosis in Duchenne Muscular Dystrophy?","long_answer":"Dp140 isoform is related to increased risk of cognitive impairment and thus worse prognosis.","answer":"Dp140 isoform","context":" A strong association between the risk of cognitive disability and the involvement of groups of DMD isoforms was found. In particular, improvements in the correlation of FSIQ with mutation location were identified when a new classification system for mutations affecting the Dp140 isoform was implemented. The ACTN3 577XX Null Genotype Is Associated with Low Left Ventricular Dilation-Free Survival Rate in Patients with Duchenne Muscular Dystrophy. These results suggest that patients with Duchenne muscular dystrophy with defective cDMD have more severe disease than those without cDMD deficit. Osteopontin genotype is a genetic modifier of disease severity in Duchenne dystrophy. Inclusion of genotype data as a covariate or in inclusion criteria in DMD clinical trials would reduce intersubject variance, and increase sensitivity of the trials, particularly in older subjects. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy."}
{"id":"6277de0d56bf9aee6f000006","question":"What is the most sensitive test for the diagnosis of multiple sclerosis?","long_answer":"MRI is the most sensitive tool for the diagnosis of multiple sclerosis (MS). It can detect asymptomatic lesions in the white matter and is the most predictive test for diagnosing clinically definite multiple sclerosis (CDMS). It is also a reliable measure of the current disease activity. The presence of oligoclonal bands in the cerebrospinal fluid (CSF) provides supportive evidence for the diagnosis of MS.","answer":"Magnetic resonance imaging","context":"The initial MRI was strongly suggestive of MS in 19 of these (68%), while 27 (96%) had at least one MS-like abnormality in the initial MRI. These results support previous conclusions that MRI is the most sensitive test for detecting white matter asymptomatic lesions, and the most predictive for the diagnosis of CDMS. The most sensitive test was MRI (93%) followed by VEP (83%) and BAEP (60%) and the sensitivity of the study with high resolution CT including 59 patients explored by double enhancement and delayed cut off was very low (33%).  In diagnosis, MRI is the most sensitive test for the demonstration of dissemination of lesions in space. MRI also is a reliable measure of the extent of the MS process, serial MRI scans detect evidence of disease activity in MS not always disclosed by clinical evaluation. These results indicate that the presence of oligoclonal bands provides sensitive supporting evidence for the diagnosis of MS but that bands may be present in other disorders, including those not directly related to infection or abnormal immune response. The data suggest that oligoclonal bands may represent an immune response to neurological injury that is prominent in disorders with a particularly intense or continuous antigenic stimulus. Magnetic resonance imaging (MRI) has recently been recognised as the most sensitive method with which to detect clinically silent lesions in patients affected by multiple sclerosis Magnetic resonance imaging (MRI) is a sensitive paraclinical test for diagnosis and assessment of disease progression in multiple sclerosis (MS) and is often used to evaluate therapeutic efficacy."}
{"id":"6277e4ee56bf9aee6f000008","question":"Should acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) be used when providing supportive care for COVID-19?","long_answer":"Nonsteroidal anti-inflammatory drugs (NSAIDs) have been theorized to cause harm in patients with COVID-19, but clinical data are limited. Given the uncertainty, acetaminophen is the preferred antipyretic agent for most patients rather than NSAIDs. If NSAIDs are needed, the lowest effective dose is recommended.","answer":"Acetaminophen","context":"Although based on existing evidence, NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus, since there is no clinical trial on COVID-19 and case-reports and clinical experiences are indicative of elongation of treatment duration and exacerbation of the clinical course of patients with COVID-19, it is recommended to use substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID-19 patients until there are enough evidence. Pharmacological approaches like acetaminophen, NSAIDS, spasmolytics etc. can be used if non-pharmacological therapy is inadequate. As per the current strength of evidence, acetaminophen and ibuprofen can be safely administered for pain management in children with COVID-19. Recently, the safety of ibuprofen in COVID-19 patients has been questioned due to anecdotal reports of worsening symptoms in previously healthy young adults. Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not be used, but there is no strong evidence that NSAIDs must be avoided in all patients with COVID-19; clinicians must weigh these choices on an individual basis. Concern about the appropriate role of nonsteroidal anti-inflammatory drugs (NSAIDs) in COVID-19 speculate that NSAIDs, in particular ibuprofen, may upregulate the entry point for the virus, the angiotensin-converting enzyme (ACE)\u00a02 receptors and increase susceptibility to the virus or worsen symptoms in existing disease. The Expert Working Group on the Commission of Human Medicines in the UK and other organizations have stated that there is insufficient evidence to establish a link between ibuprofen and susceptibility to or exacerbation of COVID-19. To provide analgesia, paracetamol can be listed as the first option in these patients, and then NSAIDs can also be reliably used for pain management in patients with COVID-19 if there are no absolute contraindications such as kidney failure or gastric bleeding. There are clearly COVID-19 cases where NSAIDs should not be used, but there is no strong evidence that NSAIDs must be avoided in all patients with COVID-19; clinicians must weigh these choices on an individual basis. Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses"}
{"id":"6277e52256bf9aee6f000009","question":"What is the incubation period for COVID-19?","long_answer":"The incubation period for COVID-19 is thought to be within 14 days following exposure, with most cases occurring approximately five to seven days after exposure. The incubation period also varies by viral variant. For example, the incubation period for the Delta variant (B.1.617.2) appears to be slightly shorter, with symptoms first appearing around four days after exposure.","answer":"5-7 days","context":"We find that the incubation period has a median of 8.50\u00a0days (95% confidence interval [CI] [7.22; 9.15]). The pooled mean incubation period of COVID-19 was 6.0\u00a0days (95% confidence interval [CI] 5.6-6.5) globally, 6.5\u00a0days (95% CI 6.1-6.9) in the mainland of China, and 4.6\u00a0days (95% CI 4.1-5.1) outside the mainland of China (P\u2009=\u20090.006). The incubation period varied with age (P\u2009=\u20090.005). Meanwhile, in 11 545 patients, the mean incubation period was 7.1\u00a0days (95% CI 7.0-7.2), which was similar to the finding in our meta-analysis. For COVID-19, the mean incubation period was 6.0\u00a0days globally but near 7.0\u00a0days in the mainland of China, which will help identify the time of infection and make disease control decisions. The mean incubation period ranged from 5.6 (95% CI: 5.2 to 6.0) to 6.7 days (95% CI: 6.0 to 7.4) according to the statistical model. The 95th percentile was 12.5 days when the mean age of patients was 60 years, increasing 1 day for every 10 years. The Delta VOC yielded a significantly shorter incubation period (4.0 vs. 6.0 days), higher viral load (20.6 vs. 34.0, cycle threshold of the ORF1a\/b gene), and a longer duration of viral shedding in pharyngeal swab samples (14.0 vs. 8.0 days) compared with the wild-type strain. We estimated that the 0.95-th quantile related to people in the age group 23 \u223c55 is less than 15 days. Based on the collected data, we found that the conditional quantiles of the incubation period distribution of COVID-19 vary by age. The estimated mean incubation period we obtain is 6.74 days (95% Confidence Interval(CI): 6.35 to 7.13), and the 90th percentile is 11.64 days (95% CI: 11.22 to 12.17), corresponding to a good agreement with statistical supported studies. The mean and median incubation period were of maximum 8 days and 12 days respectively. In various parametric models, the 95th percentiles were in the range 10.3-16 days. The highest 99th percentile would be as long as 20.4 days. The mean incubation period ranged from 5.2 (95% CI 4.4 to 5.9) to 6.65 days (95% CI 6.0 to 7.2). This work provides additional evidence of incubation period for COVID-19 and showed that it is prudent not to dismiss the possibility of incubation periods up to 14 days at this stage of the epidemic. For COVID-19, average incubation period times commonly span 5-7 days which are generally longer than for most typical other respiratory viruses. Our estimated median incubation period of COVID-19 is 5.4 days (bootstrapped 95% confidence interval (CI) 4.8-6.0), and the 2.5th and 97.5th percentiles are 1 and 15 days, respectively; while the estimated serial interval of COVID-19 falls within the range of -4 to 13 days with 95% confidence and has a median of 4.6 days (95% CI 3.7-5.5). We conducted a systematic review and meta-analysis on published estimates of the incubation period distribution of COVID-19, and showed that the pooled median of the point estimates of the mean, median and 95 th percentile for incubation period are 6.3 days (range: 1.8 to 11.9 days), 5.4 days (range: 2.0 to 17.9 days) and 13.1 days (range: 3.2 to 17.8 days) respectively. The incubation period in COVID-19 (6.4 days estimated) was longer than influenza type A (3.4 days). Children (aged below 18 years) are susceptible to COVID-19, with an average incubation period of about 6.5 days. At present, the quarantine duration in most countries is 14 d due to the fact that the incubation period of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is usually identified as 1-14 d with median estimate of 4-7.5 d. The median COVID-19 incubation period was 8.3 (90% confidence interval [CI], 7.4-9.2) days for all patients, 7.6 (90% CI, 6.7-8.6) days for younger adults, and 11.2 (90% CI, 9.0-13.5) days for older adults. This analysis provides evidence for an average incubation period for COVID-19 of approximately 6.4 days."}
